
<html lang="en"     class="pb-page"  data-request-id="3f34362b-6168-4c3b-abec-b5006aac7002"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.5b01354;issue:issue:10.1021/jmcmar.2016.59.issue-3;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novobiocin Analogues That Inhibit the MAPK Pathway" /></meta><meta name="dc.Creator" content="Jessica A.  Hall" /></meta><meta name="dc.Creator" content="Sahithi  Seedarala" /></meta><meta name="dc.Creator" content="Huiping  Zhao" /></meta><meta name="dc.Creator" content="Gaurav  Garg" /></meta><meta name="dc.Creator" content="Suman  Ghosh" /></meta><meta name="dc.Creator" content="Brian S. J.  Blagg" /></meta><meta name="dc.Description" content="Heat shock protein 90 (Hsp90) inhibition by modulation of its N- or C-terminal binding site has become an attractive strategy for the development of anticancer chemotherapeutics. The first Hsp90 C-..." /></meta><meta name="Description" content="Heat shock protein 90 (Hsp90) inhibition by modulation of its N- or C-terminal binding site has become an attractive strategy for the development of anticancer chemotherapeutics. The first Hsp90 C-..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 27, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01354" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01354" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01354" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01354" /></link>
        
    
    

<title>Novobiocin Analogues That Inhibit the MAPK Pathway | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01354" /></meta><meta property="og:title" content="Novobiocin Analogues That Inhibit the MAPK Pathway" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0011.jpeg" /></meta><meta property="og:description" content="Heat shock protein 90 (Hsp90) inhibition by modulation of its N- or C-terminal binding site has become an attractive strategy for the development of anticancer chemotherapeutics. The first Hsp90 C-terminus inhibitor, novobiocin, manifested a relatively high IC50 value of ∼700 μM. Therefore, investigation of the novobiocin scaffold has led to analogues with improved antiproliferative activity (nanomolar concentrations) against several cancer cell lines. During these studies, novobiocin analogues that do not inhibit Hsp90 were identified; however, these analogues demonstrated potent antiproliferative activity. Compound 2, a novobiocin analogue, was identified as a MAPK pathway signaling disruptor that lacked Hsp90 inhibitory activity. In addition, structural modifications of compound 2 were identified that segregated Hsp90 inhibition from MAPK signaling disruption. These studies indicate that compound 2 represents a novel scaffold for disruption of MAPK pathway signaling and may serve as a useful structure for the generation of new anticancer agents." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01354"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01354">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01354&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01354&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01354&amp;href=/doi/10.1021/acs.jmedchem.5b01354" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 925-933</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01333" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01378" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novobiocin Analogues That Inhibit the MAPK Pathway</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jessica+A.++Hall">Jessica A. Hall</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sahithi++Seedarala">Sahithi Seedarala</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huiping++Zhao">Huiping Zhao</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gaurav++Garg">Gaurav Garg</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suman++Ghosh">Suman Ghosh</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+S.+J.++Blagg">Brian S. J. Blagg</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#1775757b767070577c6239727362"><span class="__cf_email__" data-cfemail="a5c7c7c9c4c2c2e5ced08bc0c1d0">[email protected]</span></a>. Phone: (785) 864-2288. Fax: (785) 864-5326.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01354&amp;href=/doi/10.1021%2Facs.jmedchem.5b01354" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 925–933</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 8, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 September 2015</li><li><span class="item_label"><b>Published</b> online</span>27 January 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 February 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01354" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01354</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D925%26pageCount%3D9%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJessica%2BA.%2BHall%252C%2BSahithi%2BSeedarala%252C%2BHuiping%2BZhao%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D3%26contentID%3Dacs.jmedchem.5b01354%26title%3DNovobiocin%2BAnalogues%2BThat%2BInhibit%2Bthe%2BMAPK%2BPathway%26numPages%3D9%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D933%26publicationDate%3DFebruary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01354"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1292</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">9</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01354" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novobiocin Analogues That Inhibit the MAPK Pathway&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jessica&quot;,&quot;last_name&quot;:&quot;A. Hall&quot;},{&quot;first_name&quot;:&quot;Sahithi&quot;,&quot;last_name&quot;:&quot;Seedarala&quot;},{&quot;first_name&quot;:&quot;Huiping&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Gaurav&quot;,&quot;last_name&quot;:&quot;Garg&quot;},{&quot;first_name&quot;:&quot;Suman&quot;,&quot;last_name&quot;:&quot;Ghosh&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;S. J. Blagg&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;27&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;925-933&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01354&quot;},&quot;abstract&quot;:&quot;Heat shock protein 90 (Hsp90) inhibition by modulation of its N- or C-terminal binding site has become an attractive strategy for the development of anticancer chemotherapeutics. The first Hsp90 C-terminus inhibitor, novobiocin, manifested a relatively high IC50 value of ∼700 μM. Therefore, investigation of the novobiocin scaffold has led to analogues with improved antiproliferative activity (nanomolar concentrations) against several cancer cell lines. During these studies, novobiocin analogues that do not inhibit Hsp90 were identified; however, these analogues demonstrated potent antiproliferative activity. Compound 2, a novobiocin analogue, was identified as a MAPK pathway signaling disruptor that lacked Hsp90 inhibitory activity. In addition, structural modifications of compound 2 were identified that segregated Hsp90 inhibition from MAPK signaling disruption. These studies indicate that compound 2 represents a novel scaffold for disruption of MAPK pathway signaling and may serve as a useful structure for &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01354&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01354" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01354&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01354" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01354&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01354" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01354&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01354&amp;href=/doi/10.1021/acs.jmedchem.5b01354" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01354" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01354" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01354%26sid%3Dliteratum%253Aachs%26pmid%3D26745854%26genre%3Darticle%26aulast%3DHall%26date%3D2016%26atitle%3DNovobiocin%2BAnalogues%2BThat%2BInhibit%2Bthe%2BMAPK%2BPathway%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D3%26spage%3D925%26epage%3D933%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291297" title="Cell signaling">Cell signaling</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/jmcmar.2016.59.issue-3/20160211/jmcmar.2016.59.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0011.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Heat shock protein 90 (Hsp90) inhibition by modulation of its N- or C-terminal binding site has become an attractive strategy for the development of anticancer chemotherapeutics. The first Hsp90 C-terminus inhibitor, novobiocin, manifested a relatively high IC<sub>50</sub> value of ∼700 μM. Therefore, investigation of the novobiocin scaffold has led to analogues with improved antiproliferative activity (nanomolar concentrations) against several cancer cell lines. During these studies, novobiocin analogues that do not inhibit Hsp90 were identified; however, these analogues demonstrated potent antiproliferative activity. Compound <b>2</b>, a novobiocin analogue, was identified as a MAPK pathway signaling disruptor that lacked Hsp90 inhibitory activity. In addition, structural modifications of compound <b>2</b> were identified that segregated Hsp90 inhibition from MAPK signaling disruption. These studies indicate that compound <b>2</b> represents a novel scaffold for disruption of MAPK pathway signaling and may serve as a useful structure for the generation of new anticancer agents.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Heat shock protein 90 (Hsp90) is a molecular chaperone that facilitates the conformational maturation of other cellular proteins, termed clients, via the Hsp90 chaperone cycle. Hsp90 functions as a homodimer, and each monomer comprises an N-terminal domain (the site of ATP-binding and hydrolysis), a middle domain, and a C-terminal dimerization domain. Inhibitors that target the N- and C-termini of Hsp90 can halt client maturation and lead to ubiquitinylation and degradation of the substrate via the proteasome.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5">(1-5)</a> N-Terminal inhibitors perturb ATPase activity at the N-terminus and include derivatives of the natural product geldanamycin. However, N-terminal inhibition also leads to induction of the prosurvival heat shock response (HSR) via heat shock factor-1. This led to the development of C-terminal inhibitors, in which the HSR is avoided and client degradation is maintained. There are several therapeutic opportunities for small molecules that target the Hsp90 N- or C-terminus, including the development of anticancer chemotherapeutics.<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20">(6-20)</a></div><div class="NLM_p">Novobiocin is a natural product that inhibits the Hsp90 C-terminus and was found to exhibit an IC<sub>50</sub> value of ∼700 μM against the SKBr3 breast cancer cell line (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Extensive structure–activity relationship (SAR) studies on novobiocin have resulted in greatly improved antiproliferative activity against many different cancer cell lines and identified structural elements necessary for Hsp90 inhibition; however, exploration of the amide linker has yet to be fully investigated.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25 ref26 ref27 ref28 ref29 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40">(22-40)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of novobiocin and compounds <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">During SAR studies of the urea linker that was probed as a surrogate for the amide, analogues were identified that exhibited potent antiproliferative activity against several cancer cell lines. However, some of the compounds did not inhibit Hsp90. Investigation of these analogues led to identification of <b>2</b>, a novobiocin analogue that exhibited potent antiproliferative activity against the MCF7 breast and A549 lung cancer cell lines without Hsp90 inhibitory activity. Instead, compound <b>2</b> was shown to disrupt mitogen-activated protein kinase (MAPK) signaling, and in a time-dependent manner, it inhibited the phosphorylation of MEK and ERK. Since oncogenic mutations frequently occur within the MAPK pathway, much research has been devoted to the development of inhibitors of this pathway, including EGFR, Raf, MEK, and ERK.<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41-43)</a> Preliminary SAR studies of <b>2</b> examined the necessity of each methoxy substitution on the biaryl side chain and identified moieties that transition novobiocin analogues from Hsp90 inhibitory activity, such as compound <b>1</b>, to MAPK pathway inhibitors (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21225" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21225" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, compound <b>1</b> was prepared in one step by coupling the previously reported aniline <b>6</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> with the commercially available phenylisocyanate, <b>7a</b>. Compound <b>2</b> was synthesized from biaryl acid <b>8</b>,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> using diphenylphosphorylazide to give the corresponding azide, which underwent Curtius rearrangement to afford phenylisocyanate, <b>7b</b>. Subsequent coupling of <b>7b</b> with intermediate <b>6</b> provided compound <b>2</b> in good yield.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Novobiocin-Based Urea Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Many client proteins that depend upon Hsp90 are upregulated and often represent signaling pathways that are hijacked during malignant transformation.<a onclick="showRef(event, 'ref16 ref18 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref16 ref18 ref44 ref45">(16, 18, 44, 45)</a> Compounds that inhibit Hsp90, or the Hsp90 chaperone cycle, lead to client protein degradation via the ubiquitin proteasome pathway and deprive cancer the use of clients that drive progression and growth.<a onclick="showRef(event, 'ref1 ref4 ref5 ref46'); return false;" href="javascript:void(0);" class="ref ref1 ref4 ref5 ref46">(1, 4, 5, 46)</a> Therefore, decreased client protein levels are observed at the IC<sub>50</sub> values obtained in cell proliferation assays for Hsp90 inhibitors. To determine whether a compound inhibits Hsp90, IC<sub>50</sub> values are generated against cancer cell lines that depend upon functional Hsp90. The estrogen receptor-expressing MCF7 breast cancer cell line and the KRAS-driven A549 lung cancer cell line both depend upon Hsp90 for client protein maturation. Therefore, compounds that exhibit potent antiproliferative activity against these cell lines may inhibit Hsp90. <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> shows the IC<sub>50</sub> values for compounds <b>1</b> and <b>2</b> generated against these cancer cell lines, as well as the normalized cell line, MRC-5. <b>1</b> and <b>2</b> were shown to exhibit potent inhibition of cancer cell growth compared to that against the MRC-5 line, indicating the cellular target(s) for these compounds facilitate cancer growth.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values Determined for Compounds <b>1</b> and <b>2</b> against the MCF7 and A549 Cancer Cell Lines as Well as the Normal Human Cell Line, MRC5</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> values (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center"><b>2</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MCF7</td><td class="colsep0 rowsep0" align="left">0.77 ± 0.01</td><td class="colsep0 rowsep0" align="left">0.17 ± 0.07</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">A549</td><td class="colsep0 rowsep0" align="left">0.24 ± 0.00</td><td class="colsep0 rowsep0" align="left">0.15 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MRC-5</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">4.3</td></tr></tbody></table></div></div><div class="NLM_p">Client protein levels in MCF7 and A549 cells were determined via western blot analysis after incubation with low and high concentrations of <b>1</b> and <b>2</b> (L = half the IC<sub>50</sub> value; H = five-times the IC<sub>50</sub> value, respectively; <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). If client levels are unaffected upon incubation with low concentrations of the compound and decreased at high concentrations, then the compound is likely to inhibit Hsp90 function.</div><div class="NLM_p">Incubation with high concentrations of <b>1</b> led to decreased levels of the Hsp90-dependent clients EGFR, Her2, and C-Raf in both MCF7 and A549 cell lysates, when compared to those of the vehicle control (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Hsp90 levels at low and high concentrations of <b>1</b> were comparable to vehicle and indicative of Hsp90 C-terminal inhibition.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Furthermore, incubation with the N-terminal inhibitor, geldanamycin (GDA), led to decreased client levels at concentrations that increased cellular levels of Hsp90 (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf" class="ext-link">Supporting Information Figure S1</a>).<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47, 48)</a> These data suggest the mechanism of action manifested by compound <b>1</b> is inhibition of the Hsp90 C-terminus, as opposed to N-terminal inhibition.</div><div class="NLM_p">In contrast, client protein levels were unchanged after incubation with low and high concentrations of <b>2</b> against both MCF7 and A549 cells. Since no Hsp90-dependent client protein degradation was observed with compound <b>2</b>, the data suggests that this compound inhibits cancer cell growth unrelated to Hsp90 inhibition. The luciferase refolding activity was measured for compound <b>2</b> to confirm whether this compound has Hsp90 inhibitory activity. The data demonstrates that compound <b>2</b> does not inhibit the rematuration of firefly luciferase, similar to DMSO-treated cells (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). In contrast, the novobiocin analogue, KU-257, which inhibits Hsp90,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> was shown to inhibit luciferase rematuration (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). These results further confirm that compound <b>2</b> inhibits cancer cell growth unrelated to Hsp90 inhibition. Given the potent antiproliferative activity manifested by <b>2</b> against both cancer cell lines as well as the selective inhibition of cancer cell growth, the mechanism by which <b>2</b> manifests this anticancer activity was pursued.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Western blot for Hsp90 client proteins (EGFR, Her2, and Raf) and Hsp90 using lysates from MCF7 and A549 cells treated for 12 h with vehicle (0.25% DMSO) or a low concentration (L; half the IC<sub>50</sub> value) or high concentration (H; five-times the IC<sub>50</sub> value) of compound <b>1</b> or <b>2</b>. (B) Luciferase refolding activity of Hsp90 in PC3-MM2 cells with vehicle (DMSO), compounds <b>1</b> and <b>2</b>, and the positive control, KU-257. The concentrations used were 0–100 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since <b>2</b> exhibited potent antiproliferative activity against the nonsmall cell lung cancer cell line A549 and generated an IC<sub>50</sub> value of 0.15 ± 0.02 μM, subsequent studies were initiated with this cell line. The A549 cell line expresses wild-type B-Raf and C-Raf and mutant KRAS. Proliferation of the A549 cell line is driven by overactivation/expression of proteins involved in the Ras–Raf–MEK–ERK (MAPK) pathway; consequently, this cell line is commonly utilized to identify small molecule kinase inhibitors that target Raf, MEK, and/or ERK.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Interestingly, many inhibitors that target kinases involved in the MAPK pathway display structural similarities to compound <b>2</b> (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures and the overlay of compound <b>2</b> (green) with sorafenib (gray; a kinase inhibitor that targets B-Raf and C-Raf), TAK-632 (magenta; a kinase inhibitor that targets C-Raf and wild-type B-Raf), and vemurafenib (yellow; an inhibitor of mutant B-Raf).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the potent antiproliferative activity exhibited by <b>2</b> against the MAPK-driven A549 cancer cell line and the structural similarities between <b>2</b> and known disruptors of this pathway, it was hypothesized that <b>2</b> may inhibit A549 growth through disruption of MAPK signaling. Therefore, to determine whether <b>2</b> inhibits kinases within the MAPK pathway, western blots for phosphorylated proteins involved in the MAPK pathway were performed using A549 lysates treated with <b>2</b> at 750 nM (five-times the IC<sub>50</sub> value) for 2–12 h (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>A). Treatment with <b>2</b> led to a time-dependent decrease in phosphorylated MEK and ERK, suggesting that this compound inhibits kinase activity; however, decreased levels of phospho-MEK (p-MEK) and phospho-ERK (p-ERK) were observed at different incubation times. Decreased p-MEK levels occurred after 4 h of incubation with <b>2</b> and were undetectable after 12 h incubation. In contrast, decreased p-ERK levels were observed only after 6 h of incubation and continued to decrease during the 12 h incubation. These data indicate that <b>2</b> disrupts kinase activity upstream of MEK and ERK; <b>2</b> prevented phosphorylation of MEK, which subsequently prevented phosphorylation of ERK. The levels of other proteins crucial for MAPK signaling, such as EGFR and C-Raf, remained constant at each time point and were comparable to those of the vehicle control. C-Raf is an Hsp90 client and undergoes proteolytic degradation upon 12 h of incubation with Hsp90 inhibitors. After 12 h of incubation with <b>2</b>, C-Raf levels were similar to vehicle and remained constant at each time point, which demonstrates that compound <b>2</b> inhibits cancer cell growth by a mechanism unrelated to Hsp90 inhibition. Total MEK and ERK levels also remained constant at each time point and were comparable to vehicle, indicating that decreased p-MEK and p-ERK levels were not the result of decreased MEK and ERK levels. To determine whether <b>2</b> inhibits general kinase activity, western blots were generated for phosphorylated Akt (p-Akt) and total Akt levels using A549 cell lysates after 2–12 h of incubation. Akt is phosphorylated by phosphoinositide 3-kinase (PI3K), and p-Akt formation is unrelated to the MAPK pathway.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a><a href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf" class="ext-link">Supporting Information Figure S2</a> demonstrates that p-Akt and total Akt levels were unaffected at each time point, which suggests that <b>2</b> preferentially inhibits phosphorylation of MAPK pathway proteins.</div><div class="NLM_p"><a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B shows a concentration-dependent decrease in p-MEK and p-ERK after 12 h of incubation with <b>2</b>. A low concentration of <b>2</b> (L; half the IC<sub>50</sub> value, 70 nM) had little effect on cellular levels of p-MEK and p-ERK; however, incubation with a high concentration of <b>2</b> (five-times the IC<sub>50</sub> value, 750 nM) resulted in significantly lower levels of p-MEK and p-ERK, which is consistent with previous observations. Little effect was observed on the levels of other MAPK-associated proteins, as well as total MEK and ERK levels at either concentration.</div><div class="NLM_p">It is well-established that small molecule inhibition of the MAPK pathway activates multiple feed-back mechanisms that ultimately result in upregulated MAPK pathway activity.<a onclick="showRef(event, 'ref51 ref52 ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref51 ref52 ref53 ref54">(51-54)</a> In vitro, this occurs at short incubation times and can be observed up to 24 h after incubation with inhibitors of the MAPK pathway (via increased levels of p-MEK and p-ERK as well as increased transcription of MAPK proteins and proteins that support feed-back mechanisms). Western blot analysis of MAPK pathway proteins, p-MEK, and p-ERK from A549 cell lysates treated with high concentrations of <b>2</b> (750 nM) for 12 and 24 h was conducted (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>B). After 24 h of incubation, p-MEK and p-ERK levels were only slightly increased compared to those at 12 h of incubation; however, these levels remained lower than vehicle control, which could result from the upregulation of MAPK pathway activity via a feed-back mechanism or could be a consequence of compound <b>2</b> instability, which may produce metabolites that no longer interact with the cellular target(s).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Western blot for proteins of the MAPK pathway (EGFR, C-Raf, MEK, and ERK) and phosphorylated MEK and ERK (p-MEK and p-ERK) from lysates of A549 cells treated for 2–12 h with five-times the IC<sub>50</sub> value of <b>2</b> or vehicle (0.25% DMSO). (B) Western blot for proteins of the MAPK pathway and p-MEK and p-ERK from lysates of A549 cells treated for 12 or 24 h with five-times the IC<sub>50</sub> value of <b>2</b> or vehicle (0.25% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To determine whether re-establishment of detectable p-MEK and p-ERK levels after 24 h of incubation with <b>2</b> was the result of feed-back mechanism activation, western blots for Her3 and wild-type B-Raf levels were performed. Her3 and wild type B-Raf are expressed at relatively low levels in cancer cells under normal conditions. However, inhibition of MAPK pathway activity via small molecule EGFR, Raf, or MEK inhibitors induces Her3 and wild-type B-Raf overexpression to compensate for decreased p-MEK and p-ERK signaling. After 24 h of incubation with <b>2</b>, Her3 and wild-type B-Raf levels were comparable to those of the vehicle and indicated no activation of a feed-back mechanism (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Western blots for Her3 and wild-type B-Raf levels from A549 lysates treated with control compounds (sorafenib, vemurafenib, and TAK-632) for 12 and 24 h were also performed (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Sorafenib is a kinase inhibitor, and incubation with sorafenib at five-times the reported IC<sub>50</sub> value (14 μM) resulted in decreased p-MEK and p-ERK levels and a time-dependent increase in Her3 levels (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf" class="ext-link">Supporting Information Figure S3</a> and <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Vemurafenib and TAK-632 are Raf inhibitors. Vemurafenib is a mutant B-Raf inhibitor that is relatively inactive against the A549 cell line, which expresses only wild-type B-Raf. Incubation with a high concentration of vemurafenib (five-times the reported IC<sub>50</sub> value against the A549 cancer cell line, >50 μM) had little effect on Her3 and wild-type B-Raf levels as well as MAPK pathway signaling after 12 and 24 h (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf" class="ext-link">Supporting Information Figure S3</a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> TAK-632 is a kinase inhibitor that preferentially inhibits wild-type B-Raf and C-Raf and ultimately leads to decreased p-MEK and p-ERK levels (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf" class="ext-link">Supporting Information Figure S3</a>). Her3 and wild-type B-Raf levels remained unaffected after 12 and 24 h of incubation with TAK-632 at five-times the reported IC<sub>50</sub> value (8.5 μM), which is comparable to <b>2</b> (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> These data indicate that <b>2</b> prevents p-MEK and p-ERK formation via a mechanism similar to that of TAK-632, which targets wild-type B-Raf and C-Raf.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Western blot for the proteins Her3 and wild-type B-Raf from lysates of A549 cells treated for 12 or 24 h with five-times the IC<sub>50</sub> value of <b>2</b>, sorafenib, vemurafenib, or TAK-632 or with vehicle (0.25% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It has been previously reported that Raf inhibitor treatment leads to heterodimerization between wild type B-Raf and C-Raf, causing re-establishment of MAPK pathway signaling and cancer proliferation.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Therefore, a coimmunoprecipitation assay was performed to investigate whether compound <b>2</b> activates the MAPK pathway by heterodimer formation. The results provided in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a> demonstrate that <b>2</b> does not result in dimerization of wild type B-Raf and C-Raf.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Coimmunoprecipitation of B-Raf from lysates of A549 cells treated for 24 h with five-times the IC<sub>50</sub> value of <b>2</b> or sorafenib or with vehicle (0.25% DMSO). B-Raf immunoprecipitated C-Raf in sorafenib-treated cells but not <b>2</b>-treated cells. (B) Proposed mechanism of action for compound <b>2</b> and sorafenib. In wild-type B-Raf cells, a basal level of B-Raf–C-Raf dimerization occurs. In sorafenib-treated cells, B-Raf–C-Raf dimerization is prevalent, causing activation of the MAPK pathway and resulting in growth. In contrast, compound <b>2</b> prevents heterodimerization of B-Raf and C-Raf; consequently, the MAPK pathway is not activated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In lieu of the biaryl side chain, the incorporation of a phenyl ring onto the urea linker (<b>1</b>) results in Hsp90 inhibition as observed via client protein degradation (see <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), whereas replacement of the phenyl substituent with a bulky dimethoxy biaryl side chain leads to disruption of the MAPK pathway. Therefore, compounds <b>3</b>–<b>5</b>, which contain substitutions about the biaryl side chain, were synthesized to identify substitutions that distinguish Hsp90 inhibitory activity from MAPK pathway inhibition (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Compound <b>3</b> contains a biaryl side chain with no methoxy groups, whereas <b>4</b> and <b>5</b> each contain a single methoxy substitution on the biaryl side chain. IC<sub>50</sub> values for each compound were determined against the A549 cancer cell line as shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Each compound exhibited potent antiproliferative activity within the nanomolar concentration range.</div><figure id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Continued Synthesis of Novobiocin-Based Urea Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Values of Compounds <b>3</b>–<b>5</b> against the A549 Lung Cancer Cell Line</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">A549 cell line IC<sub>50</sub> values (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char="±">0.06 ± 0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">0.41 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char="±">0.28 ± 0.04</td></tr></tbody></table></div></div><div class="NLM_p">Western blot analyses for Hsp90 clients were performed using A549 cell lysates dosed for 12 and 24 h with high concentrations of each compound (five-times the IC<sub>50</sub> value) to identify Hsp90 inhibitors (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). After 24 h of incubation with <b>3</b>, decreased levels of Hsp90-dependent client proteins were observed, whereas constant levels of Hsp90 remained, suggesting that <b>3</b> is an Hsp90 C-terminal inhibitor. Single methoxy substitutions on the biaryl side chain (<b>4</b> and <b>5</b>) did not result in decreased client levels after 12 or 24 h of incubation, indicating no Hsp90 inhibition. Western blot analyses for MAPK pathway proteins and p-MEK and p-ERK levels were performed using the lysates from A549 cells dosed for 12 and 24 h with <b>4</b> and <b>5</b> and are shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>B. Twelve hours of incubation with <b>4</b> led to decreased p-MEK and p-ERK levels compared to those of the vehicle; however, in contrast to <b>2</b>, p-MEK and p-ERK levels were re-established after 24 h of incubation with <b>4</b> and <b>5</b>. p-ERK levels were also decreased after 12 h of incubation with <b>5</b>; however, 24 h of incubation resulted in p-ERK levels that were comparable to those of the vehicle. After 12 and 24 h of incubation with <b>5</b>, p-MEK levels were unchanged.</div><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Western blot for Hsp90 client proteins (EGFR, Her2, and C-Raf) and Hsp90 using lysates from A549 cells treated for 12 or 24 h with a high concentration (five-times the IC<sub>50</sub> value) of <b>3</b>–<b>5</b> or vehicle (0.25% DMSO). (B) Western blot for proteins of the MAPK pathway (EGFR, C-Raf, MEK, asd ERK) and phosphorylated MEK and ERK (p-MEK and p-ERK) from lysates of A549 cells treated for 12 or 24 h with five-times the IC<sub>50</sub> value of <b>4</b> or <b>5</b> or with vehicle (0.25% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">These data indicate that both methoxy substitutions on the biaryl side chain are important for prolonged MAPK pathway disruption. While monomethoxy substitutions inhibited p-MEK and/or p-ERK formation, neither substitution alone was able to sustain inhibitory activity to the extent of the dimethoxy-substituted side chain present in <b>2</b>.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74684" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74684" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, <b>2</b> was synthesized during SAR studies of novobiocin-based Hsp90 C-terminal inhibitors that contain urea surrogates of the amide linker. <b>1</b> was identified as an Hsp90 inhibitor via Hsp90-dependent client degradation; however, <b>2</b> failed to exhibit Hsp90 inhibitory activity. Upon further investigation, <b>2</b> was shown to disrupt MAPK pathway signaling by preventing p-MEK formation after 4 h of incubation, which ultimately disrupted p-ERK formation. Disruption of p-MEK and p-ERK formation was comparable to that with the control compound, TAK-632, a Raf inhibitor that preferentially inhibits wild type B-Raf and C-Raf; however, <b>2</b> exerted this activity at one-tenth the IC<sub>50</sub> value of TAK-632 (IC<sub>50</sub> value of 0.15 ± 0.02 μM versus 1.7 μM against the A549 lung cancer cell line). While individual methoxy substitutions on the biaryl side chain inhibit p-MEK and/or p-ERK formation, the dimethoxy-substituted biaryl side chain is required for sustained inhibition. Therefore, <b>2</b> represents a novel, novobiocin-based scaffold for the development of MAPK pathway inhibitors and appears to manifest a similar mechanism of action as that of TAK-632, targeting C-Raf and wild-type B-Raf.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11"> General Methods</h4><div class="NLM_p last"><sup>1</sup>H NMR were recorded at 400 or 500 MHz (Bruker DRX-400 Bruker with a H/C/P/F QNP gradient probe) spectrometer, and <sup>13</sup>C NMR spectra were recorded at 100 or 125 MHz (Bruker DRX 500 with broadband, inverse triple resonance, and high-resolution magic-angle spinning HR-MA probe spectrometer); chemical shifts are reported in δ (ppm) relative to the internal reference chloroform-<i>d</i> (CDCl<sub>3</sub>, 7.27 ppm) or dimethyl sulfoxide-<i>d</i><sub>6</sub> (DMSO-<i>d</i><sub>6</sub>, 2.50 ppm). High-resolution mass spectra (FAB) were recorded with a LCT Premier (Waters Corp., Milford, MA) spectrometer. The purity of all compounds was determined to be >95%, as determined by HPLC analysis. TLC was performed on glass-backed silica gel plates (Uniplate) with spots visualized by UV light. All solvents were reagent grade and, when necessary, were purified and dried by standard methods. Concentration of solvents occurred via the use of a rotary evaporator operating at reduced pressure.</div></div><div id="sec4_1_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i12" class="anchor-spacer"></div><h4 class="article-section__title" id="_i12"> General Procedure for the Synthesis of Urea Derivatives</h4><div id="sec4_1_1_1_0" class="NLM_sec NLM_sec_level_4"><div id="ac_i13" class="anchor-spacer"></div><h5 class="article-section__title" id="_i13"> 1-(8-Methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2<i>H</i>-chromen-3-yl)-3-phenylurea (<b>1</b>)</h5><div class="NLM_p last">Phenyl isocyanate (17 mg, 0.14 mmol) was added to a solution of amine <b>6</b><a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (20 mg, 0.07 mmol) in dichloromethane (2 mL), and the mixture was stirred at rt overnight. The resulting mixture was concentrated and purified via column chromatography (SiO<sub>2</sub>, 10:1 CH<sub>2</sub>Cl<sub>2</sub>/methanol) to afford <b>1</b> as a light brown amorphous solid (22 mg, 78%): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.75 (s, 1H, NH), 8.52 (s, 1H, NH), 8.42 (s, 1H), 7.54 (d, <i>J</i> = 7.7 Hz, 2H), 7.23–7.12 (m, 3H), 6.93 (t, <i>J</i> = 7.3 Hz, 1H), 6.80 (d, <i>J</i> = 8.8 Hz, 1H), 4.39 (m, 1H), 2.70–2.62 (m, 1H), 2.40–2.33 (m, 2H), 2.32 (s, 3H), 2.32 (s, 3H), 2.06–1.82 (m, 2H), 1.90–1.88 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 158.31, 155.48, 152.28, 148.17, 139.27, 128.93, 125.25, 122.61, 122.21, 120.39, 117.99, 113.45, 113.40, 110.96, 71.60, 51.58, 45.14, 29.77, 8.16. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> [M + H<sup>+</sup>] calcd for C<sub>23</sub>H<sub>26</sub>N<sub>3</sub>O<sub>4</sub>, 408.1923; found, 408.1919.</div></div><div id="sec4_1_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i14" class="anchor-spacer"></div><h5 class="article-section__title" id="_i14"> 1-(3′,6-Dimethoxy-[1,1′-biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2<i>H</i>-chromen-3-yl)urea (<b>2</b>)</h5><div class="NLM_p last">Compound <b>2</b> was obtained as a white amorphous solid (15 mg, 82%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub> + CH<sub>3</sub>OH) δ 8.26 (s, 1H), 7.33–7.29 (m, 2H), 7.19–7.14 (m, 2H), 6.97–6.95 (m, 2H), 6.82 (d, <i>J</i> = 8.8 Hz, 1H), 6.74 (d, <i>J</i> = 8.1 Hz, 2H), 4.39 (m, 1H), 3.70 (s, 3H), 3.65 (s, 3H), 2.60 (m, 2H), 2.40 (m, 2H), 2.25 (s, 3H), 2.17 (s, 3H), 1.91 (m, 2H), 1.81 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CH<sub>3</sub>OH) δ 159.62, 159.02, 155.78, 153.52, 152.56, 148.66, 139.45, 131.64, 130.85, 128.82, 124.95, 122.57, 122.49, 121.91, 121.75, 120.06, 115.08, 114.68, 113.90, 112.45, 111.94, 110.44, 55.79, 55.04, 51.66, 45.41, 29.78, 7.97. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> [M + H<sup>+</sup>] calcd for C<sub>31</sub>H<sub>34</sub>N<sub>3</sub>O<sub>6</sub>, 544.2448; found, 544.2443.</div></div><div id="sec4_1_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15"> 1-([1,1′-Biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2<i>H</i>-chromen-3-yl)urea (<b>3</b>)</h5><div class="NLM_p last">Compound <b>3</b> was obtained as a brown amorphous solid (27 mg, 76%): <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.60 (s, 1H, NH), 8.73 (s, 1H, NH), 8.44 (s, 1H), 7.88 (s, 1H), 7.65–7.61 (dd, <i>J</i> = 8.3, 1.1 Hz, 2H), 7.52–7.47 (m, 2H), 7.42–7.37 (m, 2H), 7.36–7.32 (m, 1H), 7.31–7.27 (dt, <i>J</i> = 7.6, 1.3 Hz, 1H), 7.11–7.06 (d, <i>J</i> = 8.9 Hz, 1H), 4.54 (m, 1H), 2.59 (m, 2H), 2.31 (m, 2H), 2.23 (s, 3H), 2.22 (s, 3H), 1.95 (m, 2H), 1.73 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 158.29, 155.55, 152.31, 148.14, 140.93, 140.19, 139.81, 129.48, 128.93, 127.54, 126.61, 125.21, 122.46, 120.62, 120.49, 117.04, 116.17, 113.35, 113.28, 110.93, 72.06, 51.83, 45.66, 30.23, 8.09. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> [M + H<sup>+</sup>] calcd for C<sub>29</sub>H<sub>30</sub>N<sub>3</sub>O<sub>4</sub>, 484.2236; found, 484.2232.</div></div><div id="sec4_1_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16"> 1-(6-Methoxy-[1,1′-biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2<i>H</i>-chromen-3-yl)urea (<b>4</b>)</h5><div class="NLM_p last">Compound <b>4</b> was obtained as a white amorphous solid (22 mg, 71%): <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 8.43 (s, broad, 2H, NH), 7.60 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 7.55–7.50 (m, 3H), 7.39 (t, <i>J</i> = 7.5 Hz, 2H), 7.35–7.31 (m, 1H), 7.25 (d, <i>J</i> = 8.6 Hz, 1H), 6.93 (d, <i>J</i> = 8.9 Hz, 1H), 6.83 (d, <i>J</i> = 8.8 Hz, 1H), 4.42 (m, 1H), 3.79 (s, 3H), 2.68 (m, 2H), 2.42 (m, 2H), 2.38 (s, 3H), 2.09 (s, 3H), 2.04 (m, 2H), 1.91 (m, 2H). <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub> + CH<sub>3</sub>OH) δ 159.65, 155.85, 153.56, 152.57, 148.66, 138.05, 131.68, 131.04, 129.29, 127.81, 126.87, 124.91, 122.60, 122.43, 121.77, 119.91, 114.68, 113.83, 111.90, 110.45, 71.37, 55.75, 51.76, 45.52, 29.90, 7.96. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> [M + H<sup>+</sup>] calcd for C<sub>30</sub>H<sub>32</sub>N<sub>3</sub>O<sub>5</sub>, 514.2342; found, 514.2339.</div></div><div id="sec4_1_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17"> 1-(3′-Methoxy-[1,1′-biphenyl]-3-yl)-3-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2<i>H</i>-chromen-3-yl)urea (<b>5</b>)</h5><div class="NLM_p last">Compound <b>5</b> was obtained as a brown amorphous solid (15 mg, 76%): <sup>1</sup>H NMR (500 MHz, DMSO) δ 9.59 (s, 1H, NH), 8.73 (s, 1H, NH), 8.44 (s, 1H), 7.84 (s, 1H), 7.52–7.49 (d, <i>J</i> = 8.6 Hz, 1H), 7.43–7.35 (m, 3H), 7.32–7.28 (dt, <i>J</i> = 7.0, 1.8 Hz, 1H), 7.22–7.18 (m, 1H), 7.16–7.13 (t, <i>J</i> = 2.1 Hz, 1H), 7.11–7.07 (d, <i>J</i> = 8.9 Hz, 1H), 6.99–6.94 (dd, <i>J</i> = 8.2, 2.5 Hz, 1H), 4.55 (m, 1H), 3.83 (s, 3H), 2.60 (m, 2H), 2.33 (m, 2H), 2.24 (s, 3H), 2.23 (s, 3H), 1.96–1.92 (m, 2H), 1.73–1.72 (m, 2H). <sup>13</sup>C NMR (126 MHz, DMSO) δ 159.66, 158.29, 155.54, 152.30, 148.15, 141.71, 140.80, 139.74, 130.00, 129.43, 125.23, 122.46, 120.73, 120.50, 118.95, 117.19, 116.27, 113.36, 113.29, 112.95, 112.24, 110.93, 71.99, 55.10, 51.80, 45.60, 30.17, 8.10. HRMS (ESI<sup>+</sup>) <i>m</i>/<i>z</i> [M + H<sup>+</sup>] calcd for C<sub>30</sub>H<sub>32</sub>N<sub>3</sub>O<sub>5</sub>, 514.2342; found, 514.2346.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Biology</h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Antibodies and Reagents</h4><div class="NLM_p last">Antibodies targeting Akt 1/2/3 and actin were purchased from Santa Cruz Biotechnology. The antibody targeting Hsp90 was purchased from Thermo Scientific (PA3-013). The following antibodies were purchased from Cell Signaling: EGF receptor, p44/42 MAPK, p-p44/42 MAPK, MEK1/2, p-MEK1/2, pAkt, B-Raf, C-Raf, Her3/ErbB3, and Her2/ErbB2. Geldanamycin was purchased from Sigma-Aldrich, and sorafinib, vemurafinib and TAK-632 were purchased from Selleckchem.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Cell Culture</h4><div class="NLM_p last">The media for each cell line was supplemented with streptomycin (500 μg/mL), penicillin (100 units/mL), and 10% FBS. MCF7 cells were maintained in advanced DMEM/F12 (1:1; Gibco) supplemented with <span class="smallcaps smallerCapital">l</span>-glutamine (2 mM). A549 cells were maintained in F12K (Cellgro). MRC-5 cells were maintained in DMEM (Cellgro). Cells were grown in a humidified atmosphere (37 °C, 5% CO<sub>2</sub>) and passaged when confluent.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Antiproliferation</h4><div class="NLM_p last">Cells were grown to confluence, seeded (2000 cells/well, 100 μL total media) in clear, flat-bottomed 96-well plates, and allowed to attach overnight. Compound at varying concentrations in DMSO (1% DMSO final concentration) was added. Cells were returned to the incubator for an additional 72 h. After 72 h, cell growth was determined using an MTS/PMS cell proliferation kit (Promega) per the manufacturer’s instructions. Cells incubated in 1% DMSO were used as 100% proliferation (i.e., DMSO = 100% growth), and the relative growth for each compound concentration was compared to that with 1% DMSO. IC<sub>50</sub> values were calculated from two separate experiments performed in triplicate using GraphPad Prism 6.0.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> Western Blot</h4><div class="NLM_p last">Cells were grown to confluence and seeded at 0.4 × 10<sup>6</sup> cells/well/2 mL. Cells were incubated for 24 h and treated with compound in DMSO (0.25% DMSO final concentration) or vehicle (DMSO) for the indicated amount of time. Cells were harvested in cold PBS and lysed using MPER (Thermo Scientific) supplemented with protease and phosphatase inhibitors (Roche) according to the manufacturer’s directions. Lysates were clarified at 14 000<i>g</i> for 15 min at 4 °C. Protein concentrations were determined using the Pierce BCA protein assay kit per the manufacturer’s instructions. Equal amounts of protein (15 μg) were electrophoresed under reducing conditions (10% acrylamide gels), transferred to PVDF, and immunoblotted with the corresponding antibody. Membranes were incubated with an appropriate horseradish peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and visualized.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> Coimmunoprecipitation</h4><div class="NLM_p last">A549 cell lines were plated in 10 cm cell culture dishes or T25 flasks and allowed to grow to ∼80% confluence. A549 cell lines were received DMSO (0.1%) (vehicle) or the indicated drugs dissolved in DMSO at the indicated concentrations for 24 h. After drug treatments, A549 cell lines were harvested in lysis buffer containing 0.1% NP-40, 50 mM Tris (pH 7.5), 150 mM NaCl, and protease and phosphatase inhibitor cocktails (Roche). Lysates were clarified, and protein concentration was determined using the BCA assay. For coimmunoprecipitation, 500 μg of total protein was diluted to 500 μL total volume in lysis buffer and incubated with 10 μL of primary antibody overnight at 4 °C with rocking. Immune complexes were captured with 30 μL of DynaBeads Protein G (Invitrogen) for 3 h with rocking at 4 °C. Protein G bead complexes were washed three times with lysis buffer and eluted with sample buffer. Samples were then boiled and subjected to SDS-PAGE and western blot analysis.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> Luciferase Refolding Assay</h4><div class="NLM_p last">Compound at varying concentrations in DMSO (1% DMSO final concentration) was added to wells of a white, round-bottomed 96-well plate containing 50 μL of DMEM media. Luciferase-expressing PC3-MM2 cells were grown to confluence, collected, and incubated for 8–12 min at 50 °C in prewarmed DMEM media until bioluminescence of luciferase was reduced to 1% of the initial counts. Cells were added (60 000 cells/50 μL) to wells (final concentration of 60 000 cells/100 μL), and the plate was returned to the incubator for 1 h. After 1 h, 100 μL of luciferase substrate reagent (75 mM tricine at pH 7.8, 24 mM MgSO<sub>4</sub>, 0.3 mM EDTA, 2 mM DTT, 0.313 <span class="smallcaps smallerCapital">d</span>-luciferin, 0.64 mM coenzyme A, 0.66 mM ATP, 150 mM KCl, 10% Triton-X, 20% glycerol, and 3.5% DMSO) was added to wells, and the bioluminescence was immediately read (0.5 s integration time). Cells that were incubated in 1% DMSO were used as 100% bioluminescence (i.e., DMSO = 100% refolding), and the relative refolding for each compound concentration was compared to that in 1% DMSO. The concentrations for each compound were measured in triplicate, and dose–response curves were generated using GraphPad Prism 5.0.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01354">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62645" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62645" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01354" class="ext-link">10.1021/acs.jmedchem.5b01354</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">A549 cell lysate western blot experiments and NMR and HPLC data (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf">jm5b01354_si_001.pdf (3.2 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01354" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08077" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08077" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian S. J. Blagg</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, The
University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1d7f7f717c7a7a5d766833787968"><span class="__cf_email__" data-cfemail="81e3e3ede0e6e6c1eaf4afe4e5f4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jessica A. Hall</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, The
University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sahithi Seedarala</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, The
University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huiping Zhao</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, The
University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gaurav Garg</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, The
University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suman Ghosh</span> - <span class="hlFld-Affiliation affiliation">Department of Medicinal Chemistry, The
University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d45e1446-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31120" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31120" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by NIH grants CA120458 and CA167079. We would like to thank Dr. Daniel L. Flynn for his insights and assistance throughout this project.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14622" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14622" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 57 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Bagatell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine-Murrieta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitesell, L.</span><span> </span><span class="NLM_article-title">Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs A Ligand-independent Approach to Hormonal Therapy of Breast Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2076</span><span class="NLM_x">–</span> <span class="NLM_lpage">2084</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=11448926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlslalu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=2076-2084&author=R.+Bagatellauthor=O.+Khanauthor=G.+Paine-Murrietaauthor=C.+W.+Taylorauthor=S.+Akinagaauthor=L.+Whitesell&title=Destabilization+of+Steroid+Receptors+by+Heat+Shock+Protein+90-binding+Drugs+A+Ligand-independent+Approach+to+Hormonal+Therapy+of+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer</span></div><div class="casAuthors">Bagatell, Rochelle; Khan, Omar; Paine-Murrieta, Gillian; Taylor, Charles W.; Akinaga, Shiro; Whitesell, Luke</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2076-2084</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Steroid hormone receptors have become an important target in the management of breast cancers.  Despite a good initial response rate, however, most tumors become refractory to current hormonal therapies within a year of starting treatment.  To address this problem, we evaluated the effects of agents that bind the mol. chaperone heat shock protein 90 (Hsp90) on estrogen receptor function in breast cancer.  Unstimulated estrogen and progesterone receptors exist as multimol. complexes consisting of the hormone-binding protein itself and several essential mol. chaperones including Hsp90.  We found that interaction of the Hsp90-binding drugs geldanamycin and radicicol with the chaperone destabilizes these hormone receptors in a ligand-independent manner, leading to profound and prolonged depletion of their levels in breast cancer cells cultured in vitro.  Consistent with these findings, in vivo administration of the geldanamycin deriv. 17-allylaminogeldanamycin (17AAG; NSC330507) to estrogen-supplemented, tumor-bearing SCID mice resulted in marked depletion of progesterone receptor levels in both uterus and tumor.  Drug administration also delayed the growth of established, hormone-responsive MCF-7 and T47D human tumor xenografts for up to 3 wk after the initiation of therapy.  We conclude that in light of their novel mechanism of antihormone action, consideration should be given to examg. the activity of 17AAG and other Hsp90-binding agents in patients with refractory breast cancer in future clin. trials, either alone or in combination with conventional hormone antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-zaiC8aLBu7Vg90H21EOLACvtfcHk0lg81XHcNpV2HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlslalu7g%253D&md5=a74f8b6d9319e1da4b9feb74e0d2173c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBagatell%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DO.%26aulast%3DPaine-Murrieta%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DC.%2BW.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DWhitesell%26aufirst%3DL.%26atitle%3DDestabilization%2520of%2520Steroid%2520Receptors%2520by%2520Heat%2520Shock%2520Protein%252090-binding%2520Drugs%2520A%2520Ligand-independent%2520Approach%2520to%2520Hormonal%2520Therapy%2520of%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D2076%26epage%3D2084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Connell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinger, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohfeld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, C.</span><span> </span><span class="NLM_article-title">The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1038/35050618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2F35050618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=11146632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=93-96&author=P.+Connellauthor=C.+A.+Ballingerauthor=J.+Jiangauthor=Y.+Wuauthor=L.+J.+Thompsonauthor=J.+Hohfeldauthor=C.+Patterson&title=The+co-chaperone+CHIP+regulates+protein+triage+decisions+mediated+by+heat-shock+proteins&doi=10.1038%2F35050618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins</span></div><div class="casAuthors">Connell, Patrice; Ballinger, Carol A.; Jiang, Jihong; Wu, Yaxu; Thompson, Larry J.; Hohfeld, Jorg; Patterson, Cam</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-96</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To maintain quality control in cells, mechanisms distinguish among improperly folded peptides, mature and functional proteins, and proteins to be targeted for degrdn.  The mol. chaperones, including heat-shock protein Hsp90, have the ability to recognize misfolded proteins and assist in their conversion to a functional conformation.  Disruption of Hsp90 heterocomplexes by the Hsp90 inhibitor geldanamycin leads to substrate degrdn. through the ubiquitin-proteasome pathway, implicating this system in protein triage decisions.  We previously identified CHIP (carboxyl terminus of Hsc70-interacting protein) to be an interaction partner of Hsc70 (ref. 4).  CHIP also interacts directly with a tetratricopeptide repeat acceptor site of Hsp90, incorporating into Hsp90 heterocomplexes and eliciting release of the regulatory cofactor p23.  Here we show that CHIP abolishes the steroid-binding activity and transactivation potential of the glucocorticoid receptor, a well-characterized Hsp90 substrate, even though it has little effect on its synthesis.  Instead, CHIP induces ubiquitination of the glucocorticoid receptor and degrdn. through the proteasome.  By remodelling Hsp90 heterocomplexes to favor substrate degrdn., CHIP modulates protein triage decisions that regulate the balance between protein folding and degrdn. for chaperone substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLcICHJwNISLVg90H21EOLACvtfcHk0lg81XHcNpV2HQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslGqsQ%253D%253D&md5=575a74b738bee74e5e5d4d9a27bc6a04</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F35050618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35050618%26sid%3Dliteratum%253Aachs%26aulast%3DConnell%26aufirst%3DP.%26aulast%3DBallinger%26aufirst%3DC.%2BA.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DThompson%26aufirst%3DL.%2BJ.%26aulast%3DHohfeld%26aufirst%3DJ.%26aulast%3DPatterson%26aufirst%3DC.%26atitle%3DThe%2520co-chaperone%2520CHIP%2520regulates%2520protein%2520triage%2520decisions%2520mediated%2520by%2520heat-shock%2520proteins%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D93%26epage%3D96%26doi%3D10.1038%2F35050618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kundrat, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, L.</span><span> </span><span class="NLM_article-title">Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7428</span><span class="NLM_x">–</span> <span class="NLM_lpage">7438</span><span class="refDoi"> DOI: 10.1021/bi100386w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100386w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=7428-7438&author=L.+Kundratauthor=L.+Regan&title=Balance+between+folding+and+degradation+for+Hsp90-dependent+client+proteins%3A+a+key+role+for+CHIP&doi=10.1021%2Fbi100386w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fbi100386w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100386w%26sid%3Dliteratum%253Aachs%26aulast%3DKundrat%26aufirst%3DL.%26aulast%3DRegan%26aufirst%3DL.%26atitle%3DBalance%2520between%2520folding%2520and%2520degradation%2520for%2520Hsp90-dependent%2520client%2520proteins%253A%2520a%2520key%2520role%2520for%2520CHIP%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D7428%26epage%3D7438%26doi%3D10.1021%2Fbi100386w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Murata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span> </span><span class="NLM_article-title">CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1138</span><span class="refDoi"> DOI: 10.1093/embo-reports/kve246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1093%2Fembo-reports%2Fkve246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=11743028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1Ciug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=1133-1138&author=S.+Murataauthor=Y.+Minamiauthor=M.+Minamiauthor=T.+Chibaauthor=K.+Tanaka&title=CHIP+is+a+chaperone-dependent+E3+ligase+that+ubiquitylates+unfolded+protein&doi=10.1093%2Fembo-reports%2Fkve246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein</span></div><div class="casAuthors">Murata, Shigeo; Minami, Yasufumi; Minami, Michiko; Chiba, Tomoki; Tanaka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1138</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system catalyzes the immediate destruction of misfolded or impaired proteins generated in cells, but how this proteolytic machinery recognizes abnormality of cellular proteins for selective elimination remains elusive.  Here, we report that the C-terminus of Hsc70-interacting protein (CHIP) with a U-box domain is an E3 ubiquitin-ligase collaborating with mol. chaperones Hsp90 and Hsc70.  Thermally denatured firefly luciferase was multiubiquitylated by CHIP in the presence of E1 and E2 (Ubc4 or UbcH5c) in vitro, only when the unfolded substrate was captured by Hsp90 or Hsc70 and Hsp40.  No ubiquitylating activity was detected in CHIP lacking the U-box region.  CHIP efficiently ubiquitylated denatured luciferase trapped by the C-terminal region of Hsp90, which contains a CHIP binding site.  CHIP also showed self-ubiquitylating activity independent of target ubiquitylation.  Our results indicate that CHIP can be regarded as "a quality-control E3" that selectively ubiquitylates unfolded protein(s) by collaborating with mol. chaperones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRqke0yhJ4NbVg90H21EOLACvtfcHk0ljb-RGB_t69MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1Ciug%253D%253D&md5=06a57e11ed0a550cf5a2392dd58b94f2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fembo-reports%2Fkve246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fembo-reports%252Fkve246%26sid%3Dliteratum%253Aachs%26aulast%3DMurata%26aufirst%3DS.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DMinami%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DCHIP%2520is%2520a%2520chaperone-dependent%2520E3%2520ligase%2520that%2520ubiquitylates%2520unfolded%2520protein%26jtitle%3DEMBO%2520Rep.%26date%3D2001%26volume%3D2%26spage%3D1133%26epage%3D1138%26doi%3D10.1093%2Fembo-reports%2Fkve246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mimnaugh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">12847</span><span class="NLM_x">–</span> <span class="NLM_lpage">12852</span><span class="refDoi"> DOI: 10.1073/pnas.202365899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1073%2Fpnas.202365899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=12847-12852&author=W.+Xuauthor=M.+Marcuauthor=X.+Yuanauthor=E.+Mimnaughauthor=C.+Pattersonauthor=L.+Neckers&title=Chaperone-dependent+E3+ubiquitin+ligase+CHIP+mediates+a+degradative+pathway+for+c-ErbB2%2FNeu&doi=10.1073%2Fpnas.202365899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.202365899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.202365899%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%26aulast%3DMarcu%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DMimnaugh%26aufirst%3DE.%26aulast%3DPatterson%26aufirst%3DC.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DChaperone-dependent%2520E3%2520ubiquitin%2520ligase%2520CHIP%2520mediates%2520a%2520degradative%2520pathway%2520for%2520c-ErbB2%252FNeu%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D12847%26epage%3D12852%26doi%3D10.1073%2Fpnas.202365899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Water, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perret, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.-C.</span><span> </span><span class="NLM_article-title">Heat Shock Protein 90: Inhibitors in Clinical Trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span><span class="refDoi"> DOI: 10.1021/jm9004708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3-17&author=M.+A.+Biamonteauthor=R.+Van+de+Waterauthor=J.+W.+Arndtauthor=R.+H.+Scannevinauthor=D.+Perretauthor=W.-C.+Lee&title=Heat+Shock+Protein+90%3A+Inhibitors+in+Clinical+Trials&doi=10.1021%2Fjm9004708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90: Inhibitors in Clinical Trials</span></div><div class="casAuthors">Biamonte, Marco A.; Van de Water, Ryan; Arndt, Joseph W.; Scannevin, Robert H.; Perret, Daniel; Lee, Wen-Cherng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HSP90 is the 90 kDa member of the family and exists as two isoforms: HSP90 is an inducible form overexpressed in cancer cells, while HSP90 is the constitutive form.  Since inhibition of HSP90 can lead to the degrdn. of a large no. of oncogenic proteins, HSP90 has become a target of interest for oncol.  A major advantage of HSP90 inhibitors is that they simultaneously attack several pathways necessary for cancer development, reducing the likelihood of the tumor acquiring resistance to any single therapeutic pathway.  It has also been proposed that HSP90 occurs in an activated form in cancer cells, whereas in normal somatic cells only the latent form is found.  This has given rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the activated form and thus more specifically target cancer cells, but this assertion has been challenged.  Cancer cells seem to have a higher HSP90 activity than normal cells, and oncogenes are more dependent on HSP90 than house-keeping proteins.  In cell cultures, HSP90 inhibitors kill tumor cells at concns. much lower than those required to kill normal cells.  In mice, efficacy can be obsd. at nontoxic doses, and in humans, the first signs of clin. benefit are emerging.  It remains to be verified, however, if HSP90 inhibitors will truly provide a sufficient safety margin in the clinic.  Nononcol. indications may also emerge; besides cancer, the prevalent conditions mentioned in the literature with respect to HSP90 are Parkinson's disease, Alzheimer's disease, and fungal infections.  For the time being, however, the focus is oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYseMVVt55b7Vg90H21EOLACvtfcHk0ljb-RGB_t69MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ&md5=14eee1036fc22e45da13b49cc93ed845</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm9004708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004708%26sid%3Dliteratum%253Aachs%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DR.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.-C.%26atitle%3DHeat%2520Shock%2520Protein%252090%253A%2520Inhibitors%2520in%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3%26epage%3D17%26doi%3D10.1021%2Fjm9004708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Brandt, G. E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1447</span><span class="NLM_x">–</span> <span class="NLM_lpage">1461</span><span class="refDoi"> DOI: 10.2174/156802609789895683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F156802609789895683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=19860731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFakurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1447-1461&author=G.+E.+L.+Brandtauthor=B.+S.+J.+Blagg&title=Alternate+strategies+of+Hsp90+modulation+for+the+treatment+of+cancer+and+other+diseases&doi=10.2174%2F156802609789895683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases</span></div><div class="casAuthors">Brandt, Gary E. L.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1447-1461</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The 90 kDa heat shock protein (Hsp90) has become a validated target for the development of anti-cancer agents.  Several Hsp90 inhibitors are currently under clin. trial investigation for the treatment of cancer.  All of these agents inhibit Hsp90's protein folding activity by binding to the N-terminal ATP binding site of the Hsp90 mol. chaperone.  Administration of these investigational drugs elicits induction of the heat shock response, or the overexpression of several Hsps, which exhibit antiapoptotic and pro-survival effects that may complicate the application of these inhibitors.  To circumvent this issue, alternate mechanisms for Hsp90 inhibition that do not elicit the heat shock response have been identified and pursued.  After providing background on the structure, function, and mechanism of the Hsp90 protein folding machinery, this review describes several mechanisms of Hsp90 modulation via small mols. that do not induce the heat shock response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoam5PRtPpdGbVg90H21EOLACvtfcHk0ljAKVjiiok4gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFakurk%253D&md5=5e6bd3443f775532f23e7de42b2dce87</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F156802609789895683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789895683%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DG.%2BE.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DAlternate%2520strategies%2520of%2520Hsp90%2520modulation%2520for%2520the%2520treatment%2520of%2520cancer%2520and%2520other%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1447%26epage%3D1461%26doi%3D10.2174%2F156802609789895683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Csermely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnaider, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So'ti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prohászka, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardai, G.</span><span> </span><span class="NLM_article-title">The 90-kDa Molecular Chaperone Family: Structure, Function, and Clinical Applications. A Comprehensive Review</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span><span class="refDoi"> DOI: 10.1016/S0163-7258(98)00013-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2FS0163-7258%2898%2900013-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=9749880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADyaK1cXltVOktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1998&pages=129-168&author=P.+Csermelyauthor=T.+Schnaiderauthor=C.+So%27tiauthor=Z.+Proh%C3%A1szkaauthor=G.+Nardai&title=The+90-kDa+Molecular+Chaperone+Family%3A+Structure%2C+Function%2C+and+Clinical+Applications.+A+Comprehensive+Review&doi=10.1016%2FS0163-7258%2898%2900013-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review</span></div><div class="casAuthors">Csermely, Peter; Schnaider, Tamas; Soti, Csaba; Prohaszka, Zoltan; Nardai, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-168</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 515 refs.  The 90-kDa mol. chaperone family (which comprises, among other proteins, the 90-kDa heat-shock protein, hsp90 and the 94-kDa glucose-regulated protein, grp94, major mol. chaperones of the cytosol and of the endoplasmic reticulum, resp.) has become an increasingly active subject of research in the past couple of years.  These ubiquitous, well-conserved proteins account for 1-2% of all cellular proteins in most cells.  However, their precise function is still far from being elucidated.  Their involvement in the etiol. of several autoimmune diseases, in various infections, in recognition of malignant cells, and in antigen-presentation already demonstrates the essential role they likely will play in clin. practice of the next decade.  The present review summarizes our current knowledge about the cellular functions, expression, and clin. implications of the 90-kDa mol. chaperone family and some approaches for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEoCjt7EH4AbVg90H21EOLACvtfcHk0ljAKVjiiok4gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltVOktrc%253D&md5=63030ad5f3d3f9de5c598caab57afe69</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900013-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900013-8%26sid%3Dliteratum%253Aachs%26aulast%3DCsermely%26aufirst%3DP.%26aulast%3DSchnaider%26aufirst%3DT.%26aulast%3DSo%2527ti%26aufirst%3DC.%26aulast%3DProh%25C3%25A1szka%26aufirst%3DZ.%26aulast%3DNardai%26aufirst%3DG.%26atitle%3DThe%252090-kDa%2520Molecular%2520Chaperone%2520Family%253A%2520Structure%252C%2520Function%252C%2520and%2520Clinical%2520Applications.%2520A%2520Comprehensive%2520Review%26jtitle%3DPharmacol.%2520Ther.%26date%3D1998%26volume%3D79%26spage%3D129%26epage%3D168%26doi%3D10.1016%2FS0163-7258%2898%2900013-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Garcia-Carbonero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Inhibition of HSP90 molecular chaperones: moving into the clinic</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">e358</span><span class="NLM_x">–</span> <span class="NLM_lpage">e369</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70169-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2FS1470-2045%2813%2970169-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=23896275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=e358-e369&author=R.+Garcia-Carboneroauthor=A.+Carneroauthor=L.+Paz-Ares&title=Inhibition+of+HSP90+molecular+chaperones%3A+moving+into+the+clinic&doi=10.1016%2FS1470-2045%2813%2970169-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 molecular chaperones: moving into the clinic</span></div><div class="casAuthors">Garcia-Carbonero, Rocio; Carnero, Amancio; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e358-e369</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (HSP90) is a mol. chaperone that is crucial for the stability and function of many proteins essential for cell survival.  Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90.  Inhibition of HSP90 causes client protein degrdn. via the ubiquitin-proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumor development.  HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumors (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematol. malignancies (eg, multiple myeloma).  Here, we review the current status of HSP90 inhibitors in clin. development, including geldanamycin derivs., resorcinol derivs., purine analogs, and other synthetic inhibitors.  We also discuss novel strategies and future perspectives on how to optimize the therapeutic potential of this exciting new class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulM7j4PFcx7Vg90H21EOLACvtfcHk0ljAKVjiiok4gw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI&md5=4821e86073624fb17d7343105d6e82cd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970169-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970169-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Carbonero%26aufirst%3DR.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520HSP90%2520molecular%2520chaperones%253A%2520moving%2520into%2520the%2520clinic%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3De358%26epage%3De369%26doi%3D10.1016%2FS1470-2045%2813%2970169-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Goetz, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span> </span><span class="NLM_article-title">The Hsp90 chaperone complex as a novel target for cancer therapy</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1169</span><span class="NLM_x">–</span> <span class="NLM_lpage">1176</span><span class="refDoi"> DOI: 10.1093/annonc/mdg316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1093%2Fannonc%2Fmdg316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=12881371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A280%3ADC%252BD3szkvVaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=1169-1176&author=M.+P.+Goetzauthor=D.+O.+Toftauthor=M.+M.+Amesauthor=C.+Erlichman&title=The+Hsp90+chaperone+complex+as+a+novel+target+for+cancer+therapy&doi=10.1093%2Fannonc%2Fmdg316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Hsp90 chaperone complex as a novel target for cancer therapy</span></div><div class="casAuthors">Goetz M P; Toft D O; Ames M M; Erlichman C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1169-76</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  Heat shock protein 90 (Hsp90) is responsible for chaperoning proteins involved in cell signaling, proliferation and survival. 17-allylamino-17-demethoxygeldanamycin (17-AAG) is an anticancer agent currently in phase I trials in the USA and UK.  It represents a class of drugs, the benzoquinone ansamycin antibiotics, capable of binding and disrupting the function of Hsp90, leading to the depletion of multiple oncogenic client proteins.  MATERIALS AND METHODS:  Studies were identified through a PubMed search, review of bibliographies of relevant articles and review of abstracts from national meetings.  RESULTS:  Preclinical studies have demonstrated that disruption of many client proteins chaperoned by Hsp90 is achievable and associated with significant growth inhibition, both in vitro and in tumor xenografts.  Following an overview of the mechanism of action of ansamycin antibiotics and the pathways they disrupt, we review the current clinical status of 17-AAG, and discuss future directions for combinations of traditional antineoplastics with 17-AAG.  CONCLUSIONS:  17-AAG represents a class of drugs capable of affecting multiple targets in the signal transduction pathway involved in tumor cell proliferation and survival.  Early results from phase I studies indicate that 17-AAG administration results in an acceptable toxicity profile while achieving in vivo disruption of client proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwp3u3lGv0RBWfpMXQLRstfW6udTcc2eZsBxl5BeINhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3szkvVaktA%253D%253D&md5=97213fab19fed8466e0217c9b0e88dc8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdg316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdg316%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DM.%2BP.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DErlichman%26aufirst%3DC.%26atitle%3DThe%2520Hsp90%2520chaperone%2520complex%2520as%2520a%2520novel%2520target%2520for%2520cancer%2520therapy%26jtitle%3DAnn.%2520Oncol.%26date%3D2003%26volume%3D14%26spage%3D1169%26epage%3D1176%26doi%3D10.1093%2Fannonc%2Fmdg316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Holzbeierlein, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsperger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span> </span><span class="NLM_article-title">Hsp90: a drug target? Curr</span> <span class="citation_source-journal">Curr. Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1007/s11912-010-0086-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1007%2Fs11912-010-0086-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20425593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=95-101&author=J.+M.+Holzbeierleinauthor=A.+Windspergerauthor=G.+Vielhauer&title=Hsp90%3A+a+drug+target%3F+Curr&doi=10.1007%2Fs11912-010-0086-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90: a drug target?</span></div><div class="casAuthors">Holzbeierlein, Jeffrey M.; Windsperger, Andrew; Vielhauer, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Oncology Reports</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-101</span>CODEN:
                <span class="NLM_cas:coden">CORUAT</span>;
        ISSN:<span class="NLM_cas:issn">1534-6269</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (Hsp90) is a mol. chaperone involved in the trafficking of proteins in the cell.  Under stressful conditions, Hsp90 stabilizes its client proteins and provides protection to the cell against cellular stressors such as in cancer cells.  Disruption of Hsp90 leads to client protein degrdn. and often cell death.  As Hsp90 has been found to be either overexpressed or constitutively more active in cancer cells, inhibitors of Hsp90 may have cancer cell selectivity.  The N-terminal inhibitors, geldanamycin and radiciol, were the first two described inhibitors of Hsp90, but were not clin. useful.  Subsequent analogs-17 allylamino-17demethoxygeldanamycin and 17 dimethylaminoethylamino-17-demethoxygeldanamycin-were found to be more clin. appropriate and have been studied in a no. of clin. trials since 1999.  In addn., to the N-terminal site of Hsp90, the C-terminal site appears to be another target for inhibition of Hsp90.  More recently, inhibitors of the C terminus of Hsp90 have been developed and studied in vitro with promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqR8ds07kZc7Vg90H21EOLACvtfcHk0lhM-RZJj8nteA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsb%252FO&md5=a81b2ea571f42173863c0435831e42e4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs11912-010-0086-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-010-0086-3%26sid%3Dliteratum%253Aachs%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DWindsperger%26aufirst%3DA.%26aulast%3DVielhauer%26aufirst%3DG.%26atitle%3DHsp90%253A%2520a%2520drug%2520target%253F%2520Curr%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2010%26volume%3D12%26spage%3D95%26epage%3D101%26doi%3D10.1007%2Fs11912-010-0086-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Jego, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazoumé, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigneuric, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, C.</span><span> </span><span class="NLM_article-title">Targeting heat shock proteins in cancer</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span><span class="refDoi"> DOI: 10.1016/j.canlet.2010.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.canlet.2010.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=21078542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVWitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2013&pages=275-285&author=G.+Jegoauthor=A.+Hazoum%C3%A9author=R.+Seigneuricauthor=C.+Garrido&title=Targeting+heat+shock+proteins+in+cancer&doi=10.1016%2Fj.canlet.2010.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting heat shock proteins in cancer</span></div><div class="casAuthors">Jego, Gaetan; Hazoume, Adonis; Seigneuric, Renaud; Garrido, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-285</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Heat shock proteins (HSPs) HSP27, HSP70 and HSP90 are powerful chaperones.  Their expression is induced in response to a wide variety of physiol. and environmental insults including anti-cancer chemotherapy, thus allowing the cell to survive to lethal conditions.  Different functions of HSPs have been described to account for their cytoprotective function, including their role as mol. chaperones as they play a central role in the correct folding of misfolded proteins, but also their anti-apoptotic properties.  HSPs are often overexpressed in cancer cells and this constitutive expression is necessary for cancer cells' survival.  HSPs may have oncogene-like functions and likewise mediate "non-oncogene addiction" of stressed tumor cells that must adapt to a hostile microenvironment, thereby becoming dependent for their survival on HSPs.  HSP-targeting drugs have therefore emerged as potential anti-cancer agents.  This review describes the different mols. and approaches being used or proposed in cancer therapy based on the in inhibition of HSP90, HSP70 and HSP27.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLEf_H0f1H3rVg90H21EOLACvtfcHk0lhM-RZJj8nteA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVWitLs%253D&md5=4e1dcc15387cbb33d4a2d18f5defdd16</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2010.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2010.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DJego%26aufirst%3DG.%26aulast%3DHazoum%25C3%25A9%26aufirst%3DA.%26aulast%3DSeigneuric%26aufirst%3DR.%26aulast%3DGarrido%26aufirst%3DC.%26atitle%3DTargeting%2520heat%2520shock%2520proteins%2520in%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D332%26spage%3D275%26epage%3D285%26doi%3D10.1016%2Fj.canlet.2010.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1823</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2011.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bbamcr.2011.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22062686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=742-755&author=K.+Jhaveriauthor=T.+Taldoneauthor=S.+Modiauthor=G.+Chiosis&title=Advances+in+the+clinical+development+of+heat+shock+protein+90+%28Hsp90%29+inhibitors+in+cancers&doi=10.1016%2Fj.bbamcr.2011.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span></div><div class="casAuthors">Jhaveri, Komal; Taldone, Tony; Modi, Shanu; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-755</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is an ATP dependent mol. chaperone protein which integrates multiple oncogenic pathways.  As such, Hsp90 inhibition is a promising anti-cancer strategy.  Several inhibitors that act on Hsp90 by binding to its N-terminal ATP pocket have entered clin. evaluation.  Robust pre-clin. data suggested anti-tumor activity in multiple cancer types.  Clin., encouraging results have been demonstrated in melanoma, acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple myeloma.  In breast cancer, proof-of-concept was demonstrated by first generation Hsp90 inhibitors in combination with trastuzumab mainly in human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer.  There are a multitude of second generation Hsp90 inhibitors currently under investigation.  To date, however, there is no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition.  This review summarizes the current status of both first and second generation Hsp90 inhibitors based on their chem. classification and stage of clin. development.  It also discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors.  Ultimately, these efforts will aid in maximizing the full potential of this class of agents.  This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrDTpRQxfYrVg90H21EOLACvtfcHk0lhM-RZJj8nteA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D&md5=03cef7dc96667a4698324f635aacee7a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2011.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2011.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAdvances%2520in%2520the%2520clinical%2520development%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%2520in%2520cancers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2012%26volume%3D1823%26spage%3D742%26epage%3D755%26doi%3D10.1016%2Fj.bbamcr.2011.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Hsp90 molecular chaperone inhibitors: are we there yet? Clin</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">64</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1158%2F1078-0432.CCR-11-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22215907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=64-76&author=L.+Neckersauthor=P.+Workman&title=Hsp90+molecular+chaperone+inhibitors%3A+are+we+there+yet%3F+Clin&doi=10.1158%2F1078-0432.CCR-11-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</span></div><div class="casAuthors">Neckers, Len; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-76</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein (Hsp) 90 is an ATP-dependent mol. chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-assocd. kinases and transcription factors, and it is essential for oncogenic transformation.  Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clin. trials.  Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity.  Preclin. data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clin. activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer.  Many optimized synthetic, small-mol. Hsp90 inhibitors from diverse chemotypes are now in clin. trials.  Here, we review the discovery and development of Hsp90 inhibitors and assess their potential.  There has been significant learning from studies of the basic biol. of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chem. probes.  Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (esp. multiple myeloma) in which buffering of proteotoxic stress is crit. for survival.  We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.  Clin Cancer Res; 18(1); 64-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfICmNu1IWFbVg90H21EOLACvtfcHk0lg0OPcNz7IpDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D&md5=f67c3c11b5847e3866c91af2a16a63b8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1000%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DHsp90%2520molecular%2520chaperone%2520inhibitors%253A%2520are%2520we%2520there%2520yet%253F%2520Clin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D64%26epage%3D76%26doi%3D10.1158%2F1078-0432.CCR-11-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Patel, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span> </span><span class="NLM_article-title">Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1517/17460441.2011.563296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1517%2F17460441.2011.563296" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=559-587&author=H.+J.+Patelauthor=S.+Modiauthor=G.+Chiosisauthor=T.+Taldone&title=Advances+in+the+discovery+and+development+of+heat-shock+protein+90+inhibitors+for+cancer+treatment&doi=10.1517%2F17460441.2011.563296"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.563296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.563296%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DTaldone%26aufirst%3DT.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520and%2520development%2520of%2520heat-shock%2520protein%252090%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D559%26epage%3D587%26doi%3D10.1517%2F17460441.2011.563296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Prodromou, C.</span><span> </span><span class="NLM_article-title">Strategies for stalling malignancy: targeting cancer’s addiction to Hsp90</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1352</span><span class="NLM_x">–</span> <span class="NLM_lpage">1368</span><span class="refDoi"> DOI: 10.2174/156802609789895656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F156802609789895656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=19860736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFakurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1352-1368&author=C.+Prodromou&title=Strategies+for+stalling+malignancy%3A+targeting+cancer%E2%80%99s+addiction+to+Hsp90&doi=10.2174%2F156802609789895656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for stalling malignancy: targeting cancer's addiction to Hsp90</span></div><div class="casAuthors">Prodromou, Chrisostomos</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1352-1368</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is involved in the maturation and activation of client proteins.  Often these are key proteins involved in signal transduction and regulatory pathways that in a mutated and/or deregulated form sustain an oncogenic cellular state.  Consequently, the malignancy is maintained with the aid of Hsp90 upon which the mutated proteins have become particularly dependent for their activity.  The requirement for the Hsp90 chaperone machine to drive the malignancy makes Hsp90 a prime anticancer target, an 'axle in a wheel' that when disrupted has been shown to be effective in killing cancerous cells.  This review aims to identify potential drug targets, based on the current structural knowledge of the Hsp90-chaperone machine, that could be targeted with the aim of disrupting its functioning and promoting an anti-cancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwOal7ujNdSrVg90H21EOLACvtfcHk0lg0OPcNz7IpDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFakurw%253D&md5=6974085b3d0c1ad21e0931c512de5a51</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F156802609789895656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789895656%26sid%3Dliteratum%253Aachs%26aulast%3DProdromou%26aufirst%3DC.%26atitle%3DStrategies%2520for%2520stalling%2520malignancy%253A%2520targeting%2520cancer%25E2%2580%2599s%2520addiction%2520to%2520Hsp90%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1352%26epage%3D1368%26doi%3D10.2174%2F156802609789895656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Sidera, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patsavoudi, E.</span><span> </span><span class="NLM_article-title">HSP90 inhibitors: current development and potential in cancer therapy</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.2174/15748928113089990031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F15748928113089990031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=1-20&author=K.+Sideraauthor=E.+Patsavoudi&title=HSP90+inhibitors%3A+current+development+and+potential+in+cancer+therapy&doi=10.2174%2F15748928113089990031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F15748928113089990031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15748928113089990031%26sid%3Dliteratum%253Aachs%26aulast%3DSidera%26aufirst%3DK.%26aulast%3DPatsavoudi%26aufirst%3DE.%26atitle%3DHSP90%2520inhibitors%253A%2520current%2520development%2520and%2520potential%2520in%2520cancer%2520therapy%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2013%26volume%3D9%26spage%3D1%26epage%3D20%26doi%3D10.2174%2F15748928113089990031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Trepel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollapour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Targeting the dynamic HSP90 complex in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1038/nrc2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnrc2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20651736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=537-549&author=J.+Trepelauthor=M.+Mollapourauthor=G.+Giacconeauthor=L.+Neckers&title=Targeting+the+dynamic+HSP90+complex+in+cancer&doi=10.1038%2Fnrc2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dynamic HSP90 complex in cancer</span></div><div class="casAuthors">Trepel, Jane; Mollapour, Mehdi; Giaccone, Giuseppe; Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">537-549</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The mol. chaperone, heat-shock protein 90 (HSP90), has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90.  However, although recent reports of the early clin. efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGEqkx6m7p7Vg90H21EOLACvtfcHk0liLmMps8xwOoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D&md5=8acba020073ebb93cf1dee577420dc32</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrc2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2887%26sid%3Dliteratum%253Aachs%26aulast%3DTrepel%26aufirst%3DJ.%26aulast%3DMollapour%26aufirst%3DM.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520dynamic%2520HSP90%2520complex%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D537%26epage%3D549%26doi%3D10.1038%2Fnrc2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, N. U.</span><span> </span><span class="NLM_article-title">HSP90 as a platform for the assembly of more effective cancer chemotherapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1823</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2011.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bbamcr.2011.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22222203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtV2qs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=756-766&author=L.+Whitesellauthor=N.+U.+Lin&title=HSP90+as+a+platform+for+the+assembly+of+more+effective+cancer+chemotherapy&doi=10.1016%2Fj.bbamcr.2011.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 as a platform for the assembly of more effective cancer chemotherapy</span></div><div class="casAuthors">Whitesell, Luke; Lin, Nancy U.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">756-766</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since initial discovery of the first HSP90 inhibitor over a decade and a half ago, tremendous progress has been made in developing potent and selective compds. with which to target this chaperone in the treatment of cancers.  These compds. have been invaluable in dissecting how HSP90 supports the dramatic alterations in cellular physiol. that constitute the malignant phenotype and give rise to the clin. manifestations of diverse cancers.  Unfortunately, single agent activity for HSP90 inhibitors has been disappointingly modest against recurrent, refractory cancers in most of the clin. trials that have been reported to date.  This problem could be due to pharmacol. limitations of the first-generation inhibitors that have been most extensively studied.  But we suggest it may well be intrinsic to the target itself.  This review will focus on how the utilization of HSP90 by cancer cells might be targeted to enhance the activity of other anticancer drugs while at the same time limiting the ability of advanced cancers to adapt and evolve drug resistance; the net result being more durable disease control.  A better understanding of these fundamental issues will surely make the ongoing clin. development of HSP90 inhibitors as anticancer drugs less empiric, more efficient and hopefully more successful.  This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQycmhIHXy7Vg90H21EOLACvtfcHk0liLmMps8xwOoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtV2qs78%253D&md5=bee2159799a412673527f05332e7f677</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2011.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2011.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DN.%2BU.%26atitle%3DHSP90%2520as%2520a%2520platform%2520for%2520the%2520assembly%2520of%2520more%2520effective%2520cancer%2520chemotherapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2012%26volume%3D1823%26spage%3D756%26epage%3D766%26doi%3D10.1016%2Fj.bbamcr.2011.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Yamaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, N.</span><span> </span><span class="NLM_article-title">Molecular basis for the actions of Hsp90 inhibitors and cancer therapy</span> <span class="citation_source-journal">J. Antibiot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span><span class="refDoi"> DOI: 10.1038/ja.2011.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fja.2011.60" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2011&pages=635-644&author=H.+Yamakiauthor=M.+Nakajimaauthor=K.+W.+Shimotohnoauthor=N.+Tanaka&title=Molecular+basis+for+the+actions+of+Hsp90+inhibitors+and+cancer+therapy&doi=10.1038%2Fja.2011.60"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fja.2011.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2011.60%26sid%3Dliteratum%253Aachs%26aulast%3DYamaki%26aufirst%3DH.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DShimotohno%26aufirst%3DK.%2BW.%26aulast%3DTanaka%26aufirst%3DN.%26atitle%3DMolecular%2520basis%2520for%2520the%2520actions%2520of%2520Hsp90%2520inhibitors%2520and%2520cancer%2520therapy%26jtitle%3DJ.%2520Antibiot.%26date%3D2011%26volume%3D64%26spage%3D635%26epage%3D644%26doi%3D10.1038%2Fja.2011.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Burlison, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">15529</span><span class="NLM_x">–</span> <span class="NLM_lpage">15536</span><span class="refDoi"> DOI: 10.1021/ja065793p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja065793p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFykur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=15529-15536&author=J.+A.+Burlisonauthor=L.+Neckersauthor=A.+B.+Smithauthor=A.+Maxwellauthor=B.+S.+J.+Blagg&title=Novobiocin%3A+redesigning+a+DNA+gyrase+inhibitor+for+selective+inhibition+of+hsp90&doi=10.1021%2Fja065793p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Novobiocin: Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90</span></div><div class="casAuthors">Burlison, Joseph A.; Neckers, Len; Smith, Andrew B.; Maxwell, Anthony; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">15529-15536</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novobiocin is a member of the coumermycin family of antibiotics and is a well-established inhibitor of DNA gyrase.  Recent studies have shown that novobiocin binds to a previously unrecognized ATP-binding site at the C-terminus of Hsp90 and induces degrdn. of Hsp90-dependent client proteins at ∼700 μM.  In an effort to develop more efficacious inhibitors of the C-terminal binding site, a library of novobiocin analogs was prepd. and initial structure-activity relationships revealed.  These data suggested that the 4-hydroxy moiety of the coumarin ring and the 3'-carbamate of the noviose appendage were detrimental to Hsp90 inhibitory activity.  In an effort to confirm these findings, 4-deshydroxynovobiocin (DHN1) and 3'-descarbamoyl-4-deshydroxynovobiocin (DHN2) were prepd. and evaluated against Hsp90.  Both compds. were significantly more potent than the natural product, and DHN2 proved to be more active than DHN1.  In an effort to det. whether these moieties are important for DNA gyrase inhibition, these compds. were tested for their ability to inhibit DNA gyrase and found to exhibit significant redn. in gyrase activity.  Thus, we have established the first set of compds. that clearly differentiate between the C-terminus of Hsp90 and DNA gyrase, converted a well-established gyrase inhibitor into a selective Hsp90 inhibitor, and confirmed essential structure-activity relationships for the coumermycin family of antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZJ-UWkhOYnLVg90H21EOLACvtfcHk0liLmMps8xwOoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFykur3I&md5=975936180c6bf06502c8ffdee28eaf1e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fja065793p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja065793p%26sid%3Dliteratum%253Aachs%26aulast%3DBurlison%26aufirst%3DJ.%2BA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DMaxwell%26aufirst%3DA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DNovobiocin%253A%2520redesigning%2520a%2520DNA%2520gyrase%2520inhibitor%2520for%2520selective%2520inhibition%2520of%2520hsp90%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D15529%26epage%3D15536%26doi%3D10.1021%2Fja065793p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Le Bras, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radanyi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrat, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brion, J.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsaud, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renoir, J.-M.</span><span> </span><span class="NLM_article-title">New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">6189</span><span class="NLM_x">–</span> <span class="NLM_lpage">6200</span><span class="refDoi"> DOI: 10.1021/jm0707774</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0707774" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KitrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6189-6200&author=G.+Le+Brasauthor=C.+Radanyiauthor=J.-F.+Peyratauthor=J.-D.+Brionauthor=M.+Alamiauthor=V.+Marsaudauthor=B.+Stellaauthor=J.-M.+Renoir&title=New+novobiocin+analogues+as+antiproliferative+agents+in+breast+cancer+cells+and+potential+inhibitors+of+heat+shock+protein+90&doi=10.1021%2Fjm0707774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">New Novobiocin Analogues as Antiproliferative Agents in Breast Cancer Cells and Potential Inhibitors of Heat Shock Protein 90</span></div><div class="casAuthors">Le Bras, Gaeelle; Radanyi, Christine; Peyrat, Jean-Francois; Brion, Jean-Daniel; Alami, Mouad; Marsaud, Veronique; Stella, Barbara; Renoir, Jack-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6189-6200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective hsp90 inhibitors simultaneously destabilize and deplete key signaling proteins involved in cell proliferation and survival, angiogenesis, and metastasis.  Investigation of novobiocin analogs lacking the noviose moiety as novel inhibitors of hsp90 was carried out.  A novel series of 3-aminocoumarin analogs has been produced and screened in cell proliferation, and the mol. signature of hsp90 inhibition was assessed by depletion of estrogen receptor, HER2, Raf-1, and cdk4 in human breast cancer cells.  This structure-activity relationship study highlights the crucial role of the C-4 and/or C-7 positions of coumarin which appeared to be essential for degrdn. of hsp90 client proteins.  Removal of the noviose moiety in novobiocin together with introduction of a tosyl substituent at C-4 or C-7 coumarins provides two compds. (I and II) as lead structures which compared favorably with novobiocin as demonstrated by enhanced rates of cell death.  The processing and activation of caspases 7 and 8 and the subsequent cleavage of PARP by I suggest stimulation of the extrinsic apoptosis pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Z-0jegYY_LVg90H21EOLACvtfcHk0ljkAMHuGFrRig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KitrnM&md5=8ae2bde5c8e0d5d97a2f6fde241a5e83</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm0707774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0707774%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBras%26aufirst%3DG.%26aulast%3DRadanyi%26aufirst%3DC.%26aulast%3DPeyrat%26aufirst%3DJ.-F.%26aulast%3DBrion%26aufirst%3DJ.-D.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DMarsaud%26aufirst%3DV.%26aulast%3DStella%26aufirst%3DB.%26aulast%3DRenoir%26aufirst%3DJ.-M.%26atitle%3DNew%2520novobiocin%2520analogues%2520as%2520antiproliferative%2520agents%2520in%2520breast%2520cancer%2520cells%2520and%2520potential%2520inhibitors%2520of%2520heat%2520shock%2520protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6189%26epage%3D6200%26doi%3D10.1021%2Fjm0707774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Burlison, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avila, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubbers, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">2130</span><span class="NLM_x">–</span> <span class="NLM_lpage">2137</span><span class="refDoi"> DOI: 10.1021/jo702191a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo702191a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlOmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=2130-2137&author=J.+A.+Burlisonauthor=C.+Avilaauthor=G.+Vielhauerauthor=D.+J.+Lubbersauthor=J.+Holzbeierleinauthor=B.+S.+J.+Blagg&title=Development+of+novobiocin+analogues+that+manifest+anti-proliferative+activity+against+several+cancer+cell+lines&doi=10.1021%2Fjo702191a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against Several Cancer Cell Lines</span></div><div class="casAuthors">Burlison, Joseph A.; Avila, Christopher; Vielhauer, George; Lubbers, Donna J.; Holzbeierlein, Jeffrey; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2130-2137</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent studies have shown that the DNA gyrase inhibitor, novobiocin, binds to a previously unrecognized ATP-binding site located at the C-terminus of Hsp90 and induces degrdn. of Hsp90-dependent client proteins at ∼700 μM.  As a result of these studies, several analogs of the coumarin family of antibiotics have been reported and shown to exhibit increased Hsp90 inhibitory activity; however, the monomeric species lacked the ability to manifest anti-proliferative activity against cancer cell lines at concns. tested.  In an effort to develop more efficacious compds. that produce growth inhibitory activity against cancer cell lines, structure-activity relationships were investigated surrounding the prenylated benzamide side chain of the natural product.  Results obtained from these studies have produced the first novobiocin analogs, e.g. I, that manifest anti-proliferative activity against several cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkVgns7ITFAbVg90H21EOLACvtfcHk0ljkAMHuGFrRig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlOmsLk%253D&md5=b8b808cf8c34780fae33215943cde182</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjo702191a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo702191a%26sid%3Dliteratum%253Aachs%26aulast%3DBurlison%26aufirst%3DJ.%2BA.%26aulast%3DAvila%26aufirst%3DC.%26aulast%3DVielhauer%26aufirst%3DG.%26aulast%3DLubbers%26aufirst%3DD.%2BJ.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520novobiocin%2520analogues%2520that%2520manifest%2520anti-proliferative%2520activity%2520against%2520several%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D2130%26epage%3D2137%26doi%3D10.1021%2Fjo702191a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Cohen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukerji, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samadi, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span> </span><span class="NLM_article-title">Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents</span> <span class="citation_source-journal">Ann. Surgical Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span><span class="refDoi"> DOI: 10.1245/s10434-011-1971-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1245%2Fs10434-011-1971-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=483-490&author=S.+M.+Cohenauthor=R.+Mukerjiauthor=A.+K.+Samadiauthor=H.+Zhaoauthor=B.+S.+J.+Blaggauthor=M.+S.+Cohen&title=Novel+C-terminal+Hsp90+inhibitor+for+head+and+neck+squamous+cell+cancer+%28HNSCC%29+with+in+vivo+efficacy+and+improved+toxicity+profiles+compared+with+standard+agents&doi=10.1245%2Fs10434-011-1971-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1245%2Fs10434-011-1971-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-011-1971-1%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%2BM.%26aulast%3DMukerji%26aufirst%3DR.%26aulast%3DSamadi%26aufirst%3DA.%2BK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26atitle%3DNovel%2520C-terminal%2520Hsp90%2520inhibitor%2520for%2520head%2520and%2520neck%2520squamous%2520cell%2520cancer%2520%2528HNSCC%2529%2520with%2520in%2520vivo%2520efficacy%2520and%2520improved%2520toxicity%2520profiles%2520compared%2520with%2520standard%2520agents%26jtitle%3DAnn.%2520Surgical%2520Oncol.%26date%3D2012%26volume%3D19%26spage%3D483%26epage%3D490%26doi%3D10.1245%2Fs10434-011-1971-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Donnelly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2702</span><span class="NLM_x">–</span> <span class="NLM_lpage">2717</span><span class="refDoi"> DOI: 10.2174/092986708786242895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F092986708786242895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=18991631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWiur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2702-2717&author=A.+Donnellyauthor=B.+S.+J.+Blagg&title=Novobiocin+and+additional+inhibitors+of+the+Hsp90+C-terminal+nucleotide-binding+pocket&doi=10.2174%2F092986708786242895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide binding pocket</span></div><div class="casAuthors">Donnelly, Alison; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2702-2717</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The 90 kDa heat shock proteins (Hsp90), which are integrally involved in cell signaling, proliferation, and survival, are ubiquitously expressed in cells.  Many proteins in tumor cells are dependent upon the Hsp90 protein folding machinery for their stability, refolding, and maturation.  Inhibition of Hsp90 uniquely targets client proteins assocd. with all six hallmarks of cancer.  Thus, Hsp90 has emerged as a promising target for the treatment of cancer.  Hsp90 exists as a homodimer, which contains three domains.  The N-terminal domain contains an ATP-binding site that binds the natural products geldanamycin and radicicol.  The middle domain is highly charged and has high affinity for cochaperones and client proteins.  Initial studies by Csermely and co-workers suggested a second ATP-binding site in the C-terminus of Hsp90.  This C-terminal nucleotide binding pocket has been shown to not only bind ATP, but cisplatin, novobiocin, epigallocatechin-3-gallate (EGCG) and taxol.  The coumarin antibiotics novobiocin, clorobiocin, and coumermycin A1 were isolated from several streptomyces strains and exhibit potent activity against Gram-pos. bacteria.  These compds. bind type II topoisomerases, including DNA gyrase, and inhibit the enzyme-catalyzed hydrolysis of ATP.  As a result, novobiocin analogs have garnered the attention of numerous researchers as an attractive agent for the treatment of bacterial infection.  Novobiocin was reported to bind weakly to the newly discovered Hsp90 C-terminal ATP binding site (∼700 M in SkBr3 cells) and induce degrdn. of Hsp90 client proteins.  Structural modification of this compds. has led to an increase of 1000-fold in activity in antiproliferative assays.  Recent studies of structure-activity relationship (SAR) by Renoir and co-workers highlighted the crucial role of the C-4 and/or C-7 positions of the coumarin and removal of the noviose moiety, which appeared to be essential for degrdn. of Hsp90 client proteins.  Unlike the N-terminal ATP binding site, there is no reported co-crystal structure of Hsp90 C-terminus bound to any inhibitor.  The Hsp90 C-terminal domain however, is known to contain a conserved pentapeptide sequence (MEEVD) which is recognized by co-chaperones.  Cisplatin is a platinum-contg. chemotherapeutic used to treat various types of cancers, including testicular, ovarian, bladder, and small cell lung cancer.  Most notably, cisplatin coordinates to DNA bases, resulting in cross-linked DNA, which prohibits rapidly dividing cells from duplicating DNA for mitosis.  Itoh and co-workers reported that cisplatin decreases the chaperone activity of Hsp90.  This group applied bovine brain cytosol to a cisplatin affinity column, eluted with cisplatin and detected Hsp90 in the eluent.  Subsequent expts. indicated that cisplatin exhibits high affinity for Hsp90.  Moreover Csermely and co-workers detd. that the cisplatin binding site is located proximal to the C-terminal ATP binding site.  EGCG is one of the active ingredients found in green tea.  EGCG is known to inhibit the activity of many Hsp90-dependent client proteins, including telomerase, several kinases, and the aryl hydrocarbon receptor (AhR).  Recently Gasiewicz and co-workers reported that EGCG manifests its antagonistic activity against AhR through binding Hsp90.  Similar to novobiocin, EGCG was shown to bind the C-terminus of Hsp90.  Unlike previously identified N-terminal Hsp90 inhibitors, EGCG does not appear to prevent Hsp90 from forming multiprotein complexes.  Studies are currently underway to det. whether EGCG competes with novobiocin or cisplatin binding.  Taxol, a well-known drug for the treatment of cancer, is responsible for the stabilization of microtubules and the inhibition of mitosis.  Previous studies have shown that taxol induces the activation of kinases and transcription factors, and mimics the effect of bacterial lipopolysaccharide (LPS), an attribute unrelated to its tubulin-binding properties.  Rosen and co-workers prepd. a biotinylated taxol deriv. and performed affinity chromatog. expts. with lysates from both mouse brain and macrophage cell lines.  These studies led to identification of two chaperones, Hsp70 and Hsp90, by mass spectrometry.  In contrast to typical Hsp90-binding drugs, taxol exhibits a stimulatory response.  Recently it was reported that the geldanamycin deriv. 17-AAG behaves synergistically with taxol-induced apoptosis.  This review describes the different C-terminal inhibitors of Hsp90, with specific emphasis on structure-activity relationship studies of novobiocin and their effects on anti-proliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ1ZxUMTyXBrVg90H21EOLACvtfcHk0ljkAMHuGFrRig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWiur3M&md5=ee456e11ec9730f446bffd75d5d22c5e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F092986708786242895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708786242895%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DNovobiocin%2520and%2520additional%2520inhibitors%2520of%2520the%2520Hsp90%2520C-terminal%2520nucleotide-binding%2520pocket%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2702%26epage%3D2717%26doi%3D10.2174%2F092986708786242895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mays, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlison, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">8901</span><span class="NLM_x">–</span> <span class="NLM_lpage">8920</span><span class="refDoi"> DOI: 10.1021/jo801312r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo801312r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1OlsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=8901-8920&author=A.+C.+Donnellyauthor=J.+R.+Maysauthor=J.+A.+Burlisonauthor=J.+T.+Nelsonauthor=G.+Vielhauerauthor=J.+Holzbeierleinauthor=B.+S.+J.+Blagg&title=The+design%2C+synthesis%2C+and+evaluation+of+coumarin+ring+derivatives+of+the+novobiocin+scaffold+that+exhibit+antiproliferative+activity&doi=10.1021%2Fjo801312r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Design, Synthesis, and Evaluation of Coumarin Ring Derivatives of the Novobiocin Scaffold that Exhibit Antiproliferative Activity</span></div><div class="casAuthors">Donnelly, Alison C.; Mays, Jared R.; Burlison, Joseph A.; Nelson, John T.; Vielhauer, George; Holzbeierlein, Jeffrey; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8901-8920</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-terminus and induces degrdn. of Hsp90-dependent client proteins at ∼700 μM in breast cancer cells (SKBr3).  Although many analogs of novobiocin have been synthesized, it was only recently demonstrated that monomeric species exhibit antiproliferative activity against various cancer cell lines.  To further refine the essential elements of the coumarin core, a series of modified coumarin derivs. was synthesized and evaluated to elucidate structure-activity relationships for novobiocin as an anticancer agent.  Results obtained from these studies have produced novobiocin analogs that manifest low micro-molar activity against several cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw2Qt4p4utRLVg90H21EOLACvtfcHk0ljYvJdcmmbolA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1OlsLvL&md5=70707e1f4635c955e80b40a06e3d80e3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjo801312r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo801312r%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DMays%26aufirst%3DJ.%2BR.%26aulast%3DBurlison%26aufirst%3DJ.%2BA.%26aulast%3DNelson%26aufirst%3DJ.%2BT.%26aulast%3DVielhauer%26aufirst%3DG.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DThe%2520design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520coumarin%2520ring%2520derivatives%2520of%2520the%2520novobiocin%2520scaffold%2520that%2520exhibit%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D8901%26epage%3D8920%26doi%3D10.1021%2Fjo801312r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusuma, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Cytotoxic sugar analogues of an optimized novobiocin scaffold</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1039/c0md00063a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1039%2Fc0md00063a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=165-170&author=A.+C.+Donnellyauthor=H.+Zhaoauthor=B.+R.+Kusumaauthor=B.+S.+J.+Blagg&title=Cytotoxic+sugar+analogues+of+an+optimized+novobiocin+scaffold&doi=10.1039%2Fc0md00063a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fc0md00063a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0md00063a%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DKusuma%26aufirst%3DB.%2BR.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DCytotoxic%2520sugar%2520analogues%2520of%2520an%2520optimized%2520novobiocin%2520scaffold%26jtitle%3DMedChemComm%26date%3D2010%26volume%3D1%26spage%3D165%26epage%3D170%26doi%3D10.1039%2Fc0md00063a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Eskew, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadikot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunwiddie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembruff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajewski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manjarrez, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matts, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G. A.</span><span> </span><span class="NLM_article-title">Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">468</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span><span class="refDoi"> DOI: 10.1186/1471-2407-11-468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1186%2F1471-2407-11-468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22039910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSrurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=468-485&author=J.+D.+Eskewauthor=T.+Sadikotauthor=P.+Moralesauthor=A.+Durenauthor=I.+Dunwiddieauthor=M.+Swinkauthor=X.+Zhangauthor=S.+Hembruffauthor=A.+Donnellyauthor=R.+A.+Rajewskiauthor=B.+S.+Blaggauthor=J.+R.+Manjarrezauthor=R.+L.+Mattsauthor=J.+M.+Holzbeierleinauthor=G.+A.+Vielhauer&title=Development+and+characterization+of+a+novel+C-terminal+inhibitor+of+Hsp90+in+androgen+dependent+and+independent+prostate+cancer+cells&doi=10.1186%2F1471-2407-11-468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells</span></div><div class="casAuthors">Eskew, Jeffery D.; Sadikot, Takrima; Morales, Pedro; Duren, Alicia; Dunwiddie, Irene; Swink, Megan; Zhang, Xiaoying; Hembruff, Stacey; Donnelly, Alison; Rajewski, Roger A.; Blagg, Brian S. J.; Manjarrez, Jacob R.; Matts, Robert L.; Holzbeierlein, Jeffrey M.; Vielhauer, George A.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">468</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The mol. chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a no. of cancers, including prostate cancer, making it an important target for drug discovery.  Unfortunately, results with N-terminal inhibitors from initial clin. trials have been disappointing, as toxicity and resistance resulting from induction of the heat shock response (HSR) has led to both scheduling and administration concerns.  Therefore, Hsp90 inhibitors that do not induce the heat shock response represent a promising new direction for the treatment of prostate cancer.  Herein, the development of a C-terminal Hsp90 inhibitor, KU174, is described, which demonstrates anti-cancer activity in prostate cancer cells in the absence of a HSR and describe a novel approach to characterize Hsp90 inhibition in cancer cells.  Methods: PC3-MM2 and LNCaP-LN3 cells were used in both direct and indirect in vitro Hsp90 inhibition assays (DARTS, Surface Plasmon Resonance, co-immunopptn., luciferase, Western blot, anti-proliferative, cytotoxicity and size exclusion chromatog.) to characterize the effects of KU174 in prostate cancer cells.  Pilot in vivo efficacy studies were also conducted with KU174 in PC3-MM2 xenograft studies.  Results: KU174 exhibits robust anti-proliferative and cytotoxic activity along with client protein degrdn. and disruption of Hsp90 native complexes without induction of a HSR.  Furthermore, KU174 demonstrates direct binding to the Hsp90 protein and Hsp90 complexes in cancer cells.  In addn., in pilot in-vivo proof-of-concept studies KU174 demonstrates efficacy at 75 mg/kg in a PC3-MM2 rat tumor model.  Conclusions: Overall, these findings suggest C-terminal Hsp90 inhibitors have potential as therapeutic agents for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgLK7KU3mfP7Vg90H21EOLACvtfcHk0ljYvJdcmmbolA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSrurzN&md5=3edc324bd2f3db190f2b96ed11e5cb8d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-11-468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-11-468%26sid%3Dliteratum%253Aachs%26aulast%3DEskew%26aufirst%3DJ.%2BD.%26aulast%3DSadikot%26aufirst%3DT.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DDuren%26aufirst%3DA.%26aulast%3DDunwiddie%26aufirst%3DI.%26aulast%3DSwink%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHembruff%26aufirst%3DS.%26aulast%3DDonnelly%26aufirst%3DA.%26aulast%3DRajewski%26aufirst%3DR.%2BA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26aulast%3DManjarrez%26aufirst%3DJ.%2BR.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DVielhauer%26aufirst%3DG.%2BA.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520a%2520novel%2520C-terminal%2520inhibitor%2520of%2520Hsp90%2520in%2520androgen%2520dependent%2520and%2520independent%2520prostate%2520cancer%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D468%26epage%3D485%26doi%3D10.1186%2F1471-2407-11-468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Gunaherath, G. M. K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marron, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijeratne, E. M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunatilaka, A. A. L.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5118</span><span class="NLM_x">–</span> <span class="NLM_lpage">5129</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.06.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bmc.2013.06.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=5118-5129&author=G.+M.+K.+B.+Gunaherathauthor=M.+T.+Marronauthor=E.+M.+K.+Wijeratneauthor=L.+Whitesellauthor=A.+A.+L.+Gunatilaka&title=Synthesis+and+biological+evaluation+of+novobiocin+analogues+as+potential+heat+shock+protein+90+inhibitors&doi=10.1016%2Fj.bmc.2013.06.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.06.042%26sid%3Dliteratum%253Aachs%26aulast%3DGunaherath%26aufirst%3DG.%2BM.%2BK.%2BB.%26aulast%3DMarron%26aufirst%3DM.%2BT.%26aulast%3DWijeratne%26aufirst%3DE.%2BM.%2BK.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DGunatilaka%26aufirst%3DA.%2BA.%2BL.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novobiocin%2520analogues%2520as%2520potential%2520heat%2520shock%2520protein%252090%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D5118%26epage%3D5129%26doi%3D10.1016%2Fj.bmc.2013.06.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Huang, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">A library of noviosylated coumarin analogues</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3609</span><span class="NLM_x">–</span> <span class="NLM_lpage">3613</span><span class="refDoi"> DOI: 10.1021/jo062083t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo062083t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=3609-3613&author=Y.-T.+Huangauthor=B.+S.+J.+Blagg&title=A+library+of+noviosylated+coumarin+analogues&doi=10.1021%2Fjo062083t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A Library of Noviosylated Coumarin Analogs</span></div><div class="casAuthors">Huang, Yung-Tzung; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3609-3613</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The DNA gyrase inhibitor, novobiocin, was recently shown to inhibit Hsp90 via a previously unrecognized C-terminal ATP-binding site.  Previous structure-activity relationship studies identified key moieties that appear important for Hsp90 inhibitory activity.  In an effort to provide a more efficacious lead compd., a parallel library of noviosylated coumarin analogs was prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Ua-e-5E017Vg90H21EOLACvtfcHk0ljYvJdcmmbolA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSiur8%253D&md5=c780fa0523dc934c067e77655c3cd653</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjo062083t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo062083t%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-T.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DA%2520library%2520of%2520noviosylated%2520coumarin%2520analogues%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D3609%26epage%3D3613%26doi%3D10.1021%2Fjo062083t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Kusuma, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duerfeldt, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">–</span> <span class="NLM_lpage">7174</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bmcl.2011.09.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22014546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVaqtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=7170-7174&author=B.+R.+Kusumaauthor=A.+S.+Duerfeldtauthor=B.+S.+J.+Blagg&title=Synthesis+and+biological+evaluation+of+arylated+novobiocin+analogs+as+Hsp90+inhibitors&doi=10.1016%2Fj.bmcl.2011.09.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors</span></div><div class="casAuthors">Kusuma, Bhaskar Reddy; Duerfeldt, Adam S.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7170-7174</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novobiocin analogs, e.g. I, lacking labile glycosidic ether have been designed, synthesized and evaluated for Hsp90 inhibitory activity.  Replacement of the synthetically complex noviose sugar with simple arom. side chains produced analogs that maintain moderate cytotoxic activity against MCF7 and SkBR3 breast cancer cell-lines.  Rationale for the prepn. of des-noviose novobiocin analogs in addn. to their synthesis and biol. evaluation are presented herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrswRCtFLZbcrVg90H21EOLACvtfcHk0lh4MOb-Cd0SmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVaqtr7K&md5=9bf52107a44ca6f6ad0562ae142ac584</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DKusuma%26aufirst%3DB.%2BR.%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520arylated%2520novobiocin%2520analogs%2520as%2520Hsp90%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D7170%26epage%3D7174%26doi%3D10.1016%2Fj.bmcl.2011.09.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Kusuma, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundstrom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrowsky, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5797</span><span class="NLM_x">–</span> <span class="NLM_lpage">5812</span><span class="refDoi"> DOI: 10.1021/jm300544c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300544c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1SmsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5797-5812&author=B.+R.+Kusumaauthor=L.+Zhangauthor=T.+Sundstromauthor=L.+B.+Petersonauthor=R.+T.+Dobrowskyauthor=B.+S.+J.+Blagg&title=Synthesis+and+evaluation+of+novologues+as+C-terminal+Hsp90+inhibitors+with+cytoprotective+activity+against+sensory+neuron+glucotoxicity&doi=10.1021%2Fjm300544c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Novologues as C-Terminal Hsp90 Inhibitors with Cytoprotective Activity against Sensory Neuron Glucotoxicity</span></div><div class="casAuthors">Kusuma, Bhaskar Reddy; Zhang, Liang; Sundstrom, Teather; Peterson, Laura B.; Dobrowsky, Rick T.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5797-5812</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compd. 2 (KU-32) is a first-generation novologue (a novobiocin-based, C-terminal, heat shock protein 90 (Hsp90) inhibitor) that decreases glucose-induced death of primary sensory neurons and reverses numerous clin. indexes of diabetic peripheral neuropathy in mice.  The current study sought to exploit the C-terminal binding site of Hsp90 to det. whether the optimization of hydrogen bonding and hydrophobic interactions of second-generation novologues could enhance neuroprotective activity.  Using a series of substituted phenylboronic acids to replace the coumarin lactone of 2, we identified that electroneg. atoms placed at the meta-position of the B-ring exhibit improved cytoprotective activity, which is believed to result from favorable interactions with Lys539 in the Hsp90 C-terminal binding pocket.  Consistent with these results, a meta-3-fluorophenyl substituted novologue (13b) exhibited a 14-fold lower ED50 for protection against glucose-induced toxicity of primary sensory neurons compared to 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS4gyFThKBPLVg90H21EOLACvtfcHk0lh4MOb-Cd0SmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1SmsL4%253D&md5=2ade8768ae7ba197b3a633babb7d6a3b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm300544c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300544c%26sid%3Dliteratum%253Aachs%26aulast%3DKusuma%26aufirst%3DB.%2BR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSundstrom%26aufirst%3DT.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DDobrowsky%26aufirst%3DR.%2BT.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novologues%2520as%2520C-terminal%2520Hsp90%2520inhibitors%2520with%2520cytoprotective%2520activity%2520against%2520sensory%2520neuron%2520glucotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5797%26epage%3D5812%26doi%3D10.1021%2Fjm300544c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Marcu, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulte, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins</span> <span class="citation_source-journal">J. Nat. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span><span class="refDoi"> DOI: 10.1093/jnci/92.3.242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1093%2Fjnci%2F92.3.242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10655441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFShsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=242-248&author=M.+G.+Marcuauthor=T.+W.+Schulteauthor=L.+Neckers&title=Novobiocin+and+related+coumarins+and+depletion+of+heat+shock+protein+90-dependent+signaling+proteins&doi=10.1093%2Fjnci%2F92.3.242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins</span></div><div class="casAuthors">Marcu, Monica G.; Schulte, Theodore W.; Neckers, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-248</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) interacts with and stabilizes several oncogenic protein kinases (e.g., p185erbB2, p60v-src, and Raf-1) and is required for the stability and dominant-neg. function of mutated p53 protein.  Two unrelated antibiotics, geldanamycin and radicicol, bind specifically to an atypical nucleotide-binding pocket of Hsp90, a site that shares homol. with the ATP-binding domain of bacterial DNA gyrase B.  This interaction leads to destabilization of proteins that interact with Hsp90.  Since the nucleotide-binding site of gyrase B is targeted by coumarin antibiotics (e.g., novobiocin), we investigated whether these drugs can also interact with Hsp90 and affect its activity.  We used immobilized novobiocin, geldanamycin, or radicicol to isolate either endogenous Hsp90 from cell lysates or Hsp90 deletion fragments translated in vitro.  Effects of the coumarin antibiotics novobiocin, chlorobiocin, and coumermycin A1 on several proteins interacting with Hsp90 were assessed in vitro and in vivo.  Hsp90 binding to immobilized novobiocin was competed by sol. coumarins and ATP but not by geldanamycin or radicicol.  A carboxy-terminal Hsp90 fragment bound immobilized novobiocin but not immobilized geldanamycin, while a geldanamycin-binding amino-terminal fragment did not bind novobiocin.  All three coumarins markedly reduced cellular levels of p185erbB2, p60v-src, Raf-1, and mutated p53.  Furthermore, novobiocin reduced Raf-1 levels in the spleens of mice treated with the drug.  These coumarin antibiotics, particularly novobiocin, represent a first-generation alternative to other Hsp90-targeting drugs that are not as well tolerated.  Novobiocin's unique interaction with Hsp90 identifies an addnl. site on this protein amenable to pharmacol. interference with small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSMDAYykmhSbVg90H21EOLACvtfcHk0liU0jnFSLSi7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFShsbk%253D&md5=05873d976f0d6a3e721576732e580ff2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.3.242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.3.242%26sid%3Dliteratum%253Aachs%26aulast%3DMarcu%26aufirst%3DM.%2BG.%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DNovobiocin%2520and%2520related%2520coumarins%2520and%2520depletion%2520of%2520heat%2520shock%2520protein%252090-dependent%2520signaling%2520proteins%26jtitle%3DJ.%2520Nat.%2520Cancer%2520Inst.%26date%3D2000%26volume%3D92%26spage%3D242%26epage%3D248%26doi%3D10.1093%2Fjnci%2F92.3.242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Matthews, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthe, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaguturu, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matts, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J. M.</span><span> </span><span class="NLM_article-title">Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells</span> <span class="citation_source-journal">Prostate</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1002/pros.21035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1002%2Fpros.21035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=19739131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=27-36&author=S.+B.+Matthewsauthor=G.+A.+Vielhauerauthor=C.+A.+Mantheauthor=V.+K.+Chaguturuauthor=K.+Szablaauthor=R.+L.+Mattsauthor=A.+C.+Donnellyauthor=B.+S.+Blaggauthor=J.+M.+Holzbeierlein&title=Characterization+of+a+novel+novobiocin+analogue+as+a+putative+C-terminal+inhibitor+of+heat+shock+protein+90+in+prostate+cancer+cells&doi=10.1002%2Fpros.21035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells</span></div><div class="casAuthors">Matthews, Shawna B.; Vielhauer, George A.; Manthe, Craig A.; Chaguturu, Vamsee K.; Szabla, Kristen; Matts, Robert L.; Donnelly, Alison C.; Blagg, Brian S. J.; Holzbeierlein, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">PURPOSE: Hsp90 is important in the folding, maturation and stabilization of pro-tumorigenic client proteins and represents a viable drug target for the design of chemotherapies.  Previously, we reported the development of novobiocin analogs designed to inhibit the C-terminal portion of Hsp90, which demonstrated the ability to decrease client protein expression.  We now report the characterization of the novel novobiocin analog, F-4, which demonstrates improved cytotoxicity in prostate cancer cell lines compared to the N-terminal inhibitor, 17-AAG.  MATERIALS AND METHODS: LNCaP and PC-3 cells were treated with 17-AAG or F-4 in anti-proliferative, apoptosis, cell cycle and cytotoxicity assays.  Western blot and prostate specific antigen (PSA) ELISAs were used to det. client protein degrdn., induction of Hsp90 and to assess the functional status of the androgen receptor (AR) in response to F-4 treatment.  Surface plasmon resonance (SPR) was also used to det. the binding properties of F-4 to Hsp90.  RESULTS: F-4 demonstrated improved potency and efficacy compared to novobiocin in anti-proliferative assays and decreased expression of client proteins.  PSA secretion was inhibited in a dose-dependent manner that paralleled a decrease in AR expression.  The binding of F-4 to Hsp90 was detd. to be saturable with a binding affinity (Kd) of 100 μM.  In addn., superior efficacy was demonstrated by F-4 compared to 17-AAG in expts. measuring cytotoxicity and apoptosis.  CONCLUSIONS: These data reveal distinct modes of action for N-terminal and C-terminal Hsp90 inhibitors, which may offer unique therapeutic benefits for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOcr8uVjuhsbVg90H21EOLACvtfcHk0liU0jnFSLSi7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KjtbY%253D&md5=aa51b9498eaf8db0f4bf167cbd231148</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fpros.21035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.21035%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DS.%2BB.%26aulast%3DVielhauer%26aufirst%3DG.%2BA.%26aulast%3DManthe%26aufirst%3DC.%2BA.%26aulast%3DChaguturu%26aufirst%3DV.%2BK.%26aulast%3DSzabla%26aufirst%3DK.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520novobiocin%2520analogue%2520as%2520a%2520putative%2520C-terminal%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DProstate%26date%3D2010%26volume%3D70%26spage%3D27%26epage%3D36%26doi%3D10.1002%2Fpros.21035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Shelton, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawgo, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajewski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matts, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. D.</span><span> </span><span class="NLM_article-title">KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1314</span><span class="NLM_x">–</span> <span class="NLM_lpage">1322</span><span class="refDoi"> DOI: 10.1124/mol.109.058545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1124%2Fmol.109.058545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=19741006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFajtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=1314-1322&author=S.+N.+Sheltonauthor=M.+E.+Shawgoauthor=S.+B.+Matthewsauthor=Y.+Luauthor=A.+C.+Donnellyauthor=K.+Szablaauthor=M.+Tanolauthor=G.+A.+Vielhauerauthor=R.+A.+Rajewskiauthor=R.+L.+Mattsauthor=B.+S.+Blaggauthor=J.+D.+Robertson&title=KU135%2C+a+novel+novobiocin-derived+C-terminal+inhibitor+of+the+90-kDa+heat+shock+protein%2C+exerts+potent+antiproliferative+effects+in+human+leukemic+cells&doi=10.1124%2Fmol.109.058545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells</span></div><div class="casAuthors">Shelton, Shary N.; Shawgo, Mary E.; Matthews, Shawna B.; Lu, Yuanming; Donnelly, Alison C.; Szabla, Kristen; Tanol, Mehmet; Vielhauer, George A.; Rajewski, Roger A.; Matts, Robert L.; Blagg, Brian S. J.; Robertson, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1314-1322</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The 90-kDa heat shock protein (Hsp90) assists in the proper folding of numerous mutated or overexpressed signal transduction proteins that are involved in cancer.  Consequently, there is considerable interest in developing chemotherapeutic drugs that specifically disrupt the function of Hsp90.  Here, we investigated the extent to which a novel novobiocin-derived C-terminal Hsp90 inhibitor, designated KU135, induced antiproliferative effects in Jurkat T-lymphocytes.  The results indicated that KU135 bound directly to Hsp90, caused the degrdn. of known Hsp90 client proteins, and induced more potent antiproliferative effects than the established N-terminal Hsp90 inhibitor 17-allylamino-demethoxygeldanamycin (17-AAG).  Closer examn. of the cellular response to KU135 and 17-AAG revealed that only 17-AAG induced a strong up-regulation of Hsp70 and Hsp90.  In addn., KU135 caused wild-type cells to undergo G2/M arrest, whereas cells treated with 17-AAG accumulated in G1.  Furthermore, KU135 but not 17-AAG was found to be a potent inducer of mitochondria-mediated apoptosis as evidenced, in part, by the fact that cell death was inhibited to a similar extent by Bcl-2/Bcl-xL overexpression or the depletion of apoptotic protease-activating factor-1 (Apaf-1).  Together, these data suggest that KU135 inhibits cell proliferation by regulating signaling pathways that are mechanistically different from those targeted by 17-AAG and as such represents a novel opportunity for Hsp90 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnRfCmPO43irVg90H21EOLACvtfcHk0liU0jnFSLSi7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFajtbzK&md5=03fe82110c457194b6a58a9222ffaeac</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.058545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.058545%26sid%3Dliteratum%253Aachs%26aulast%3DShelton%26aufirst%3DS.%2BN.%26aulast%3DShawgo%26aufirst%3DM.%2BE.%26aulast%3DMatthews%26aufirst%3DS.%2BB.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DSzabla%26aufirst%3DK.%26aulast%3DTanol%26aufirst%3DM.%26aulast%3DVielhauer%26aufirst%3DG.%2BA.%26aulast%3DRajewski%26aufirst%3DR.%2BA.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26aulast%3DRobertson%26aufirst%3DJ.%2BD.%26atitle%3DKU135%252C%2520a%2520novel%2520novobiocin-derived%2520C-terminal%2520inhibitor%2520of%2520the%252090-kDa%2520heat%2520shock%2520protein%252C%2520exerts%2520potent%2520antiproliferative%2520effects%2520in%2520human%2520leukemic%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D1314%26epage%3D1322%26doi%3D10.1124%2Fmol.109.058545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Yu, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitors identified from a library of novobiocin analogues</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">12778</span><span class="NLM_x">–</span> <span class="NLM_lpage">12779</span><span class="refDoi"> DOI: 10.1021/ja0535864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0535864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1Whs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=12778-12779&author=X.+M.+Yuauthor=G.+Shenauthor=L.+Neckersauthor=H.+Blakeauthor=J.+Holzbeierleinauthor=B.+Cronkauthor=B.+S.+J.+Blagg&title=Hsp90+inhibitors+identified+from+a+library+of+novobiocin+analogues&doi=10.1021%2Fja0535864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Inhibitors Identified from a Library of Novobiocin Analogues</span></div><div class="casAuthors">Yu, Xiao Ming; Shen, Gang; Neckers, Len; Blake, Helen; Holzbeierlein, Jeff; Cronk, Benjamin; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">12778-12779</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novobiocin is a C-terminal inhibitor of the Hsp90 protein folding machinery, which is responsible for the conformational maturation of numerous proteins involved in cancer growth and survival.  Due to novobiocin's poor inhibitory activity (∼700 μM), very little attention has been paid toward the development of novobiocin analogs for Hsp90 inhibition.  In this study, a parallel library of 20 novobiocin derivs. was prepd. and the biol. activity of each evaluated by Western blot anal. of Hsp90 client proteins.  A4 was found to be a potent inhibitor of Hsp90 as detd. by its ability to cause the degrdn. of several Hsp90 client proteins in both breast and prostate cancer cell lines.  In the presence of 1 μM A4, several Hsp90 client proteins were degraded, including AKT, Her2, Hif-1α, and the androgen receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB6oRUcNBq9rVg90H21EOLACvtfcHk0lhwGCLgc-agGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1Whs7g%253D&md5=85673a4859f2dd938c5d9f0cc28737e0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fja0535864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0535864%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DX.%2BM.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DBlake%26aufirst%3DH.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DCronk%26aufirst%3DB.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DHsp90%2520inhibitors%2520identified%2520from%2520a%2520library%2520of%2520novobiocin%2520analogues%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D12778%26epage%3D12779%26doi%3D10.1021%2Fja0535864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Zhao, H.; Blagg, B. S. J.</span> In  <span class="citation_source-book">Inhibitors of Molecular Chaperones as Therapeutic Agents</span>; <span class="NLM_contrib-group">Machajewski, T.; Gao, Z.</span>, Eds.; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">37</span>, p  <span class="NLM_fpage">259</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1039%2F9781849739689-00259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=259&author=H.+Zhao&author=B.+S.+J.+Blaggauthor=T.+Machajewski&author=Z.+Gao&title=Inhibitors+of+Molecular+Chaperones+as+Therapeutic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1039%2F9781849739689-00259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849739689-00259%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26btitle%3DInhibitors%2520of%2520Molecular%2520Chaperones%2520as%2520Therapeutic%2520Agents%26aulast%3DMachajewski%26aufirst%3DT.%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2013%26volume%3D37%26spage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Novobiocin analogues with second-generation noviose surrogates</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">552</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bmcl.2012.11.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=552-557&author=H.+Zhaoauthor=B.+S.+J.+Blagg&title=Novobiocin+analogues+with+second-generation+noviose+surrogates&doi=10.1016%2Fj.bmcl.2012.11.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DNovobiocin%2520analogues%2520with%2520second-generation%2520noviose%2520surrogates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D552%26epage%3D557%26doi%3D10.1016%2Fj.bmcl.2012.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusuma, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajewski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3839</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span><span class="refDoi"> DOI: 10.1021/jm200148p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200148p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVSltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3839-3853&author=H.+Zhaoauthor=A.+C.+Donnellyauthor=B.+R.+Kusumaauthor=G.+E.+Brandtauthor=D.+Brownauthor=R.+A.+Rajewskiauthor=G.+Vielhauerauthor=J.+Holzbeierleinauthor=M.+S.+Cohenauthor=B.+S.+J.+Blagg&title=Engineering+an+antibiotic+to+fight+cancer%3A+optimization+of+the+novobiocin+scaffold+to+produce+anti-proliferative+agents&doi=10.1021%2Fjm200148p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-proliferative Agents</span></div><div class="casAuthors">Zhao, Huiping; Donnelly, Alison C.; Kusuma, Bhaskar R.; Brandt, Gary E. L.; Brown, Douglas; Rajewski, Roger A.; Vielhauer, George; Holzbeierlein, Jeffrey; Cohen, Mark S.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3839-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety.  These species exhibit ∼700-fold improved anti-proliferative activity vs. the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines.  Utilization of structure-activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest mid-nanomolar activity against a panel of cancer cell lines and serve as lead compds. that manifest their activities through Hsp90 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7QwyWM4aQ1rVg90H21EOLACvtfcHk0lhwGCLgc-agGw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVSltL8%253D&md5=3ab2c790e0155c35edadf87f24c9d42b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm200148p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200148p%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DKusuma%26aufirst%3DB.%2BR.%26aulast%3DBrandt%26aufirst%3DG.%2BE.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DRajewski%26aufirst%3DR.%2BA.%26aulast%3DVielhauer%26aufirst%3DG.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DEngineering%2520an%2520antibiotic%2520to%2520fight%2520cancer%253A%2520optimization%2520of%2520the%2520novobiocin%2520scaffold%2520to%2520produce%2520anti-proliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3839%26epage%3D3853%26doi%3D10.1021%2Fjm200148p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">331</span><span class="refDoi"> DOI: 10.1021/ml300018e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300018e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=327-331&author=H.+Zhaoauthor=B.+Yanauthor=L.+B.+Petersonauthor=B.+S.+J.+Blagg&title=3-Arylcoumarin+derivatives+manifest+anti-proliferative+activity+through+Hsp90+inhibition&doi=10.1021%2Fml300018e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fml300018e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300018e%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3D3-Arylcoumarin%2520derivatives%2520manifest%2520anti-proliferative%2520activity%2520through%2520Hsp90%2520inhibition%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D327%26epage%3D331%26doi%3D10.1021%2Fml300018e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haling, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, J. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luoh, S.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">501</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span><span class="refDoi"> DOI: 10.1038/nature12441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnature12441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=23934108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2013&pages=232-236&author=G.+Hatzivassiliouauthor=J.+R.+Halingauthor=H.+Chenauthor=K.+Songauthor=S.+Priceauthor=R.+Healdauthor=J.+F.+M.+Hewittauthor=M.+Zakauthor=A.+Peckauthor=C.+Orrauthor=M.+Merchantauthor=K.+P.+Hoeflichauthor=J.+Chanauthor=S.-M.+Luohauthor=D.+J.+Andersonauthor=M.+J.+C.+Ludlamauthor=C.+Wiesmannauthor=M.+Ultschauthor=L.+S.+Friedmanauthor=S.+Malekauthor=M.+Belvin&title=Mechanism+of+MEK+inhibition+determines+efficacy+in+mutant+KRAS-+versus+BRAF-driven+cancers&doi=10.1038%2Fnature12441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Haling, Jacob R.; Chen, Huifen; Song, Kyung; Price, Steve; Heald, Robert; Hewitt, Joanne F. M.; Zak, Mark; Peck, Ariana; Orr, Christine; Merchant, Mark; Hoeflich, Klaus P.; Chan, Jocelyn; Luoh, Shiuh-Ming; Anderson, Daniel J.; Ludlam, Mary J. C.; Wiesmann, Christian; Ultsch, Mark; Friedman, Lori S.; Malek, Shiva; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">501</span>
        (<span class="NLM_cas:issue">7466</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of the MAPK pathway.  As these tumors represent an area of high unmet medical need, multiple allosteric MEK inhibitors, which inhibit MAPK signaling in both genotypes, are being tested in clin. trials.  Impressive single-agent activity in BRAF-mutant melanoma has been obsd.; however, efficacy has been far less robust in KRAS-mutant disease.  Owing to distinct mechanisms regulating MEK activation in KRAS- vs. BRAF-driven tumors, different mechanisms of inhibition are required for optimal antitumor activity in each genotype.  Structural and functional anal. illustrates that MEK inhibitors with superior efficacy in KRAS-driven tumors (GDC-0623 and G-573, the former currently in phase I clin. trials) form a strong hydrogen-bond interaction with S212 in MEK that is crit. for blocking MEK feedback phosphorylation by wild-type RAF.  Conversely, potent inhibition of active, phosphorylated MEK is required for strong inhibition of the MAPK pathway in BRAF-mutant tumors, resulting in superior efficacy in this genotype with GDC-0973 (also known as cobimetinib), a MEK inhibitor currently in phase III clin. trials.  The authors' study highlights that differences in the activation state of MEK in KRAS-mutant tumors vs. BRAF-mutant tumors can be exploited through the design of inhibitors that uniquely target these distinct activation states of MEK.  These inhibitors are currently being evaluated in clin. trials to det. whether improvements in therapeutic index within KRAS vs. BRAF preclin. models translate to improved clin. responses in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUdtElnPqJLVg90H21EOLACvtfcHk0lhklRMD8-eGVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3N&md5=12ceb67132291cbaff64c20c67b61b32</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnature12441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12441%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHewitt%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DLuoh%26aufirst%3DS.-M.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520MEK%2520inhibition%2520determines%2520efficacy%2520in%2520mutant%2520KRAS-%2520versus%2520BRAF-driven%2520cancers%26jtitle%3DNature%26date%3D2013%26volume%3D501%26spage%3D232%26epage%3D236%26doi%3D10.1038%2Fnature12441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Holderfield, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deuker, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, M.</span><span> </span><span class="NLM_article-title">Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1038/nrc3760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnrc3760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24957944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVamur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=455-467&author=M.+Holderfieldauthor=M.+M.+Deukerauthor=F.+McCormickauthor=M.+McMahon&title=Targeting+RAF+kinases+for+cancer+therapy%3A+BRAF-mutated+melanoma+and+beyond&doi=10.1038%2Fnrc3760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond</span></div><div class="casAuthors">Holderfield, Matthew; Deuker, Marian M.; McCormick, Frank; McMahon, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">455-467</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The identification of mutationally activated BRAF in many cancers altered our conception of the part played by the RAF family of protein kinases in oncogenesis.  In this Review, we describe the development of BRAF inhibitors and the results that have emerged from their anal. in both the lab. and the clinic.  We discuss the spectrum of RAF mutations in human cancer and the complex interplay between the tissue of origin and the response to RAF inhibition.  Finally, we enumerate mechanisms of resistance to BRAF inhibition that have been characterized and postulate how strategies of RAF pathway inhibition may be extended in scope to benefit not only the thousands of patients who are diagnosed annually with BRAF-mutated metastatic melanoma but also the larger patient population with malignancies harboring mutationally activated RAF genes that are ineffectively treated with the current generation of BRAF kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocz-DIK1jK5LVg90H21EOLACvtfcHk0lhklRMD8-eGVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVamur3M&md5=d7de7a5409dbb2aefaf3fc9ef6d8f944</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrc3760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3760%26sid%3Dliteratum%253Aachs%26aulast%3DHolderfield%26aufirst%3DM.%26aulast%3DDeuker%26aufirst%3DM.%2BM.%26aulast%3DMcCormick%26aufirst%3DF.%26aulast%3DMcMahon%26aufirst%3DM.%26atitle%3DTargeting%2520RAF%2520kinases%2520for%2520cancer%2520therapy%253A%2520BRAF-mutated%2520melanoma%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D455%26epage%3D467%26doi%3D10.1038%2Fnrc3760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Diab, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarasiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proud, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">MAP kinase-interacting kinases - emerging targets against cancer</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2014.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.chembiol.2014.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24613018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=441-452&author=S.+Diabauthor=M.+Kumarasiriauthor=M.+Yuauthor=T.+Teoauthor=C.+Proudauthor=R.+Milneauthor=S.+Wang&title=MAP+kinase-interacting+kinases+-+emerging+targets+against+cancer&doi=10.1016%2Fj.chembiol.2014.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">MAP Kinase-Interacting Kinases-Emerging Targets against Cancer</span></div><div class="casAuthors">Diab, Sarah; Kumarasiri, Malika; Yu, Mingfeng; Teo, Theodosia; Proud, Christopher; Milne, Robert; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) regulate the initiation of translation through phosphorylation of eukaryotic initiation factor 4E (eIF4E).  Mnk-mediated eIF4E activation promotes cancer development and progression.  While the phosphorylation of eIF4E is necessary for oncogenic transformation, the kinase activity of Mnks seems dispensable for normal development.  For this reason, pharmacol. inhibition of Mnks could represent an ideal mechanism-based and nontoxic therapeutic strategy for cancer treatment.  In this review, we discuss the current understanding of Mnk biol. roles, structures, and functions, as well as clin. implications.  Importantly, we propose different strategies for identification of highly selective small mol. inhibitors of Mnks, including exploring a structural feature of their kinase domain, DFD motif, which is unique within the human kinome.  We also argue that a combined targeting of Mnks and other pathways should be considered given the complexity of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8J4FNfWRq27Vg90H21EOLACvtfcHk0liUklg7FZqgfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslyitb0%253D&md5=472ef0f62dc9dc457139367b3a573c49</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DProud%26aufirst%3DC.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DMAP%2520kinase-interacting%2520kinases%2520-%2520emerging%2520targets%2520against%2520cancer%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.chembiol.2014.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsperger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span> </span><span class="NLM_article-title">Hsp90: a drug target? Curr</span> <span class="citation_source-journal">Curr. Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1007/s11912-010-0086-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1007%2Fs11912-010-0086-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20425593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=95-101&author=J.+Holzbeierleinauthor=A.+Windspergerauthor=G.+Vielhauer&title=Hsp90%3A+a+drug+target%3F+Curr&doi=10.1007%2Fs11912-010-0086-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90: a drug target?</span></div><div class="casAuthors">Holzbeierlein, Jeffrey M.; Windsperger, Andrew; Vielhauer, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Oncology Reports</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-101</span>CODEN:
                <span class="NLM_cas:coden">CORUAT</span>;
        ISSN:<span class="NLM_cas:issn">1534-6269</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (Hsp90) is a mol. chaperone involved in the trafficking of proteins in the cell.  Under stressful conditions, Hsp90 stabilizes its client proteins and provides protection to the cell against cellular stressors such as in cancer cells.  Disruption of Hsp90 leads to client protein degrdn. and often cell death.  As Hsp90 has been found to be either overexpressed or constitutively more active in cancer cells, inhibitors of Hsp90 may have cancer cell selectivity.  The N-terminal inhibitors, geldanamycin and radiciol, were the first two described inhibitors of Hsp90, but were not clin. useful.  Subsequent analogs-17 allylamino-17demethoxygeldanamycin and 17 dimethylaminoethylamino-17-demethoxygeldanamycin-were found to be more clin. appropriate and have been studied in a no. of clin. trials since 1999.  In addn., to the N-terminal site of Hsp90, the C-terminal site appears to be another target for inhibition of Hsp90.  More recently, inhibitors of the C terminus of Hsp90 have been developed and studied in vitro with promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqR8ds07kZc7Vg90H21EOLACvtfcHk0liUklg7FZqgfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsb%252FO&md5=a81b2ea571f42173863c0435831e42e4</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs11912-010-0086-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-010-0086-3%26sid%3Dliteratum%253Aachs%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DWindsperger%26aufirst%3DA.%26aulast%3DVielhauer%26aufirst%3DG.%26atitle%3DHsp90%253A%2520a%2520drug%2520target%253F%2520Curr%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2010%26volume%3D12%26spage%3D95%26epage%3D101%26doi%3D10.1007%2Fs11912-010-0086-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S. L.</span><span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span><span class="refDoi"> DOI: 10.1038/nrc1716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+L.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer&doi=10.1038%2Fnrc1716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0liKmesxmv7OHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%2BL.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fnrc1716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Pratt, W. B.</span><span> </span><span class="NLM_article-title">The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">21455</span><span class="NLM_x">–</span> <span class="NLM_lpage">21458</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=21455-21458&author=W.+B.+Pratt&title=The+role+of+heat+shock+proteins+in+regulating+the+function%2C+folding%2C+and+trafficking+of+the+glucocorticoid+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPratt%26aufirst%3DW.%2BB.%26atitle%3DThe%2520role%2520of%2520heat%2520shock%2520proteins%2520in%2520regulating%2520the%2520function%252C%2520folding%252C%2520and%2520trafficking%2520of%2520the%2520glucocorticoid%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D21455%26epage%3D21458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Hadden, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubbers, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1173</span><span class="NLM_x">–</span> <span class="NLM_lpage">1182</span><span class="refDoi"> DOI: 10.2174/156802606777812031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F156802606777812031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=16842154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1ejtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=1173-1182&author=M.+K.+Haddenauthor=D.+J.+Lubbersauthor=B.+S.+J.+Blagg&title=Geldanamycin%2C+radicicol%2C+and+chimeric+inhibitors+of+the+Hsp90+N-terminal+ATP+binding+site&doi=10.2174%2F156802606777812031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site</span></div><div class="casAuthors">Hadden, M. Kyle; Lubbers, Donna J.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1173-1182</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Natural products have continued to drive the development of new chemotherapeutics and elucidation of new biol. targets for the treatment of disease.  Since Whitesell and Neckers' original discovery that geldanamycin does not directly inhibit v-Src, but instead manifests its biol. activity through inhibition of the Hsp90 mol. chaperone, addnl. natural products and natural product derivs. have been identified and developed to inhibit the Hsp90 protein folding machinery.  17-AAG, a geldanamycin analog, is currently in clin. trials for the treatment of several types of cancer.  Recent work has produced improved radicicol analogs that show promising Hsp90 inhibitory activity in vitro.  In addn., chimeric mols. of these two natural products are active in vitro and represent a novel class of Hsp90 inhibitors for cancer treatment.  In addn. to their chemotherapeutic uses, natural product inhibitors and their derivs. have been utilized to probe the biol. mechanisms by which Hsp90 inhibition regulates tumor cell growth.  As a consequence of these studies, the mol. chaperones have emerged as an exciting new class of therapeutic targets.  This review will highlight the utility of the natural products, geldanamycin and radicicol, as well as improved analogs and the activities exhibited by these compds. against various cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogseEm4_LdKrVg90H21EOLACvtfcHk0liKmesxmv7OHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1ejtL8%253D&md5=6f0493f45767b9a364fadb9cc466a9a2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2174%2F156802606777812031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802606777812031%26sid%3Dliteratum%253Aachs%26aulast%3DHadden%26aufirst%3DM.%2BK.%26aulast%3DLubbers%26aufirst%3DD.%2BJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DGeldanamycin%252C%2520radicicol%252C%2520and%2520chimeric%2520inhibitors%2520of%2520the%2520Hsp90%2520N-terminal%2520ATP%2520binding%2520site%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D1173%26epage%3D1182%26doi%3D10.2174%2F156802606777812031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Kobayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dote, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span> </span><span class="NLM_article-title">The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2011.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.lungcan.2011.04.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2012&pages=161-166&author=N.+Kobayashiauthor=S.+Toyookaauthor=J.+Sohauthor=H.+Yamamotoauthor=H.+Doteauthor=K.+Kawasakiauthor=H.+Otaniauthor=T.+Kuboauthor=M.+Jidaauthor=T.+Uenoauthor=M.+Andoauthor=A.+Oginoauthor=K.+Kiuraauthor=S.+Miyoshi&title=The+anti-proliferative+effect+of+heat+shock+protein+90+inhibitor%2C+17-DMAG%2C+on+non-small-cell+lung+cancers+being+resistant+to+EGFR+tyrosine+kinase+inhibitor&doi=10.1016%2Fj.lungcan.2011.04.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2011.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2011.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DN.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DDote%26aufirst%3DH.%26aulast%3DKawasaki%26aufirst%3DK.%26aulast%3DOtani%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DJida%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DS.%26atitle%3DThe%2520anti-proliferative%2520effect%2520of%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%252017-DMAG%252C%2520on%2520non-small-cell%2520lung%2520cancers%2520being%2520resistant%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DLung%2520Cancer%26date%3D2012%26volume%3D75%26spage%3D161%26epage%3D166%26doi%3D10.1016%2Fj.lungcan.2011.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Takezawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonesaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatashita, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6515</span><span class="NLM_x">–</span> <span class="NLM_lpage">6521</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-1076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1158%2F0008-5472.CAN-09-1076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6515-6521&author=K.+Takezawaauthor=I.+Okamotoauthor=K.+Yonesakaauthor=E.+Hatashitaauthor=Y.+Yamadaauthor=M.+Fukuokaauthor=K.+Nakagawa&title=Sorafenib+inhibits+non-small+cell+lung+cancer+cell+growth+by+targeting+B-RAF+in+KRAS+wild-type+cells+and+C-RAF+in+KRAS+mutant+cells&doi=10.1158%2F0008-5472.CAN-09-1076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-1076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-1076%26sid%3Dliteratum%253Aachs%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DYonesaka%26aufirst%3DK.%26aulast%3DHatashita%26aufirst%3DE.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DFukuoka%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DSorafenib%2520inhibits%2520non-small%2520cell%2520lung%2520cancer%2520cell%2520growth%2520by%2520targeting%2520B-RAF%2520in%2520KRAS%2520wild-type%2520cells%2520and%2520C-RAF%2520in%2520KRAS%2520mutant%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6515%26epage%3D6521%26doi%3D10.1158%2F0008-5472.CAN-09-1076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Sarbassov, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guertin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">–</span> <span class="NLM_lpage">1101</span><span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lhgwX2TkafUYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Sanchez-Laorden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saturno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turajlic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">ra30</span><span class="refDoi"> DOI: 10.1126/scisignal.2004815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1126%2Fscisignal.2004815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24667377" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=ra30&author=B.+Sanchez-Laordenauthor=A.+Virosauthor=M.+R.+Girottiauthor=M.+Pedersenauthor=G.+Saturnoauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=S.+Turajlicauthor=A.+Hayesauthor=M.+Goreauthor=J.+Larkinauthor=P.+Loriganauthor=M.+Cookauthor=C.+Springerauthor=R.+Marais&title=BRAF+Inhibitors+Induce+Metastasis+in+RAS+Mutant+or+Inhibitor-Resistant+Melanoma+Cells+by+Reactivating+MEK+and+ERK+Signaling&doi=10.1126%2Fscisignal.2004815"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004815%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Laorden%26aufirst%3DB.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DTurajlic%26aufirst%3DS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DM.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DBRAF%2520Inhibitors%2520Induce%2520Metastasis%2520in%2520RAS%2520Mutant%2520or%2520Inhibitor-Resistant%2520Melanoma%2520Cells%2520by%2520Reactivating%2520MEK%2520and%2520ERK%2520Signaling%26jtitle%3DSci.%2520Signaling%26date%3D2014%26volume%3D7%26spage%3Dra30%26doi%3D10.1126%2Fscisignal.2004815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Marusiak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotter, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gartside, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawdar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitwieser, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brognard, J.</span><span> </span><span class="NLM_article-title">Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3901</span><span class="refDoi"> DOI: 10.1038/ncomms4901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fncomms4901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24849047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2mu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3901&author=A.+A.+Marusiakauthor=Z.+C.+Edwardsauthor=W.+Hugoauthor=E.+W.+Trotterauthor=M.+R.+Girottiauthor=N.+L.+Stephensonauthor=X.+Kongauthor=M.+G.+Gartsideauthor=S.+Fawdarauthor=A.+Hudsonauthor=W.+Breitwieserauthor=N.+K.+Haywardauthor=R.+Maraisauthor=R.+S.+Loauthor=J.+Brognard&title=Mixed+lineage+kinases+activate+MEK+independently+of+RAF+to+mediate+resistance+to+RAF+inhibitors&doi=10.1038%2Fncomms4901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors</span></div><div class="casAuthors">Marusiak, Anna A.; Edwards, Zoe C.; Hugo, Willy; Trotter, Eleanor W.; Girotti, Maria R.; Stephenson, Natalie L.; Kong, Xiangju; Gartside, Michael G.; Fawdar, Shameem; Hudson, Andrew; Breitwieser, Wolfgang; Hayward, Nicholas K.; Marais, Richard; Lo, Roger S.; Brognard, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3901</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF inhibitor therapy yields significant redns. in tumor burden in the majority of V600E-pos. melanoma patients; however, resistance occurs within 2-18 mo.  Here we demonstrate that the mixed lineage kinases (MLK1-4) are MEK kinases that reactivate the MEK/ERK pathway in the presence of RAF inhibitors.  Expression of MLK1-4 mediates resistance to RAF inhibitors and promotes survival in V600E-pos. melanoma cell lines.  Furthermore, we observe upregulation of the MLKs in 9 of 21 melanoma patients with acquired drug resistance.  Consistent with this observation, MLKs promote resistance to RAF inhibitors in mouse models and contribute to acquired resistance in a cell line model.  Lastly, we observe that a majority of MLK1 mutations identified in patients are gain-of-function mutations.  In summary, our data demonstrate a role for MLKs as direct activators of the MEK/ERK pathway with implications for melanomagenesis and resistance to RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2UDIQWhrwhbVg90H21EOLACvtfcHk0lhgwX2TkafUYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2mu7rO&md5=e98da6e7d453ca3cff433deaec3ea136</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fncomms4901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4901%26sid%3Dliteratum%253Aachs%26aulast%3DMarusiak%26aufirst%3DA.%2BA.%26aulast%3DEdwards%26aufirst%3DZ.%2BC.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DTrotter%26aufirst%3DE.%2BW.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DStephenson%26aufirst%3DN.%2BL.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DGartside%26aufirst%3DM.%2BG.%26aulast%3DFawdar%26aufirst%3DS.%26aulast%3DHudson%26aufirst%3DA.%26aulast%3DBreitwieser%26aufirst%3DW.%26aulast%3DHayward%26aufirst%3DN.%2BK.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DBrognard%26aufirst%3DJ.%26atitle%3DMixed%2520lineage%2520kinases%2520activate%2520MEK%2520independently%2520of%2520RAF%2520to%2520mediate%2520resistance%2520to%2520RAF%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3901%26doi%3D10.1038%2Fncomms4901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Abel, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basile, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugel, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkiewicz, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amaravadi, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karakousis, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortina, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aplin, A. E.</span><span> </span><span class="NLM_article-title">Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2155</span><span class="NLM_x">–</span> <span class="NLM_lpage">2168</span><span class="refDoi"> DOI: 10.1172/JCI65780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1172%2FJCI65780" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=2155-2168&author=E.+V.+Abelauthor=K.+J.+Basileauthor=C.+H.+Kugelauthor=A.+K.+Witkiewiczauthor=K.+Leauthor=R.+K.+Amaravadiauthor=G.+C.+Karakousisauthor=X.+Xuauthor=W.+Xuauthor=L.+M.+Schuchterauthor=J.+B.+Leeauthor=A.+Ertelauthor=P.+Fortinaauthor=A.+E.+Aplin&title=Melanoma+adapts+to+RAF%2FMEK+inhibitors+through+FOXD3-mediated+upregulation+of+ERBB3&doi=10.1172%2FJCI65780"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1172%2FJCI65780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI65780%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DE.%2BV.%26aulast%3DBasile%26aufirst%3DK.%2BJ.%26aulast%3DKugel%26aufirst%3DC.%2BH.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DKarakousis%26aufirst%3DG.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DSchuchter%26aufirst%3DL.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BB.%26aulast%3DErtel%26aufirst%3DA.%26aulast%3DFortina%26aufirst%3DP.%26aulast%3DAplin%26aufirst%3DA.%2BE.%26atitle%3DMelanoma%2520adapts%2520to%2520RAF%252FMEK%2520inhibitors%2520through%2520FOXD3-mediated%2520upregulation%2520of%2520ERBB3%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D2155%26epage%3D2168%26doi%3D10.1172%2FJCI65780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Carnahan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderfecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagapudi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, T. L.</span><span> </span><span class="NLM_article-title">Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2399</span><span class="NLM_x">–</span> <span class="NLM_lpage">23410</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1158%2F1535-7163.MCT-10-0181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20663930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2399-23410&author=J.+Carnahanauthor=P.+J.+Beltranauthor=C.+Babijauthor=Q.+Leauthor=M.+J.+Roseauthor=S.+Vonderfechtauthor=J.+L.+Kimauthor=A.+L.+Smithauthor=K.+Nagapudiauthor=M.+A.+Broomeauthor=M.+Fernandoauthor=H.+Khaauthor=B.+Belmontesauthor=R.+Radinskyauthor=R.+Kendallauthor=T.+L.+Burgess&title=Selective+and+potent+Raf+inhibitors+paradoxically+stimulate+normal+cell+proliferation+and+tumor+growth&doi=10.1158%2F1535-7163.MCT-10-0181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth</span></div><div class="casAuthors">Carnahan, Josette; Beltran, Pedro J.; Babij, Carol; Le, Quynh; Rose, Mark J.; Vonderfecht, Steven; Kim, Joseph L.; Smith, Adrian L.; Nagapudi, Karthik; Broome, Martin A.; Fernando, Manory; Kha, Hue; Belmontes, Brian; Radinsky, Robert; Kendall, Richard; Burgess, Teresa L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2399-2410</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Raf inhibitors are under clin. investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf.  Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg).  However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling.  In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo.  Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf.  Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner.  These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo.  Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested.  An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.  Mol Cancer Ther; 9(8); 2399-410.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN5Uws5uZF4rVg90H21EOLACvtfcHk0ljwm1Fq0unrFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D&md5=c2958b3c22d623571dea9bedf6835834</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0181%26sid%3Dliteratum%253Aachs%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DBeltran%26aufirst%3DP.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DKha%26aufirst%3DH.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DBurgess%26aufirst%3DT.%2BL.%26atitle%3DSelective%2520and%2520potent%2520Raf%2520inhibitors%2520paradoxically%2520stimulate%2520normal%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2399%26epage%3D23410%26doi%3D10.1158%2F1535-7163.MCT-10-0181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Joshi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belani, C. P.</span><span> </span><span class="NLM_article-title">Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0118210</span><span class="refDoi"> DOI: 10.1371/journal.pone.0118210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1371%2Fjournal.pone.0118210" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0118210&author=M.+Joshiauthor=S.+J.+Riceauthor=X.+Liuauthor=B.+Millerauthor=C.+P.+Belani&title=Trametinib+with+or+without+vemurafenib+in+BRAF+mutated+non-small+cell+lung+cancer&doi=10.1371%2Fjournal.pone.0118210"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0118210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0118210%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DM.%26aulast%3DRice%26aufirst%3DS.%2BJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMiller%26aufirst%3DB.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26atitle%3DTrametinib%2520with%2520or%2520without%2520vemurafenib%2520in%2520BRAF%2520mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0118210%26doi%3D10.1371%2Fjournal.pone.0118210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Nakamura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donelan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chouitar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carideo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span> </span><span class="NLM_article-title">Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">7043</span><span class="NLM_x">–</span> <span class="NLM_lpage">7055</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1158%2F0008-5472.CAN-13-1825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24121489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKhu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=7043-7055&author=A.+Nakamuraauthor=T.+Aritaauthor=S.+Tsuchiyaauthor=J.+Donelanauthor=J.+Chouitarauthor=E.+Carideoauthor=K.+Galvinauthor=M.+Okaniwaauthor=T.+Ishikawaauthor=S.+Yoshida&title=Antitumor+activity+of+the+selective+pan-RAF+inhibitor+TAK-632+in+BRAF+inhibitor-resistant+melanoma&doi=10.1158%2F0008-5472.CAN-13-1825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma</span></div><div class="casAuthors">Nakamura, Akito; Arita, Takeo; Tsuchiya, Shuntarou; Donelan, Jill; Chouitar, Jouhara; Carideo, Elizabeth; Galvin, Katherine; Okaniwa, Masanori; Ishikawa, Tomoyasu; Yoshida, Sei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7043-7055</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of melanoma cells.  Somatic mutations in BRAF and NKAS are frequently obsd. in melanoma.  Recently, the BRAF inhibitors vemurafenib and dabrafenib have emerged as promising agents for the treatment of melanoma patients with BRAF-activating mutations.  Flowever, as BRAF inhibitors induce RAF paradoxical activation via RAF dimerization in BRAF wild-type cells, rapid emergence of acquired resistance and secondary skin tumors as well as presence of few effective treatment options for melanoma bearing wild- type BRAF (including NRAS-mutant melanoma) are clin. concerns.  Here, we demonstrate that the selective pan-RAF inhibitor TAK-632 suppresses RAF activity in BRAF wild-type cells with minimal RAF paradoxical activation.  Our anal. using RNAi and TAK-632 in preclin. models reveals that the MAPK pathway of NRAS-mutated melanoma cells is highly dependent on RAF.  We also show that TAK-632 induces RAF dimerization but inhibits the kinase activity of the RAF dimer, probably because of its slow dissocn. from RAF.  As a result, TAK-632 demonstrates potent antiproliferative effects both on NRAS-mutated melanoma cells and BRAF-mutated melanoma cells with acquired resistance to BRAF inhibitors through NRAS mutation or BRAF truncation.  Furthermore, we demonstrate that the combination of TAK-632 and the MAPK kinase (MEK) inhibitor TAK-733 exhibits synergistic antiproliferative effects on these cells.  Our findings characterize the unique features of TAK-632 as a pan-RAF inhibitor and provide rationale for its further investigation in NRAS-mutated melanoma and a subset of BRAF-mutated melanomas refractory to BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1LknpOlxiFrVg90H21EOLACvtfcHk0ljwm1Fq0unrFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKhu77L&md5=beeec0a6c53216a97762c91af9df8c0e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1825%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DDonelan%26aufirst%3DJ.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DCarideo%26aufirst%3DE.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DS.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520selective%2520pan-RAF%2520inhibitor%2520TAK-632%2520in%2520BRAF%2520inhibitor-resistant%2520melanoma%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D7043%26epage%3D7055%26doi%3D10.1158%2F0008-5472.CAN-13-1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span><span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0ljwm1Fq0unrFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 9 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhuoling  Zheng</span>, <span class="hlFld-ContribAuthor ">Jingwen  Xie</span>, <span class="hlFld-ContribAuthor ">Lixiong  Xiong</span>, <span class="hlFld-ContribAuthor ">Min  Gao</span>, <span class="hlFld-ContribAuthor ">Li  Qin</span>, <span class="hlFld-ContribAuthor ">Chunmei  Dai</span>, <span class="hlFld-ContribAuthor ">Zhikun  Liang</span>, <span class="hlFld-ContribAuthor ">Yiting  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Xue</span>, <span class="hlFld-ContribAuthor ">Qinbo  Wang</span>, <span class="hlFld-ContribAuthor ">Wenhui  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of candidate biomarkers and therapeutic drugs of colorectal cancer by integrated bioinformatics analysis. </span><span class="cited-content_cbyCitation_journal-name">Medical Oncology</span><span> <strong>2020,</strong> <em>37 </em>
                                    (11)
                                     <a href="https://doi.org/10.1007/s12032-020-01425-2" title="DOI URL">https://doi.org/10.1007/s12032-020-01425-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12032-020-01425-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12032-020-01425-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMedical%2520Oncology%26atitle%3DIdentification%252Bof%252Bcandidate%252Bbiomarkers%252Band%252Btherapeutic%252Bdrugs%252Bof%252Bcolorectal%252Bcancer%252Bby%252Bintegrated%252Bbioinformatics%252Banalysis%26aulast%3DZheng%26aufirst%3DZhuoling%26date%3D2020%26date%3D2020%26volume%3D37%26issue%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandra A  Malico</span>, <span class="hlFld-ContribAuthor ">Miles A  Calzini</span>, <span class="hlFld-ContribAuthor ">Anuran K  Gayen</span>, <span class="hlFld-ContribAuthor ">Gavin J  Williams</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic biology, combinatorial biosynthesis, and chemo‑enzymatic synthesis of isoprenoids. </span><span class="cited-content_cbyCitation_journal-name">Journal of Industrial Microbiology and Biotechnology</span><span> <strong>2020,</strong> <em>47 </em>
                                    (9-10)
                                     , 675-702. <a href="https://doi.org/10.1007/s10295-020-02306-3" title="DOI URL">https://doi.org/10.1007/s10295-020-02306-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10295-020-02306-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10295-020-02306-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Industrial%2520Microbiology%2520and%2520Biotechnology%26atitle%3DSynthetic%252Bbiology%25252C%252Bcombinatorial%252Bbiosynthesis%25252C%252Band%252Bchemo%2525E2%252580%252591enzymatic%252Bsynthesis%252Bof%252Bisoprenoids%26aulast%3DMalico%26aufirst%3DAlexandra%2BA%26date%3D2020%26date%3D2020%26volume%3D47%26issue%3D9-10%26spage%3D675%26epage%3D702" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gennady M.  Verkhivker</span>, <span class="hlFld-ContribAuthor ">Steve  Agajanian</span>, <span class="hlFld-ContribAuthor ">Guang  Hu</span>, <span class="hlFld-ContribAuthor ">Peng  Tao</span>. </span><span class="cited-content_cbyCitation_article-title">Allosteric Regulation at the Crossroads of New Technologies: Multiscale Modeling, Networks, and Machine Learning. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Molecular Biosciences</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fmolb.2020.00136" title="DOI URL">https://doi.org/10.3389/fmolb.2020.00136</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fmolb.2020.00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffmolb.2020.00136%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Molecular%2520Biosciences%26atitle%3DAllosteric%252BRegulation%252Bat%252Bthe%252BCrossroads%252Bof%252BNew%252BTechnologies%25253A%252BMultiscale%252BModeling%25252C%252BNetworks%25252C%252Band%252BMachine%252BLearning%26aulast%3DVerkhivker%26aufirst%3DGennady%2BM.%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jay K.  Singh</span>, <span class="hlFld-ContribAuthor ">Darren M.  Hutt</span>, <span class="hlFld-ContribAuthor ">Bradley  Tait</span>, <span class="hlFld-ContribAuthor ">Naihsuan C.  Guy</span>, <span class="hlFld-ContribAuthor ">Jeffrey C.  Sivils</span>, <span class="hlFld-ContribAuthor ">Nina R.  Ortiz</span>, <span class="hlFld-ContribAuthor ">Ashley N.  Payan</span>, <span class="hlFld-ContribAuthor ">Shravan Kumar  Komaragiri</span>, <span class="hlFld-ContribAuthor ">Jazzmin Jovonna  Owens</span>, <span class="hlFld-ContribAuthor ">David  Culbertson</span>, <span class="hlFld-ContribAuthor ">Laura J.  Blair</span>, <span class="hlFld-ContribAuthor ">Chad  Dickey</span>, <span class="hlFld-ContribAuthor ">Szu Yu  Kuo</span>, <span class="hlFld-ContribAuthor ">Dan  Finley</span>, <span class="hlFld-ContribAuthor ">H. Jane  Dyson</span>, <span class="hlFld-ContribAuthor ">Marc B.  Cox</span>, <span class="hlFld-ContribAuthor ">Jaideep  Chaudhary</span>, <span class="hlFld-ContribAuthor ">Jason E.  Gestwicki</span>, <span class="hlFld-ContribAuthor ">William E.  Balch</span>. </span><span class="cited-content_cbyCitation_article-title">Management of Hsp90-Dependent Protein Folding by Small Molecules Targeting the Aha1 Co-Chaperone. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2020,</strong> <em>27 </em>
                                    (3)
                                     , 292-305.e6. <a href="https://doi.org/10.1016/j.chembiol.2020.01.008" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.01.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.01.008%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DManagement%252Bof%252BHsp90-Dependent%252BProtein%252BFolding%252Bby%252BSmall%252BMolecules%252BTargeting%252Bthe%252BAha1%252BCo-Chaperone%26aulast%3DSingh%26aufirst%3DJay%2BK.%26date%3D2020%26volume%3D27%26issue%3D3%26spage%3D292%26epage%3D305.e6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">José CJMDS  Menezes</span>, <span class="hlFld-ContribAuthor ">Marc  Diederich</span>. </span><span class="cited-content_cbyCitation_article-title">Translational role of natural coumarins and their derivatives as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2019,</strong> <em>11 </em>
                                    (9)
                                     , 1057-1082. <a href="https://doi.org/10.4155/fmc-2018-0375" title="DOI URL">https://doi.org/10.4155/fmc-2018-0375</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0375&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0375%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DTranslational%252Brole%252Bof%252Bnatural%252Bcoumarins%252Band%252Btheir%252Bderivatives%252Bas%252Banticancer%252Bagents%26aulast%3DMenezes%26aufirst%3DJos%25C3%25A9%2BCJMDS%26date%3D2019%26volume%3D11%26issue%3D9%26spage%3D1057%26epage%3D1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fazul  Nabi</span>, <span class="hlFld-ContribAuthor ">Muhammad K.  Iqbal</span>, <span class="hlFld-ContribAuthor ">Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Mujeeb Ur  Rehman</span>, <span class="hlFld-ContribAuthor ">Muhammad  Shahzad</span>, <span class="hlFld-ContribAuthor ">Shucheng  Huang</span>, <span class="hlFld-ContribAuthor ">Zhaoqing  Han</span>, <span class="hlFld-ContribAuthor ">Khalid  Mehmood</span>, <span class="hlFld-ContribAuthor ">Nisar  Ahmed</span>, <span class="hlFld-ContribAuthor ">Bahram  Chachar</span>, <span class="hlFld-ContribAuthor ">Muhammad A.  Arain</span>, <span class="hlFld-ContribAuthor ">Jiakui  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical efficiency and safety of Hsp90 inhibitor Novobiocin in avian tibial dyschondroplasia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Veterinary Pharmacology and Therapeutics</span><span> <strong>2018,</strong> <em>41 </em>
                                    (6)
                                     , 902-911. <a href="https://doi.org/10.1111/jvp.12692" title="DOI URL">https://doi.org/10.1111/jvp.12692</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jvp.12692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjvp.12692%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Veterinary%2520Pharmacology%2520and%2520Therapeutics%26atitle%3DClinical%252Befficiency%252Band%252Bsafety%252Bof%252BHsp90%252Binhibitor%252BNovobiocin%252Bin%252Bavian%252Btibial%252Bdyschondroplasia%26aulast%3DNabi%26aufirst%3DFazul%26date%3D2018%26date%3D2018%26volume%3D41%26issue%3D6%26spage%3D902%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anthony  Maxwell</span>, <span class="hlFld-ContribAuthor ">Natassja G.  Bush</span>, <span class="hlFld-ContribAuthor ">Thomas  Germe</span>, <span class="hlFld-ContribAuthor ">Shannon J.  McKie</span>. </span><span class="cited-content_cbyCitation_article-title">Non-quinolone Topoisomerase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 593-618. <a href="https://doi.org/10.1007/978-3-319-78538-7_19" title="DOI URL">https://doi.org/10.1007/978-3-319-78538-7_19</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-78538-7_19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-78538-7_19%26sid%3Dliteratum%253Aachs%26atitle%3DNon-quinolone%252BTopoisomerase%252BInhibitors%26aulast%3DMaxwell%26aufirst%3DAnthony%26date%3D2018%26date%3D2018%26spage%3D593%26epage%3D618%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DAntimicrobial%252BResistance%252Bin%252Bthe%252B21st%252BCentury%26aulast%3DFong%26aufirst%3DI.%2BW.%26date%3D2018%26volume%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lindsey B.  Shelton</span>, <span class="hlFld-ContribAuthor ">Jeremy D.  Baker</span>, <span class="hlFld-ContribAuthor ">Dali  Zheng</span>, <span class="hlFld-ContribAuthor ">Leia E.  Sullivan</span>, <span class="hlFld-ContribAuthor ">Parth K.  Solanki</span>, <span class="hlFld-ContribAuthor ">Jack M.  Webster</span>, <span class="hlFld-ContribAuthor ">Zheying  Sun</span>, <span class="hlFld-ContribAuthor ">Jonathan J.  Sabbagh</span>, <span class="hlFld-ContribAuthor ">Bryce A.  Nordhues</span>, <span class="hlFld-ContribAuthor ">John  Koren</span>, <span class="hlFld-ContribAuthor ">Suman  Ghosh</span>, <span class="hlFld-ContribAuthor ">Brian S. J.  Blagg</span>, <span class="hlFld-ContribAuthor ">Laura J.  Blair</span>, <span class="hlFld-ContribAuthor ">Chad A.  Dickey</span>. </span><span class="cited-content_cbyCitation_article-title">Hsp90 activator Aha1 drives production of pathological tau aggregates. </span><span class="cited-content_cbyCitation_journal-name">Proceedings of the National Academy of Sciences</span><span> <strong>2017,</strong> <em>114 </em>
                                    (36)
                                     , 9707-9712. <a href="https://doi.org/10.1073/pnas.1707039114" title="DOI URL">https://doi.org/10.1073/pnas.1707039114</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1073/pnas.1707039114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1073%2Fpnas.1707039114%26sid%3Dliteratum%253Aachs%26jtitle%3DProceedings%2520of%2520the%2520National%2520Academy%2520of%2520Sciences%26atitle%3DHsp90%252Bactivator%252BAha1%252Bdrives%252Bproduction%252Bof%252Bpathological%252Btau%252Baggregates%26aulast%3DShelton%26aufirst%3DLindsey%2BB.%26date%3D2017%26date%3D2017%26volume%3D114%26issue%3D36%26spage%3D9707%26epage%3D9712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Federica  Pellati</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>. </span><span class="cited-content_cbyCitation_article-title">Novel and less explored chemotypes of natural origin for the inhibition of Hsp90. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2016,</strong> <em>7 </em>
                                    (11)
                                     , 2063-2075. <a href="https://doi.org/10.1039/C6MD00340K" title="DOI URL">https://doi.org/10.1039/C6MD00340K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MD00340K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MD00340K%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DNovel%252Band%252Bless%252Bexplored%252Bchemotypes%252Bof%252Bnatural%252Borigin%252Bfor%252Bthe%252Binhibition%252Bof%252BHsp90%26aulast%3DPellati%26aufirst%3DFederica%26date%3D2016%26date%3D2016%26volume%3D7%26issue%3D11%26spage%3D2063%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0011.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of novobiocin and compounds <b>1</b> and <b>2</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Novobiocin-Based Urea Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Western blot for Hsp90 client proteins (EGFR, Her2, and Raf) and Hsp90 using lysates from MCF7 and A549 cells treated for 12 h with vehicle (0.25% DMSO) or a low concentration (L; half the IC<sub>50</sub> value) or high concentration (H; five-times the IC<sub>50</sub> value) of compound <b>1</b> or <b>2</b>. (B) Luciferase refolding activity of Hsp90 in PC3-MM2 cells with vehicle (DMSO), compounds <b>1</b> and <b>2</b>, and the positive control, KU-257. The concentrations used were 0–100 μM.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structures and the overlay of compound <b>2</b> (green) with sorafenib (gray; a kinase inhibitor that targets B-Raf and C-Raf), TAK-632 (magenta; a kinase inhibitor that targets C-Raf and wild-type B-Raf), and vemurafenib (yellow; an inhibitor of mutant B-Raf).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) Western blot for proteins of the MAPK pathway (EGFR, C-Raf, MEK, and ERK) and phosphorylated MEK and ERK (p-MEK and p-ERK) from lysates of A549 cells treated for 2–12 h with five-times the IC<sub>50</sub> value of <b>2</b> or vehicle (0.25% DMSO). (B) Western blot for proteins of the MAPK pathway and p-MEK and p-ERK from lysates of A549 cells treated for 12 or 24 h with five-times the IC<sub>50</sub> value of <b>2</b> or vehicle (0.25% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Western blot for the proteins Her3 and wild-type B-Raf from lysates of A549 cells treated for 12 or 24 h with five-times the IC<sub>50</sub> value of <b>2</b>, sorafenib, vemurafenib, or TAK-632 or with vehicle (0.25% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (A) Coimmunoprecipitation of B-Raf from lysates of A549 cells treated for 24 h with five-times the IC<sub>50</sub> value of <b>2</b> or sorafenib or with vehicle (0.25% DMSO). B-Raf immunoprecipitated C-Raf in sorafenib-treated cells but not <b>2</b>-treated cells. (B) Proposed mechanism of action for compound <b>2</b> and sorafenib. In wild-type B-Raf cells, a basal level of B-Raf–C-Raf dimerization occurs. In sorafenib-treated cells, B-Raf–C-Raf dimerization is prevalent, causing activation of the MAPK pathway and resulting in growth. In contrast, compound <b>2</b> prevents heterodimerization of B-Raf and C-Raf; consequently, the MAPK pathway is not activated.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Continued Synthesis of Novobiocin-Based Urea Analogues</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/medium/jm-2015-013547_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Western blot for Hsp90 client proteins (EGFR, Her2, and C-Raf) and Hsp90 using lysates from A549 cells treated for 12 or 24 h with a high concentration (five-times the IC<sub>50</sub> value) of <b>3</b>–<b>5</b> or vehicle (0.25% DMSO). (B) Western blot for proteins of the MAPK pathway (EGFR, C-Raf, MEK, asd ERK) and phosphorylated MEK and ERK (p-MEK and p-ERK) from lysates of A549 cells treated for 12 or 24 h with five-times the IC<sub>50</sub> value of <b>4</b> or <b>5</b> or with vehicle (0.25% DMSO).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-3/acs.jmedchem.5b01354/20160205/images/large/jm-2015-013547_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01354&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i27">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55428" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55428" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 57 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Bagatell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paine-Murrieta, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitesell, L.</span><span> </span><span class="NLM_article-title">Destabilization of Steroid Receptors by Heat Shock Protein 90-binding Drugs A Ligand-independent Approach to Hormonal Therapy of Breast Cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2076</span><span class="NLM_x">–</span> <span class="NLM_lpage">2084</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=11448926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlslalu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2001&pages=2076-2084&author=R.+Bagatellauthor=O.+Khanauthor=G.+Paine-Murrietaauthor=C.+W.+Taylorauthor=S.+Akinagaauthor=L.+Whitesell&title=Destabilization+of+Steroid+Receptors+by+Heat+Shock+Protein+90-binding+Drugs+A+Ligand-independent+Approach+to+Hormonal+Therapy+of+Breast+Cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer</span></div><div class="casAuthors">Bagatell, Rochelle; Khan, Omar; Paine-Murrieta, Gillian; Taylor, Charles W.; Akinaga, Shiro; Whitesell, Luke</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2076-2084</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Steroid hormone receptors have become an important target in the management of breast cancers.  Despite a good initial response rate, however, most tumors become refractory to current hormonal therapies within a year of starting treatment.  To address this problem, we evaluated the effects of agents that bind the mol. chaperone heat shock protein 90 (Hsp90) on estrogen receptor function in breast cancer.  Unstimulated estrogen and progesterone receptors exist as multimol. complexes consisting of the hormone-binding protein itself and several essential mol. chaperones including Hsp90.  We found that interaction of the Hsp90-binding drugs geldanamycin and radicicol with the chaperone destabilizes these hormone receptors in a ligand-independent manner, leading to profound and prolonged depletion of their levels in breast cancer cells cultured in vitro.  Consistent with these findings, in vivo administration of the geldanamycin deriv. 17-allylaminogeldanamycin (17AAG; NSC330507) to estrogen-supplemented, tumor-bearing SCID mice resulted in marked depletion of progesterone receptor levels in both uterus and tumor.  Drug administration also delayed the growth of established, hormone-responsive MCF-7 and T47D human tumor xenografts for up to 3 wk after the initiation of therapy.  We conclude that in light of their novel mechanism of antihormone action, consideration should be given to examg. the activity of 17AAG and other Hsp90-binding agents in patients with refractory breast cancer in future clin. trials, either alone or in combination with conventional hormone antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-zaiC8aLBu7Vg90H21EOLACvtfcHk0ljQonrJ7fGO0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlslalu7g%253D&md5=a74f8b6d9319e1da4b9feb74e0d2173c</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBagatell%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DO.%26aulast%3DPaine-Murrieta%26aufirst%3DG.%26aulast%3DTaylor%26aufirst%3DC.%2BW.%26aulast%3DAkinaga%26aufirst%3DS.%26aulast%3DWhitesell%26aufirst%3DL.%26atitle%3DDestabilization%2520of%2520Steroid%2520Receptors%2520by%2520Heat%2520Shock%2520Protein%252090-binding%2520Drugs%2520A%2520Ligand-independent%2520Approach%2520to%2520Hormonal%2520Therapy%2520of%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2001%26volume%3D7%26spage%3D2076%26epage%3D2084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Connell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballinger, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohfeld, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, C.</span><span> </span><span class="NLM_article-title">The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">93</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1038/35050618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2F35050618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=11146632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD3MXkslGqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2001&pages=93-96&author=P.+Connellauthor=C.+A.+Ballingerauthor=J.+Jiangauthor=Y.+Wuauthor=L.+J.+Thompsonauthor=J.+Hohfeldauthor=C.+Patterson&title=The+co-chaperone+CHIP+regulates+protein+triage+decisions+mediated+by+heat-shock+proteins&doi=10.1038%2F35050618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins</span></div><div class="casAuthors">Connell, Patrice; Ballinger, Carol A.; Jiang, Jihong; Wu, Yaxu; Thompson, Larry J.; Hohfeld, Jorg; Patterson, Cam</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">93-96</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">To maintain quality control in cells, mechanisms distinguish among improperly folded peptides, mature and functional proteins, and proteins to be targeted for degrdn.  The mol. chaperones, including heat-shock protein Hsp90, have the ability to recognize misfolded proteins and assist in their conversion to a functional conformation.  Disruption of Hsp90 heterocomplexes by the Hsp90 inhibitor geldanamycin leads to substrate degrdn. through the ubiquitin-proteasome pathway, implicating this system in protein triage decisions.  We previously identified CHIP (carboxyl terminus of Hsc70-interacting protein) to be an interaction partner of Hsc70 (ref. 4).  CHIP also interacts directly with a tetratricopeptide repeat acceptor site of Hsp90, incorporating into Hsp90 heterocomplexes and eliciting release of the regulatory cofactor p23.  Here we show that CHIP abolishes the steroid-binding activity and transactivation potential of the glucocorticoid receptor, a well-characterized Hsp90 substrate, even though it has little effect on its synthesis.  Instead, CHIP induces ubiquitination of the glucocorticoid receptor and degrdn. through the proteasome.  By remodelling Hsp90 heterocomplexes to favor substrate degrdn., CHIP modulates protein triage decisions that regulate the balance between protein folding and degrdn. for chaperone substrates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLcICHJwNISLVg90H21EOLACvtfcHk0ljQonrJ7fGO0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXkslGqsQ%253D%253D&md5=575a74b738bee74e5e5d4d9a27bc6a04</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F35050618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35050618%26sid%3Dliteratum%253Aachs%26aulast%3DConnell%26aufirst%3DP.%26aulast%3DBallinger%26aufirst%3DC.%2BA.%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DThompson%26aufirst%3DL.%2BJ.%26aulast%3DHohfeld%26aufirst%3DJ.%26aulast%3DPatterson%26aufirst%3DC.%26atitle%3DThe%2520co-chaperone%2520CHIP%2520regulates%2520protein%2520triage%2520decisions%2520mediated%2520by%2520heat-shock%2520proteins%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2001%26volume%3D3%26spage%3D93%26epage%3D96%26doi%3D10.1038%2F35050618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kundrat, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, L.</span><span> </span><span class="NLM_article-title">Balance between folding and degradation for Hsp90-dependent client proteins: a key role for CHIP</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7428</span><span class="NLM_x">–</span> <span class="NLM_lpage">7438</span><span class="refDoi"> DOI: 10.1021/bi100386w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi100386w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=7428-7438&author=L.+Kundratauthor=L.+Regan&title=Balance+between+folding+and+degradation+for+Hsp90-dependent+client+proteins%3A+a+key+role+for+CHIP&doi=10.1021%2Fbi100386w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fbi100386w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi100386w%26sid%3Dliteratum%253Aachs%26aulast%3DKundrat%26aufirst%3DL.%26aulast%3DRegan%26aufirst%3DL.%26atitle%3DBalance%2520between%2520folding%2520and%2520degradation%2520for%2520Hsp90-dependent%2520client%2520proteins%253A%2520a%2520key%2520role%2520for%2520CHIP%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D7428%26epage%3D7438%26doi%3D10.1021%2Fbi100386w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Murata, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, K.</span><span> </span><span class="NLM_article-title">CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein</span> <span class="citation_source-journal">EMBO Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1133</span><span class="NLM_x">–</span> <span class="NLM_lpage">1138</span><span class="refDoi"> DOI: 10.1093/embo-reports/kve246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1093%2Fembo-reports%2Fkve246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=11743028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1Ciug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=1133-1138&author=S.+Murataauthor=Y.+Minamiauthor=M.+Minamiauthor=T.+Chibaauthor=K.+Tanaka&title=CHIP+is+a+chaperone-dependent+E3+ligase+that+ubiquitylates+unfolded+protein&doi=10.1093%2Fembo-reports%2Fkve246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein</span></div><div class="casAuthors">Murata, Shigeo; Minami, Yasufumi; Minami, Michiko; Chiba, Tomoki; Tanaka, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1133-1138</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The ubiquitin-proteasome system catalyzes the immediate destruction of misfolded or impaired proteins generated in cells, but how this proteolytic machinery recognizes abnormality of cellular proteins for selective elimination remains elusive.  Here, we report that the C-terminus of Hsc70-interacting protein (CHIP) with a U-box domain is an E3 ubiquitin-ligase collaborating with mol. chaperones Hsp90 and Hsc70.  Thermally denatured firefly luciferase was multiubiquitylated by CHIP in the presence of E1 and E2 (Ubc4 or UbcH5c) in vitro, only when the unfolded substrate was captured by Hsp90 or Hsc70 and Hsp40.  No ubiquitylating activity was detected in CHIP lacking the U-box region.  CHIP efficiently ubiquitylated denatured luciferase trapped by the C-terminal region of Hsp90, which contains a CHIP binding site.  CHIP also showed self-ubiquitylating activity independent of target ubiquitylation.  Our results indicate that CHIP can be regarded as "a quality-control E3" that selectively ubiquitylates unfolded protein(s) by collaborating with mol. chaperones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRqke0yhJ4NbVg90H21EOLACvtfcHk0liGuCkt1p-NyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1Ciug%253D%253D&md5=06a57e11ed0a550cf5a2392dd58b94f2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1093%2Fembo-reports%2Fkve246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fembo-reports%252Fkve246%26sid%3Dliteratum%253Aachs%26aulast%3DMurata%26aufirst%3DS.%26aulast%3DMinami%26aufirst%3DY.%26aulast%3DMinami%26aufirst%3DM.%26aulast%3DChiba%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DK.%26atitle%3DCHIP%2520is%2520a%2520chaperone-dependent%2520E3%2520ligase%2520that%2520ubiquitylates%2520unfolded%2520protein%26jtitle%3DEMBO%2520Rep.%26date%3D2001%26volume%3D2%26spage%3D1133%26epage%3D1138%26doi%3D10.1093%2Fembo-reports%2Fkve246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mimnaugh, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">12847</span><span class="NLM_x">–</span> <span class="NLM_lpage">12852</span><span class="refDoi"> DOI: 10.1073/pnas.202365899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1073%2Fpnas.202365899" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2002&pages=12847-12852&author=W.+Xuauthor=M.+Marcuauthor=X.+Yuanauthor=E.+Mimnaughauthor=C.+Pattersonauthor=L.+Neckers&title=Chaperone-dependent+E3+ubiquitin+ligase+CHIP+mediates+a+degradative+pathway+for+c-ErbB2%2FNeu&doi=10.1073%2Fpnas.202365899"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1073%2Fpnas.202365899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.202365899%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DW.%26aulast%3DMarcu%26aufirst%3DM.%26aulast%3DYuan%26aufirst%3DX.%26aulast%3DMimnaugh%26aufirst%3DE.%26aulast%3DPatterson%26aufirst%3DC.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DChaperone-dependent%2520E3%2520ubiquitin%2520ligase%2520CHIP%2520mediates%2520a%2520degradative%2520pathway%2520for%2520c-ErbB2%252FNeu%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2002%26volume%3D99%26spage%3D12847%26epage%3D12852%26doi%3D10.1073%2Fpnas.202365899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Biamonte, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Water, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scannevin, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perret, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W.-C.</span><span> </span><span class="NLM_article-title">Heat Shock Protein 90: Inhibitors in Clinical Trials</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">17</span><span class="refDoi"> DOI: 10.1021/jm9004708</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9004708" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=3-17&author=M.+A.+Biamonteauthor=R.+Van+de+Waterauthor=J.+W.+Arndtauthor=R.+H.+Scannevinauthor=D.+Perretauthor=W.-C.+Lee&title=Heat+Shock+Protein+90%3A+Inhibitors+in+Clinical+Trials&doi=10.1021%2Fjm9004708"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90: Inhibitors in Clinical Trials</span></div><div class="casAuthors">Biamonte, Marco A.; Van de Water, Ryan; Arndt, Joseph W.; Scannevin, Robert H.; Perret, Daniel; Lee, Wen-Cherng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  HSP90 is the 90 kDa member of the family and exists as two isoforms: HSP90 is an inducible form overexpressed in cancer cells, while HSP90 is the constitutive form.  Since inhibition of HSP90 can lead to the degrdn. of a large no. of oncogenic proteins, HSP90 has become a target of interest for oncol.  A major advantage of HSP90 inhibitors is that they simultaneously attack several pathways necessary for cancer development, reducing the likelihood of the tumor acquiring resistance to any single therapeutic pathway.  It has also been proposed that HSP90 occurs in an activated form in cancer cells, whereas in normal somatic cells only the latent form is found.  This has given rise to the hypothesis that HSP90 inhibitors could be designed to selectively target the activated form and thus more specifically target cancer cells, but this assertion has been challenged.  Cancer cells seem to have a higher HSP90 activity than normal cells, and oncogenes are more dependent on HSP90 than house-keeping proteins.  In cell cultures, HSP90 inhibitors kill tumor cells at concns. much lower than those required to kill normal cells.  In mice, efficacy can be obsd. at nontoxic doses, and in humans, the first signs of clin. benefit are emerging.  It remains to be verified, however, if HSP90 inhibitors will truly provide a sufficient safety margin in the clinic.  Nononcol. indications may also emerge; besides cancer, the prevalent conditions mentioned in the literature with respect to HSP90 are Parkinson's disease, Alzheimer's disease, and fungal infections.  For the time being, however, the focus is oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYseMVVt55b7Vg90H21EOLACvtfcHk0liGuCkt1p-NyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFCjt7vJ&md5=14eee1036fc22e45da13b49cc93ed845</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm9004708&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9004708%26sid%3Dliteratum%253Aachs%26aulast%3DBiamonte%26aufirst%3DM.%2BA.%26aulast%3DVan%2Bde%2BWater%26aufirst%3DR.%26aulast%3DArndt%26aufirst%3DJ.%2BW.%26aulast%3DScannevin%26aufirst%3DR.%2BH.%26aulast%3DPerret%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DW.-C.%26atitle%3DHeat%2520Shock%2520Protein%252090%253A%2520Inhibitors%2520in%2520Clinical%2520Trials%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D3%26epage%3D17%26doi%3D10.1021%2Fjm9004708" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Brandt, G. E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1447</span><span class="NLM_x">–</span> <span class="NLM_lpage">1461</span><span class="refDoi"> DOI: 10.2174/156802609789895683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F156802609789895683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=19860731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFakurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1447-1461&author=G.+E.+L.+Brandtauthor=B.+S.+J.+Blagg&title=Alternate+strategies+of+Hsp90+modulation+for+the+treatment+of+cancer+and+other+diseases&doi=10.2174%2F156802609789895683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases</span></div><div class="casAuthors">Brandt, Gary E. L.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1447-1461</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The 90 kDa heat shock protein (Hsp90) has become a validated target for the development of anti-cancer agents.  Several Hsp90 inhibitors are currently under clin. trial investigation for the treatment of cancer.  All of these agents inhibit Hsp90's protein folding activity by binding to the N-terminal ATP binding site of the Hsp90 mol. chaperone.  Administration of these investigational drugs elicits induction of the heat shock response, or the overexpression of several Hsps, which exhibit antiapoptotic and pro-survival effects that may complicate the application of these inhibitors.  To circumvent this issue, alternate mechanisms for Hsp90 inhibition that do not elicit the heat shock response have been identified and pursued.  After providing background on the structure, function, and mechanism of the Hsp90 protein folding machinery, this review describes several mechanisms of Hsp90 modulation via small mols. that do not induce the heat shock response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoam5PRtPpdGbVg90H21EOLACvtfcHk0lhnfce2RxysHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFakurk%253D&md5=5e6bd3443f775532f23e7de42b2dce87</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F156802609789895683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789895683%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DG.%2BE.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DAlternate%2520strategies%2520of%2520Hsp90%2520modulation%2520for%2520the%2520treatment%2520of%2520cancer%2520and%2520other%2520diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1447%26epage%3D1461%26doi%3D10.2174%2F156802609789895683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Csermely, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnaider, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">So'ti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prohászka, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardai, G.</span><span> </span><span class="NLM_article-title">The 90-kDa Molecular Chaperone Family: Structure, Function, and Clinical Applications. A Comprehensive Review</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">79</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">168</span><span class="refDoi"> DOI: 10.1016/S0163-7258(98)00013-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2FS0163-7258%2898%2900013-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=9749880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADyaK1cXltVOktrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1998&pages=129-168&author=P.+Csermelyauthor=T.+Schnaiderauthor=C.+So%27tiauthor=Z.+Proh%C3%A1szkaauthor=G.+Nardai&title=The+90-kDa+Molecular+Chaperone+Family%3A+Structure%2C+Function%2C+and+Clinical+Applications.+A+Comprehensive+Review&doi=10.1016%2FS0163-7258%2898%2900013-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review</span></div><div class="casAuthors">Csermely, Peter; Schnaider, Tamas; Soti, Csaba; Prohaszka, Zoltan; Nardai, Gabor</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-168</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with 515 refs.  The 90-kDa mol. chaperone family (which comprises, among other proteins, the 90-kDa heat-shock protein, hsp90 and the 94-kDa glucose-regulated protein, grp94, major mol. chaperones of the cytosol and of the endoplasmic reticulum, resp.) has become an increasingly active subject of research in the past couple of years.  These ubiquitous, well-conserved proteins account for 1-2% of all cellular proteins in most cells.  However, their precise function is still far from being elucidated.  Their involvement in the etiol. of several autoimmune diseases, in various infections, in recognition of malignant cells, and in antigen-presentation already demonstrates the essential role they likely will play in clin. practice of the next decade.  The present review summarizes our current knowledge about the cellular functions, expression, and clin. implications of the 90-kDa mol. chaperone family and some approaches for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEoCjt7EH4AbVg90H21EOLACvtfcHk0lhnfce2RxysHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltVOktrc%253D&md5=63030ad5f3d3f9de5c598caab57afe69</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2898%2900013-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252898%252900013-8%26sid%3Dliteratum%253Aachs%26aulast%3DCsermely%26aufirst%3DP.%26aulast%3DSchnaider%26aufirst%3DT.%26aulast%3DSo%2527ti%26aufirst%3DC.%26aulast%3DProh%25C3%25A1szka%26aufirst%3DZ.%26aulast%3DNardai%26aufirst%3DG.%26atitle%3DThe%252090-kDa%2520Molecular%2520Chaperone%2520Family%253A%2520Structure%252C%2520Function%252C%2520and%2520Clinical%2520Applications.%2520A%2520Comprehensive%2520Review%26jtitle%3DPharmacol.%2520Ther.%26date%3D1998%26volume%3D79%26spage%3D129%26epage%3D168%26doi%3D10.1016%2FS0163-7258%2898%2900013-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Garcia-Carbonero, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carnero, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span> </span><span class="NLM_article-title">Inhibition of HSP90 molecular chaperones: moving into the clinic</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">e358</span><span class="NLM_x">–</span> <span class="NLM_lpage">e369</span><span class="refDoi"> DOI: 10.1016/S1470-2045(13)70169-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2FS1470-2045%2813%2970169-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=23896275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2013&pages=e358-e369&author=R.+Garcia-Carboneroauthor=A.+Carneroauthor=L.+Paz-Ares&title=Inhibition+of+HSP90+molecular+chaperones%3A+moving+into+the+clinic&doi=10.1016%2FS1470-2045%2813%2970169-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HSP90 molecular chaperones: moving into the clinic</span></div><div class="casAuthors">Garcia-Carbonero, Rocio; Carnero, Amancio; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e358-e369</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (HSP90) is a mol. chaperone that is crucial for the stability and function of many proteins essential for cell survival.  Many oncogenes, including tyrosine kinases, transcription factors, and cell-cycle regulatory proteins, are client proteins of HSP90.  Inhibition of HSP90 causes client protein degrdn. via the ubiquitin-proteasome pathway, and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumor development.  HSP90 inhibitors are currently being developed as anticancer agents, and have shown early promising results in molecularly defined subgroups of solid tumors (eg, ALK-rearranged non-small-cell lung cancer and HER2-amplified breast cancer) and some haematol. malignancies (eg, multiple myeloma).  Here, we review the current status of HSP90 inhibitors in clin. development, including geldanamycin derivs., resorcinol derivs., purine analogs, and other synthetic inhibitors.  We also discuss novel strategies and future perspectives on how to optimize the therapeutic potential of this exciting new class of drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpulM7j4PFcx7Vg90H21EOLACvtfcHk0lhnfce2RxysHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtF2iu7jI&md5=4821e86073624fb17d7343105d6e82cd</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2813%2970169-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252813%252970169-4%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Carbonero%26aufirst%3DR.%26aulast%3DCarnero%26aufirst%3DA.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520HSP90%2520molecular%2520chaperones%253A%2520moving%2520into%2520the%2520clinic%26jtitle%3DLancet%2520Oncol.%26date%3D2013%26volume%3D14%26spage%3De358%26epage%3De369%26doi%3D10.1016%2FS1470-2045%2813%2970169-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Goetz, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toft, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ames, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erlichman, C.</span><span> </span><span class="NLM_article-title">The Hsp90 chaperone complex as a novel target for cancer therapy</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">1169</span><span class="NLM_x">–</span> <span class="NLM_lpage">1176</span><span class="refDoi"> DOI: 10.1093/annonc/mdg316</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1093%2Fannonc%2Fmdg316" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=12881371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A280%3ADC%252BD3szkvVaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2003&pages=1169-1176&author=M.+P.+Goetzauthor=D.+O.+Toftauthor=M.+M.+Amesauthor=C.+Erlichman&title=The+Hsp90+chaperone+complex+as+a+novel+target+for+cancer+therapy&doi=10.1093%2Fannonc%2Fmdg316"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Hsp90 chaperone complex as a novel target for cancer therapy</span></div><div class="casAuthors">Goetz M P; Toft D O; Ames M M; Erlichman C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1169-76</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  Heat shock protein 90 (Hsp90) is responsible for chaperoning proteins involved in cell signaling, proliferation and survival. 17-allylamino-17-demethoxygeldanamycin (17-AAG) is an anticancer agent currently in phase I trials in the USA and UK.  It represents a class of drugs, the benzoquinone ansamycin antibiotics, capable of binding and disrupting the function of Hsp90, leading to the depletion of multiple oncogenic client proteins.  MATERIALS AND METHODS:  Studies were identified through a PubMed search, review of bibliographies of relevant articles and review of abstracts from national meetings.  RESULTS:  Preclinical studies have demonstrated that disruption of many client proteins chaperoned by Hsp90 is achievable and associated with significant growth inhibition, both in vitro and in tumor xenografts.  Following an overview of the mechanism of action of ansamycin antibiotics and the pathways they disrupt, we review the current clinical status of 17-AAG, and discuss future directions for combinations of traditional antineoplastics with 17-AAG.  CONCLUSIONS:  17-AAG represents a class of drugs capable of affecting multiple targets in the signal transduction pathway involved in tumor cell proliferation and survival.  Early results from phase I studies indicate that 17-AAG administration results in an acceptable toxicity profile while achieving in vivo disruption of client proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSwp3u3lGv0RBWfpMXQLRstfW6udTcc2eYTnL0CMLbd7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3szkvVaktA%253D%253D&md5=97213fab19fed8466e0217c9b0e88dc8</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdg316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdg316%26sid%3Dliteratum%253Aachs%26aulast%3DGoetz%26aufirst%3DM.%2BP.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DAmes%26aufirst%3DM.%2BM.%26aulast%3DErlichman%26aufirst%3DC.%26atitle%3DThe%2520Hsp90%2520chaperone%2520complex%2520as%2520a%2520novel%2520target%2520for%2520cancer%2520therapy%26jtitle%3DAnn.%2520Oncol.%26date%3D2003%26volume%3D14%26spage%3D1169%26epage%3D1176%26doi%3D10.1093%2Fannonc%2Fmdg316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Holzbeierlein, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsperger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span> </span><span class="NLM_article-title">Hsp90: a drug target? Curr</span> <span class="citation_source-journal">Curr. Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1007/s11912-010-0086-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1007%2Fs11912-010-0086-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20425593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=95-101&author=J.+M.+Holzbeierleinauthor=A.+Windspergerauthor=G.+Vielhauer&title=Hsp90%3A+a+drug+target%3F+Curr&doi=10.1007%2Fs11912-010-0086-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90: a drug target?</span></div><div class="casAuthors">Holzbeierlein, Jeffrey M.; Windsperger, Andrew; Vielhauer, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Oncology Reports</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-101</span>CODEN:
                <span class="NLM_cas:coden">CORUAT</span>;
        ISSN:<span class="NLM_cas:issn">1534-6269</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (Hsp90) is a mol. chaperone involved in the trafficking of proteins in the cell.  Under stressful conditions, Hsp90 stabilizes its client proteins and provides protection to the cell against cellular stressors such as in cancer cells.  Disruption of Hsp90 leads to client protein degrdn. and often cell death.  As Hsp90 has been found to be either overexpressed or constitutively more active in cancer cells, inhibitors of Hsp90 may have cancer cell selectivity.  The N-terminal inhibitors, geldanamycin and radiciol, were the first two described inhibitors of Hsp90, but were not clin. useful.  Subsequent analogs-17 allylamino-17demethoxygeldanamycin and 17 dimethylaminoethylamino-17-demethoxygeldanamycin-were found to be more clin. appropriate and have been studied in a no. of clin. trials since 1999.  In addn., to the N-terminal site of Hsp90, the C-terminal site appears to be another target for inhibition of Hsp90.  More recently, inhibitors of the C terminus of Hsp90 have been developed and studied in vitro with promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqR8ds07kZc7Vg90H21EOLACvtfcHk0lidK2HDUETdPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsb%252FO&md5=a81b2ea571f42173863c0435831e42e4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1007%2Fs11912-010-0086-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-010-0086-3%26sid%3Dliteratum%253Aachs%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DWindsperger%26aufirst%3DA.%26aulast%3DVielhauer%26aufirst%3DG.%26atitle%3DHsp90%253A%2520a%2520drug%2520target%253F%2520Curr%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2010%26volume%3D12%26spage%3D95%26epage%3D101%26doi%3D10.1007%2Fs11912-010-0086-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Jego, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hazoumé, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigneuric, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrido, C.</span><span> </span><span class="NLM_article-title">Targeting heat shock proteins in cancer</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">332</span><span class="NLM_x">, </span> <span class="NLM_fpage">275</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span><span class="refDoi"> DOI: 10.1016/j.canlet.2010.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.canlet.2010.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=21078542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvVWitLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=332&publication_year=2013&pages=275-285&author=G.+Jegoauthor=A.+Hazoum%C3%A9author=R.+Seigneuricauthor=C.+Garrido&title=Targeting+heat+shock+proteins+in+cancer&doi=10.1016%2Fj.canlet.2010.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting heat shock proteins in cancer</span></div><div class="casAuthors">Jego, Gaetan; Hazoume, Adonis; Seigneuric, Renaud; Garrido, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">332</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">275-285</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Heat shock proteins (HSPs) HSP27, HSP70 and HSP90 are powerful chaperones.  Their expression is induced in response to a wide variety of physiol. and environmental insults including anti-cancer chemotherapy, thus allowing the cell to survive to lethal conditions.  Different functions of HSPs have been described to account for their cytoprotective function, including their role as mol. chaperones as they play a central role in the correct folding of misfolded proteins, but also their anti-apoptotic properties.  HSPs are often overexpressed in cancer cells and this constitutive expression is necessary for cancer cells' survival.  HSPs may have oncogene-like functions and likewise mediate "non-oncogene addiction" of stressed tumor cells that must adapt to a hostile microenvironment, thereby becoming dependent for their survival on HSPs.  HSP-targeting drugs have therefore emerged as potential anti-cancer agents.  This review describes the different mols. and approaches being used or proposed in cancer therapy based on the in inhibition of HSP90, HSP70 and HSP27.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLEf_H0f1H3rVg90H21EOLACvtfcHk0lidK2HDUETdPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvVWitLs%253D&md5=4e1dcc15387cbb33d4a2d18f5defdd16</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2010.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2010.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DJego%26aufirst%3DG.%26aulast%3DHazoum%25C3%25A9%26aufirst%3DA.%26aulast%3DSeigneuric%26aufirst%3DR.%26aulast%3DGarrido%26aufirst%3DC.%26atitle%3DTargeting%2520heat%2520shock%2520proteins%2520in%2520cancer%26jtitle%3DCancer%2520Lett.%26date%3D2013%26volume%3D332%26spage%3D275%26epage%3D285%26doi%3D10.1016%2Fj.canlet.2010.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Jhaveri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span> </span><span class="NLM_article-title">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1823</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">755</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2011.10.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bbamcr.2011.10.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22062686" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=742-755&author=K.+Jhaveriauthor=T.+Taldoneauthor=S.+Modiauthor=G.+Chiosis&title=Advances+in+the+clinical+development+of+heat+shock+protein+90+%28Hsp90%29+inhibitors+in+cancers&doi=10.1016%2Fj.bbamcr.2011.10.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers</span></div><div class="casAuthors">Jhaveri, Komal; Taldone, Tony; Modi, Shanu; Chiosis, Gabriela</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">742-755</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is an ATP dependent mol. chaperone protein which integrates multiple oncogenic pathways.  As such, Hsp90 inhibition is a promising anti-cancer strategy.  Several inhibitors that act on Hsp90 by binding to its N-terminal ATP pocket have entered clin. evaluation.  Robust pre-clin. data suggested anti-tumor activity in multiple cancer types.  Clin., encouraging results have been demonstrated in melanoma, acute myeloid leukemia, castrate refractory prostate cancer, non-small cell lung carcinoma and multiple myeloma.  In breast cancer, proof-of-concept was demonstrated by first generation Hsp90 inhibitors in combination with trastuzumab mainly in human epidermal growth factor receptor 2 (HER2) + metastatic breast cancer.  There are a multitude of second generation Hsp90 inhibitors currently under investigation.  To date, however, there is no FDA approved Hsp90 inhibitor nor standardized assay to ascertain Hsp90 inhibition.  This review summarizes the current status of both first and second generation Hsp90 inhibitors based on their chem. classification and stage of clin. development.  It also discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors.  Ultimately, these efforts will aid in maximizing the full potential of this class of agents.  This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrDTpRQxfYrVg90H21EOLACvtfcHk0lidK2HDUETdPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFShsbY%253D&md5=03cef7dc96667a4698324f635aacee7a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2011.10.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2011.10.008%26sid%3Dliteratum%253Aachs%26aulast%3DJhaveri%26aufirst%3DK.%26aulast%3DTaldone%26aufirst%3DT.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26atitle%3DAdvances%2520in%2520the%2520clinical%2520development%2520of%2520heat%2520shock%2520protein%252090%2520%2528Hsp90%2529%2520inhibitors%2520in%2520cancers%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2012%26volume%3D1823%26spage%3D742%26epage%3D755%26doi%3D10.1016%2Fj.bbamcr.2011.10.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Workman, P.</span><span> </span><span class="NLM_article-title">Hsp90 molecular chaperone inhibitors: are we there yet? Clin</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">64</span><span class="NLM_x">–</span> <span class="NLM_lpage">76</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1158%2F1078-0432.CCR-11-1000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22215907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=64-76&author=L.+Neckersauthor=P.+Workman&title=Hsp90+molecular+chaperone+inhibitors%3A+are+we+there+yet%3F+Clin&doi=10.1158%2F1078-0432.CCR-11-1000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?</span></div><div class="casAuthors">Neckers, Len; Workman, Paul</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">64-76</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Heat shock protein (Hsp) 90 is an ATP-dependent mol. chaperone that is exploited by malignant cells to support activated oncoproteins, including many cancer-assocd. kinases and transcription factors, and it is essential for oncogenic transformation.  Originally viewed with skepticism, Hsp90 inhibitors are now being actively pursued by the pharmaceutical industry, with 17 agents having entered clin. trials.  Investigators established Hsp90's druggability using the natural products geldanamycin and radicicol, which mimic the unusual ATP structure adopted in the chaperone's N-terminal nucleotide-binding pocket and cause potent and selective blockade of ATP binding/hydrolysis, inhibit chaperone function, deplete oncogenic clients, and show antitumor activity.  Preclin. data obtained with these natural products have heightened interest in Hsp90 as a drug target, and 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) has shown clin. activity (as defined by Response Evaluation Criteria in Solid Tumors) in HER2+ breast cancer.  Many optimized synthetic, small-mol. Hsp90 inhibitors from diverse chemotypes are now in clin. trials.  Here, we review the discovery and development of Hsp90 inhibitors and assess their potential.  There has been significant learning from studies of the basic biol. of Hsp90, as well as translational drug development involving this chaperone, enhanced by the use of Hsp90 inhibitors as chem. probes.  Success will likely lie in treating cancers that are addicted to particular driver oncogene products (e.g., HER2, ALK, EGFR, and BRAF) that are sensitive Hsp90 clients, as well as malignancies (esp. multiple myeloma) in which buffering of proteotoxic stress is crit. for survival.  We discuss approaches for enhancing the effectiveness of Hsp90 inhibitors and highlight new chaperone and stress-response pathway targets, including HSF1 and Hsp70.  Clin Cancer Res; 18(1); 64-76.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfICmNu1IWFbVg90H21EOLACvtfcHk0lhpymq6BtccWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWmsw%253D%253D&md5=f67c3c11b5847e3866c91af2a16a63b8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1000%26sid%3Dliteratum%253Aachs%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DWorkman%26aufirst%3DP.%26atitle%3DHsp90%2520molecular%2520chaperone%2520inhibitors%253A%2520are%2520we%2520there%2520yet%253F%2520Clin%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D64%26epage%3D76%26doi%3D10.1158%2F1078-0432.CCR-11-1000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Patel, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Modi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiosis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taldone, T.</span><span> </span><span class="NLM_article-title">Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">587</span><span class="refDoi"> DOI: 10.1517/17460441.2011.563296</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1517%2F17460441.2011.563296" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2011&pages=559-587&author=H.+J.+Patelauthor=S.+Modiauthor=G.+Chiosisauthor=T.+Taldone&title=Advances+in+the+discovery+and+development+of+heat-shock+protein+90+inhibitors+for+cancer+treatment&doi=10.1517%2F17460441.2011.563296"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1517%2F17460441.2011.563296&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2011.563296%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%2BJ.%26aulast%3DModi%26aufirst%3DS.%26aulast%3DChiosis%26aufirst%3DG.%26aulast%3DTaldone%26aufirst%3DT.%26atitle%3DAdvances%2520in%2520the%2520discovery%2520and%2520development%2520of%2520heat-shock%2520protein%252090%2520inhibitors%2520for%2520cancer%2520treatment%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2011%26volume%3D6%26spage%3D559%26epage%3D587%26doi%3D10.1517%2F17460441.2011.563296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Prodromou, C.</span><span> </span><span class="NLM_article-title">Strategies for stalling malignancy: targeting cancer’s addiction to Hsp90</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1352</span><span class="NLM_x">–</span> <span class="NLM_lpage">1368</span><span class="refDoi"> DOI: 10.2174/156802609789895656</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F156802609789895656" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=19860736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFakurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=1352-1368&author=C.+Prodromou&title=Strategies+for+stalling+malignancy%3A+targeting+cancer%E2%80%99s+addiction+to+Hsp90&doi=10.2174%2F156802609789895656"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for stalling malignancy: targeting cancer's addiction to Hsp90</span></div><div class="casAuthors">Prodromou, Chrisostomos</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1352-1368</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Hsp90 is involved in the maturation and activation of client proteins.  Often these are key proteins involved in signal transduction and regulatory pathways that in a mutated and/or deregulated form sustain an oncogenic cellular state.  Consequently, the malignancy is maintained with the aid of Hsp90 upon which the mutated proteins have become particularly dependent for their activity.  The requirement for the Hsp90 chaperone machine to drive the malignancy makes Hsp90 a prime anticancer target, an 'axle in a wheel' that when disrupted has been shown to be effective in killing cancerous cells.  This review aims to identify potential drug targets, based on the current structural knowledge of the Hsp90-chaperone machine, that could be targeted with the aim of disrupting its functioning and promoting an anti-cancer activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwOal7ujNdSrVg90H21EOLACvtfcHk0lhpymq6BtccWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFakurw%253D&md5=6974085b3d0c1ad21e0931c512de5a51</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.2174%2F156802609789895656&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609789895656%26sid%3Dliteratum%253Aachs%26aulast%3DProdromou%26aufirst%3DC.%26atitle%3DStrategies%2520for%2520stalling%2520malignancy%253A%2520targeting%2520cancer%25E2%2580%2599s%2520addiction%2520to%2520Hsp90%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D1352%26epage%3D1368%26doi%3D10.2174%2F156802609789895656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Sidera, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patsavoudi, E.</span><span> </span><span class="NLM_article-title">HSP90 inhibitors: current development and potential in cancer therapy</span> <span class="citation_source-journal">Recent Pat. Anti-Cancer Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">20</span><span class="refDoi"> DOI: 10.2174/15748928113089990031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F15748928113089990031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=1-20&author=K.+Sideraauthor=E.+Patsavoudi&title=HSP90+inhibitors%3A+current+development+and+potential+in+cancer+therapy&doi=10.2174%2F15748928113089990031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.2174%2F15748928113089990031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F15748928113089990031%26sid%3Dliteratum%253Aachs%26aulast%3DSidera%26aufirst%3DK.%26aulast%3DPatsavoudi%26aufirst%3DE.%26atitle%3DHSP90%2520inhibitors%253A%2520current%2520development%2520and%2520potential%2520in%2520cancer%2520therapy%26jtitle%3DRecent%2520Pat.%2520Anti-Cancer%2520Drug%2520Discovery%26date%3D2013%26volume%3D9%26spage%3D1%26epage%3D20%26doi%3D10.2174%2F15748928113089990031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Trepel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mollapour, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giaccone, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Targeting the dynamic HSP90 complex in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">537</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span><span class="refDoi"> DOI: 10.1038/nrc2887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnrc2887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20651736" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=537-549&author=J.+Trepelauthor=M.+Mollapourauthor=G.+Giacconeauthor=L.+Neckers&title=Targeting+the+dynamic+HSP90+complex+in+cancer&doi=10.1038%2Fnrc2887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the dynamic HSP90 complex in cancer</span></div><div class="casAuthors">Trepel, Jane; Mollapour, Mehdi; Giaccone, Giuseppe; Neckers, Len</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">537-549</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The mol. chaperone, heat-shock protein 90 (HSP90), has been used by cancer cells to facilitate the function of numerous oncoproteins, and it can be argued that cancer cells are 'addicted' to HSP90.  However, although recent reports of the early clin. efficacy of HSP90 inhibitors are encouraging, the optimal use of HSP90-targeted therapeutics will depend on understanding the complexity of HSP90 regulation and the degree to which HSP90 participates in both neoplastic and normal cellular physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGEqkx6m7p7Vg90H21EOLACvtfcHk0lhpymq6BtccWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpt1GjtLs%253D&md5=8acba020073ebb93cf1dee577420dc32</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnrc2887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2887%26sid%3Dliteratum%253Aachs%26aulast%3DTrepel%26aufirst%3DJ.%26aulast%3DMollapour%26aufirst%3DM.%26aulast%3DGiaccone%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DTargeting%2520the%2520dynamic%2520HSP90%2520complex%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D537%26epage%3D549%26doi%3D10.1038%2Fnrc2887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, N. U.</span><span> </span><span class="NLM_article-title">HSP90 as a platform for the assembly of more effective cancer chemotherapy</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">1823</span><span class="NLM_x">, </span> <span class="NLM_fpage">756</span><span class="NLM_x">–</span> <span class="NLM_lpage">766</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2011.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bbamcr.2011.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22222203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtV2qs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1823&publication_year=2012&pages=756-766&author=L.+Whitesellauthor=N.+U.+Lin&title=HSP90+as+a+platform+for+the+assembly+of+more+effective+cancer+chemotherapy&doi=10.1016%2Fj.bbamcr.2011.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 as a platform for the assembly of more effective cancer chemotherapy</span></div><div class="casAuthors">Whitesell, Luke; Lin, Nancy U.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">1823</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">756-766</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Since initial discovery of the first HSP90 inhibitor over a decade and a half ago, tremendous progress has been made in developing potent and selective compds. with which to target this chaperone in the treatment of cancers.  These compds. have been invaluable in dissecting how HSP90 supports the dramatic alterations in cellular physiol. that constitute the malignant phenotype and give rise to the clin. manifestations of diverse cancers.  Unfortunately, single agent activity for HSP90 inhibitors has been disappointingly modest against recurrent, refractory cancers in most of the clin. trials that have been reported to date.  This problem could be due to pharmacol. limitations of the first-generation inhibitors that have been most extensively studied.  But we suggest it may well be intrinsic to the target itself.  This review will focus on how the utilization of HSP90 by cancer cells might be targeted to enhance the activity of other anticancer drugs while at the same time limiting the ability of advanced cancers to adapt and evolve drug resistance; the net result being more durable disease control.  A better understanding of these fundamental issues will surely make the ongoing clin. development of HSP90 inhibitors as anticancer drugs less empiric, more efficient and hopefully more successful.  This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxQycmhIHXy7Vg90H21EOLACvtfcHk0liqTRX7Qc7NzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtV2qs78%253D&md5=bee2159799a412673527f05332e7f677</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2011.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2011.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DN.%2BU.%26atitle%3DHSP90%2520as%2520a%2520platform%2520for%2520the%2520assembly%2520of%2520more%2520effective%2520cancer%2520chemotherapy%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2012%26volume%3D1823%26spage%3D756%26epage%3D766%26doi%3D10.1016%2Fj.bbamcr.2011.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Yamaki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakajima, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimotohno, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, N.</span><span> </span><span class="NLM_article-title">Molecular basis for the actions of Hsp90 inhibitors and cancer therapy</span> <span class="citation_source-journal">J. Antibiot.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">635</span><span class="NLM_x">–</span> <span class="NLM_lpage">644</span><span class="refDoi"> DOI: 10.1038/ja.2011.60</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fja.2011.60" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2011&pages=635-644&author=H.+Yamakiauthor=M.+Nakajimaauthor=K.+W.+Shimotohnoauthor=N.+Tanaka&title=Molecular+basis+for+the+actions+of+Hsp90+inhibitors+and+cancer+therapy&doi=10.1038%2Fja.2011.60"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fja.2011.60&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fja.2011.60%26sid%3Dliteratum%253Aachs%26aulast%3DYamaki%26aufirst%3DH.%26aulast%3DNakajima%26aufirst%3DM.%26aulast%3DShimotohno%26aufirst%3DK.%2BW.%26aulast%3DTanaka%26aufirst%3DN.%26atitle%3DMolecular%2520basis%2520for%2520the%2520actions%2520of%2520Hsp90%2520inhibitors%2520and%2520cancer%2520therapy%26jtitle%3DJ.%2520Antibiot.%26date%3D2011%26volume%3D64%26spage%3D635%26epage%3D644%26doi%3D10.1038%2Fja.2011.60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Burlison, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maxwell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">128</span><span class="NLM_x">, </span> <span class="NLM_fpage">15529</span><span class="NLM_x">–</span> <span class="NLM_lpage">15536</span><span class="refDoi"> DOI: 10.1021/ja065793p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja065793p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFykur3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=15529-15536&author=J.+A.+Burlisonauthor=L.+Neckersauthor=A.+B.+Smithauthor=A.+Maxwellauthor=B.+S.+J.+Blagg&title=Novobiocin%3A+redesigning+a+DNA+gyrase+inhibitor+for+selective+inhibition+of+hsp90&doi=10.1021%2Fja065793p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Novobiocin: Redesigning a DNA Gyrase Inhibitor for Selective Inhibition of Hsp90</span></div><div class="casAuthors">Burlison, Joseph A.; Neckers, Len; Smith, Andrew B.; Maxwell, Anthony; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">15529-15536</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novobiocin is a member of the coumermycin family of antibiotics and is a well-established inhibitor of DNA gyrase.  Recent studies have shown that novobiocin binds to a previously unrecognized ATP-binding site at the C-terminus of Hsp90 and induces degrdn. of Hsp90-dependent client proteins at ∼700 μM.  In an effort to develop more efficacious inhibitors of the C-terminal binding site, a library of novobiocin analogs was prepd. and initial structure-activity relationships revealed.  These data suggested that the 4-hydroxy moiety of the coumarin ring and the 3'-carbamate of the noviose appendage were detrimental to Hsp90 inhibitory activity.  In an effort to confirm these findings, 4-deshydroxynovobiocin (DHN1) and 3'-descarbamoyl-4-deshydroxynovobiocin (DHN2) were prepd. and evaluated against Hsp90.  Both compds. were significantly more potent than the natural product, and DHN2 proved to be more active than DHN1.  In an effort to det. whether these moieties are important for DNA gyrase inhibition, these compds. were tested for their ability to inhibit DNA gyrase and found to exhibit significant redn. in gyrase activity.  Thus, we have established the first set of compds. that clearly differentiate between the C-terminus of Hsp90 and DNA gyrase, converted a well-established gyrase inhibitor into a selective Hsp90 inhibitor, and confirmed essential structure-activity relationships for the coumermycin family of antibiotics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZJ-UWkhOYnLVg90H21EOLACvtfcHk0liqTRX7Qc7NzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFykur3I&md5=975936180c6bf06502c8ffdee28eaf1e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fja065793p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja065793p%26sid%3Dliteratum%253Aachs%26aulast%3DBurlison%26aufirst%3DJ.%2BA.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DMaxwell%26aufirst%3DA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DNovobiocin%253A%2520redesigning%2520a%2520DNA%2520gyrase%2520inhibitor%2520for%2520selective%2520inhibition%2520of%2520hsp90%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D15529%26epage%3D15536%26doi%3D10.1021%2Fja065793p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Le Bras, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radanyi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyrat, J.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brion, J.-D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsaud, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Renoir, J.-M.</span><span> </span><span class="NLM_article-title">New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">6189</span><span class="NLM_x">–</span> <span class="NLM_lpage">6200</span><span class="refDoi"> DOI: 10.1021/jm0707774</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0707774" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1KitrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6189-6200&author=G.+Le+Brasauthor=C.+Radanyiauthor=J.-F.+Peyratauthor=J.-D.+Brionauthor=M.+Alamiauthor=V.+Marsaudauthor=B.+Stellaauthor=J.-M.+Renoir&title=New+novobiocin+analogues+as+antiproliferative+agents+in+breast+cancer+cells+and+potential+inhibitors+of+heat+shock+protein+90&doi=10.1021%2Fjm0707774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">New Novobiocin Analogues as Antiproliferative Agents in Breast Cancer Cells and Potential Inhibitors of Heat Shock Protein 90</span></div><div class="casAuthors">Le Bras, Gaeelle; Radanyi, Christine; Peyrat, Jean-Francois; Brion, Jean-Daniel; Alami, Mouad; Marsaud, Veronique; Stella, Barbara; Renoir, Jack-Michel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6189-6200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective hsp90 inhibitors simultaneously destabilize and deplete key signaling proteins involved in cell proliferation and survival, angiogenesis, and metastasis.  Investigation of novobiocin analogs lacking the noviose moiety as novel inhibitors of hsp90 was carried out.  A novel series of 3-aminocoumarin analogs has been produced and screened in cell proliferation, and the mol. signature of hsp90 inhibition was assessed by depletion of estrogen receptor, HER2, Raf-1, and cdk4 in human breast cancer cells.  This structure-activity relationship study highlights the crucial role of the C-4 and/or C-7 positions of coumarin which appeared to be essential for degrdn. of hsp90 client proteins.  Removal of the noviose moiety in novobiocin together with introduction of a tosyl substituent at C-4 or C-7 coumarins provides two compds. (I and II) as lead structures which compared favorably with novobiocin as demonstrated by enhanced rates of cell death.  The processing and activation of caspases 7 and 8 and the subsequent cleavage of PARP by I suggest stimulation of the extrinsic apoptosis pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Z-0jegYY_LVg90H21EOLACvtfcHk0ljXVrfyEo-hCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1KitrnM&md5=8ae2bde5c8e0d5d97a2f6fde241a5e83</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm0707774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0707774%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BBras%26aufirst%3DG.%26aulast%3DRadanyi%26aufirst%3DC.%26aulast%3DPeyrat%26aufirst%3DJ.-F.%26aulast%3DBrion%26aufirst%3DJ.-D.%26aulast%3DAlami%26aufirst%3DM.%26aulast%3DMarsaud%26aufirst%3DV.%26aulast%3DStella%26aufirst%3DB.%26aulast%3DRenoir%26aufirst%3DJ.-M.%26atitle%3DNew%2520novobiocin%2520analogues%2520as%2520antiproliferative%2520agents%2520in%2520breast%2520cancer%2520cells%2520and%2520potential%2520inhibitors%2520of%2520heat%2520shock%2520protein%252090%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6189%26epage%3D6200%26doi%3D10.1021%2Fjm0707774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Burlison, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avila, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubbers, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">2130</span><span class="NLM_x">–</span> <span class="NLM_lpage">2137</span><span class="refDoi"> DOI: 10.1021/jo702191a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo702191a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlOmsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=2130-2137&author=J.+A.+Burlisonauthor=C.+Avilaauthor=G.+Vielhauerauthor=D.+J.+Lubbersauthor=J.+Holzbeierleinauthor=B.+S.+J.+Blagg&title=Development+of+novobiocin+analogues+that+manifest+anti-proliferative+activity+against+several+cancer+cell+lines&doi=10.1021%2Fjo702191a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Novobiocin Analogues That Manifest Anti-proliferative Activity against Several Cancer Cell Lines</span></div><div class="casAuthors">Burlison, Joseph A.; Avila, Christopher; Vielhauer, George; Lubbers, Donna J.; Holzbeierlein, Jeffrey; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2130-2137</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent studies have shown that the DNA gyrase inhibitor, novobiocin, binds to a previously unrecognized ATP-binding site located at the C-terminus of Hsp90 and induces degrdn. of Hsp90-dependent client proteins at ∼700 μM.  As a result of these studies, several analogs of the coumarin family of antibiotics have been reported and shown to exhibit increased Hsp90 inhibitory activity; however, the monomeric species lacked the ability to manifest anti-proliferative activity against cancer cell lines at concns. tested.  In an effort to develop more efficacious compds. that produce growth inhibitory activity against cancer cell lines, structure-activity relationships were investigated surrounding the prenylated benzamide side chain of the natural product.  Results obtained from these studies have produced the first novobiocin analogs, e.g. I, that manifest anti-proliferative activity against several cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkVgns7ITFAbVg90H21EOLACvtfcHk0ljXVrfyEo-hCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlOmsLk%253D&md5=b8b808cf8c34780fae33215943cde182</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjo702191a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo702191a%26sid%3Dliteratum%253Aachs%26aulast%3DBurlison%26aufirst%3DJ.%2BA.%26aulast%3DAvila%26aufirst%3DC.%26aulast%3DVielhauer%26aufirst%3DG.%26aulast%3DLubbers%26aufirst%3DD.%2BJ.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DDevelopment%2520of%2520novobiocin%2520analogues%2520that%2520manifest%2520anti-proliferative%2520activity%2520against%2520several%2520cancer%2520cell%2520lines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D2130%26epage%3D2137%26doi%3D10.1021%2Fjo702191a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Cohen, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukerji, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samadi, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span> </span><span class="NLM_article-title">Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents</span> <span class="citation_source-journal">Ann. Surgical Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">483</span><span class="NLM_x">–</span> <span class="NLM_lpage">490</span><span class="refDoi"> DOI: 10.1245/s10434-011-1971-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1245%2Fs10434-011-1971-1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=483-490&author=S.+M.+Cohenauthor=R.+Mukerjiauthor=A.+K.+Samadiauthor=H.+Zhaoauthor=B.+S.+J.+Blaggauthor=M.+S.+Cohen&title=Novel+C-terminal+Hsp90+inhibitor+for+head+and+neck+squamous+cell+cancer+%28HNSCC%29+with+in+vivo+efficacy+and+improved+toxicity+profiles+compared+with+standard+agents&doi=10.1245%2Fs10434-011-1971-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1245%2Fs10434-011-1971-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1245%252Fs10434-011-1971-1%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%2BM.%26aulast%3DMukerji%26aufirst%3DR.%26aulast%3DSamadi%26aufirst%3DA.%2BK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26atitle%3DNovel%2520C-terminal%2520Hsp90%2520inhibitor%2520for%2520head%2520and%2520neck%2520squamous%2520cell%2520cancer%2520%2528HNSCC%2529%2520with%2520in%2520vivo%2520efficacy%2520and%2520improved%2520toxicity%2520profiles%2520compared%2520with%2520standard%2520agents%26jtitle%3DAnn.%2520Surgical%2520Oncol.%26date%3D2012%26volume%3D19%26spage%3D483%26epage%3D490%26doi%3D10.1245%2Fs10434-011-1971-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Donnelly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2702</span><span class="NLM_x">–</span> <span class="NLM_lpage">2717</span><span class="refDoi"> DOI: 10.2174/092986708786242895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F092986708786242895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=18991631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlWiur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2702-2717&author=A.+Donnellyauthor=B.+S.+J.+Blagg&title=Novobiocin+and+additional+inhibitors+of+the+Hsp90+C-terminal+nucleotide-binding+pocket&doi=10.2174%2F092986708786242895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide binding pocket</span></div><div class="casAuthors">Donnelly, Alison; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2702-2717</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The 90 kDa heat shock proteins (Hsp90), which are integrally involved in cell signaling, proliferation, and survival, are ubiquitously expressed in cells.  Many proteins in tumor cells are dependent upon the Hsp90 protein folding machinery for their stability, refolding, and maturation.  Inhibition of Hsp90 uniquely targets client proteins assocd. with all six hallmarks of cancer.  Thus, Hsp90 has emerged as a promising target for the treatment of cancer.  Hsp90 exists as a homodimer, which contains three domains.  The N-terminal domain contains an ATP-binding site that binds the natural products geldanamycin and radicicol.  The middle domain is highly charged and has high affinity for cochaperones and client proteins.  Initial studies by Csermely and co-workers suggested a second ATP-binding site in the C-terminus of Hsp90.  This C-terminal nucleotide binding pocket has been shown to not only bind ATP, but cisplatin, novobiocin, epigallocatechin-3-gallate (EGCG) and taxol.  The coumarin antibiotics novobiocin, clorobiocin, and coumermycin A1 were isolated from several streptomyces strains and exhibit potent activity against Gram-pos. bacteria.  These compds. bind type II topoisomerases, including DNA gyrase, and inhibit the enzyme-catalyzed hydrolysis of ATP.  As a result, novobiocin analogs have garnered the attention of numerous researchers as an attractive agent for the treatment of bacterial infection.  Novobiocin was reported to bind weakly to the newly discovered Hsp90 C-terminal ATP binding site (∼700 M in SkBr3 cells) and induce degrdn. of Hsp90 client proteins.  Structural modification of this compds. has led to an increase of 1000-fold in activity in antiproliferative assays.  Recent studies of structure-activity relationship (SAR) by Renoir and co-workers highlighted the crucial role of the C-4 and/or C-7 positions of the coumarin and removal of the noviose moiety, which appeared to be essential for degrdn. of Hsp90 client proteins.  Unlike the N-terminal ATP binding site, there is no reported co-crystal structure of Hsp90 C-terminus bound to any inhibitor.  The Hsp90 C-terminal domain however, is known to contain a conserved pentapeptide sequence (MEEVD) which is recognized by co-chaperones.  Cisplatin is a platinum-contg. chemotherapeutic used to treat various types of cancers, including testicular, ovarian, bladder, and small cell lung cancer.  Most notably, cisplatin coordinates to DNA bases, resulting in cross-linked DNA, which prohibits rapidly dividing cells from duplicating DNA for mitosis.  Itoh and co-workers reported that cisplatin decreases the chaperone activity of Hsp90.  This group applied bovine brain cytosol to a cisplatin affinity column, eluted with cisplatin and detected Hsp90 in the eluent.  Subsequent expts. indicated that cisplatin exhibits high affinity for Hsp90.  Moreover Csermely and co-workers detd. that the cisplatin binding site is located proximal to the C-terminal ATP binding site.  EGCG is one of the active ingredients found in green tea.  EGCG is known to inhibit the activity of many Hsp90-dependent client proteins, including telomerase, several kinases, and the aryl hydrocarbon receptor (AhR).  Recently Gasiewicz and co-workers reported that EGCG manifests its antagonistic activity against AhR through binding Hsp90.  Similar to novobiocin, EGCG was shown to bind the C-terminus of Hsp90.  Unlike previously identified N-terminal Hsp90 inhibitors, EGCG does not appear to prevent Hsp90 from forming multiprotein complexes.  Studies are currently underway to det. whether EGCG competes with novobiocin or cisplatin binding.  Taxol, a well-known drug for the treatment of cancer, is responsible for the stabilization of microtubules and the inhibition of mitosis.  Previous studies have shown that taxol induces the activation of kinases and transcription factors, and mimics the effect of bacterial lipopolysaccharide (LPS), an attribute unrelated to its tubulin-binding properties.  Rosen and co-workers prepd. a biotinylated taxol deriv. and performed affinity chromatog. expts. with lysates from both mouse brain and macrophage cell lines.  These studies led to identification of two chaperones, Hsp70 and Hsp90, by mass spectrometry.  In contrast to typical Hsp90-binding drugs, taxol exhibits a stimulatory response.  Recently it was reported that the geldanamycin deriv. 17-AAG behaves synergistically with taxol-induced apoptosis.  This review describes the different C-terminal inhibitors of Hsp90, with specific emphasis on structure-activity relationship studies of novobiocin and their effects on anti-proliferative activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJ1ZxUMTyXBrVg90H21EOLACvtfcHk0ljXVrfyEo-hCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlWiur3M&md5=ee456e11ec9730f446bffd75d5d22c5e</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F092986708786242895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708786242895%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DNovobiocin%2520and%2520additional%2520inhibitors%2520of%2520the%2520Hsp90%2520C-terminal%2520nucleotide-binding%2520pocket%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2702%26epage%3D2717%26doi%3D10.2174%2F092986708786242895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mays, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burlison, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">8901</span><span class="NLM_x">–</span> <span class="NLM_lpage">8920</span><span class="refDoi"> DOI: 10.1021/jo801312r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo801312r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1OlsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2008&pages=8901-8920&author=A.+C.+Donnellyauthor=J.+R.+Maysauthor=J.+A.+Burlisonauthor=J.+T.+Nelsonauthor=G.+Vielhauerauthor=J.+Holzbeierleinauthor=B.+S.+J.+Blagg&title=The+design%2C+synthesis%2C+and+evaluation+of+coumarin+ring+derivatives+of+the+novobiocin+scaffold+that+exhibit+antiproliferative+activity&doi=10.1021%2Fjo801312r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The Design, Synthesis, and Evaluation of Coumarin Ring Derivatives of the Novobiocin Scaffold that Exhibit Antiproliferative Activity</span></div><div class="casAuthors">Donnelly, Alison C.; Mays, Jared R.; Burlison, Joseph A.; Nelson, John T.; Vielhauer, George; Holzbeierlein, Jeffrey; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">8901-8920</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novobiocin, a known DNA gyrase inhibitor, binds to a nucleotide-binding site located on the Hsp90 C-terminus and induces degrdn. of Hsp90-dependent client proteins at ∼700 μM in breast cancer cells (SKBr3).  Although many analogs of novobiocin have been synthesized, it was only recently demonstrated that monomeric species exhibit antiproliferative activity against various cancer cell lines.  To further refine the essential elements of the coumarin core, a series of modified coumarin derivs. was synthesized and evaluated to elucidate structure-activity relationships for novobiocin as an anticancer agent.  Results obtained from these studies have produced novobiocin analogs that manifest low micro-molar activity against several cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw2Qt4p4utRLVg90H21EOLACvtfcHk0lgfVBxHSZq5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1OlsLvL&md5=70707e1f4635c955e80b40a06e3d80e3</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjo801312r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo801312r%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DMays%26aufirst%3DJ.%2BR.%26aulast%3DBurlison%26aufirst%3DJ.%2BA.%26aulast%3DNelson%26aufirst%3DJ.%2BT.%26aulast%3DVielhauer%26aufirst%3DG.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DThe%2520design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520coumarin%2520ring%2520derivatives%2520of%2520the%2520novobiocin%2520scaffold%2520that%2520exhibit%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2008%26volume%3D73%26spage%3D8901%26epage%3D8920%26doi%3D10.1021%2Fjo801312r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusuma, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Cytotoxic sugar analogues of an optimized novobiocin scaffold</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">165</span><span class="NLM_x">–</span> <span class="NLM_lpage">170</span><span class="refDoi"> DOI: 10.1039/c0md00063a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1039%2Fc0md00063a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=165-170&author=A.+C.+Donnellyauthor=H.+Zhaoauthor=B.+R.+Kusumaauthor=B.+S.+J.+Blagg&title=Cytotoxic+sugar+analogues+of+an+optimized+novobiocin+scaffold&doi=10.1039%2Fc0md00063a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1039%2Fc0md00063a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0md00063a%26sid%3Dliteratum%253Aachs%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DKusuma%26aufirst%3DB.%2BR.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DCytotoxic%2520sugar%2520analogues%2520of%2520an%2520optimized%2520novobiocin%2520scaffold%26jtitle%3DMedChemComm%26date%3D2010%26volume%3D1%26spage%3D165%26epage%3D170%26doi%3D10.1039%2Fc0md00063a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Eskew, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sadikot, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duren, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dunwiddie, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swink, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hembruff, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajewski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manjarrez, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matts, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G. A.</span><span> </span><span class="NLM_article-title">Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells</span> <span class="citation_source-journal">BMC Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">468</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span><span class="refDoi"> DOI: 10.1186/1471-2407-11-468</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1186%2F1471-2407-11-468" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22039910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSrurzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=468-485&author=J.+D.+Eskewauthor=T.+Sadikotauthor=P.+Moralesauthor=A.+Durenauthor=I.+Dunwiddieauthor=M.+Swinkauthor=X.+Zhangauthor=S.+Hembruffauthor=A.+Donnellyauthor=R.+A.+Rajewskiauthor=B.+S.+Blaggauthor=J.+R.+Manjarrezauthor=R.+L.+Mattsauthor=J.+M.+Holzbeierleinauthor=G.+A.+Vielhauer&title=Development+and+characterization+of+a+novel+C-terminal+inhibitor+of+Hsp90+in+androgen+dependent+and+independent+prostate+cancer+cells&doi=10.1186%2F1471-2407-11-468"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells</span></div><div class="casAuthors">Eskew, Jeffery D.; Sadikot, Takrima; Morales, Pedro; Duren, Alicia; Dunwiddie, Irene; Swink, Megan; Zhang, Xiaoying; Hembruff, Stacey; Donnelly, Alison; Rajewski, Roger A.; Blagg, Brian S. J.; Manjarrez, Jacob R.; Matts, Robert L.; Holzbeierlein, Jeffrey M.; Vielhauer, George A.</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">468</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: The mol. chaperone, heat shock protein 90 (Hsp90) has been shown to be overexpressed in a no. of cancers, including prostate cancer, making it an important target for drug discovery.  Unfortunately, results with N-terminal inhibitors from initial clin. trials have been disappointing, as toxicity and resistance resulting from induction of the heat shock response (HSR) has led to both scheduling and administration concerns.  Therefore, Hsp90 inhibitors that do not induce the heat shock response represent a promising new direction for the treatment of prostate cancer.  Herein, the development of a C-terminal Hsp90 inhibitor, KU174, is described, which demonstrates anti-cancer activity in prostate cancer cells in the absence of a HSR and describe a novel approach to characterize Hsp90 inhibition in cancer cells.  Methods: PC3-MM2 and LNCaP-LN3 cells were used in both direct and indirect in vitro Hsp90 inhibition assays (DARTS, Surface Plasmon Resonance, co-immunopptn., luciferase, Western blot, anti-proliferative, cytotoxicity and size exclusion chromatog.) to characterize the effects of KU174 in prostate cancer cells.  Pilot in vivo efficacy studies were also conducted with KU174 in PC3-MM2 xenograft studies.  Results: KU174 exhibits robust anti-proliferative and cytotoxic activity along with client protein degrdn. and disruption of Hsp90 native complexes without induction of a HSR.  Furthermore, KU174 demonstrates direct binding to the Hsp90 protein and Hsp90 complexes in cancer cells.  In addn., in pilot in-vivo proof-of-concept studies KU174 demonstrates efficacy at 75 mg/kg in a PC3-MM2 rat tumor model.  Conclusions: Overall, these findings suggest C-terminal Hsp90 inhibitors have potential as therapeutic agents for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgLK7KU3mfP7Vg90H21EOLACvtfcHk0lgfVBxHSZq5Tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSrurzN&md5=3edc324bd2f3db190f2b96ed11e5cb8d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1186%2F1471-2407-11-468&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1471-2407-11-468%26sid%3Dliteratum%253Aachs%26aulast%3DEskew%26aufirst%3DJ.%2BD.%26aulast%3DSadikot%26aufirst%3DT.%26aulast%3DMorales%26aufirst%3DP.%26aulast%3DDuren%26aufirst%3DA.%26aulast%3DDunwiddie%26aufirst%3DI.%26aulast%3DSwink%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHembruff%26aufirst%3DS.%26aulast%3DDonnelly%26aufirst%3DA.%26aulast%3DRajewski%26aufirst%3DR.%2BA.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26aulast%3DManjarrez%26aufirst%3DJ.%2BR.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26aulast%3DVielhauer%26aufirst%3DG.%2BA.%26atitle%3DDevelopment%2520and%2520characterization%2520of%2520a%2520novel%2520C-terminal%2520inhibitor%2520of%2520Hsp90%2520in%2520androgen%2520dependent%2520and%2520independent%2520prostate%2520cancer%2520cells%26jtitle%3DBMC%2520Cancer%26date%3D2011%26volume%3D11%26spage%3D468%26epage%3D485%26doi%3D10.1186%2F1471-2407-11-468" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Gunaherath, G. M. K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marron, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wijeratne, E. M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunatilaka, A. A. L.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5118</span><span class="NLM_x">–</span> <span class="NLM_lpage">5129</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.06.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bmc.2013.06.042" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=5118-5129&author=G.+M.+K.+B.+Gunaherathauthor=M.+T.+Marronauthor=E.+M.+K.+Wijeratneauthor=L.+Whitesellauthor=A.+A.+L.+Gunatilaka&title=Synthesis+and+biological+evaluation+of+novobiocin+analogues+as+potential+heat+shock+protein+90+inhibitors&doi=10.1016%2Fj.bmc.2013.06.042"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.06.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.06.042%26sid%3Dliteratum%253Aachs%26aulast%3DGunaherath%26aufirst%3DG.%2BM.%2BK.%2BB.%26aulast%3DMarron%26aufirst%3DM.%2BT.%26aulast%3DWijeratne%26aufirst%3DE.%2BM.%2BK.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DGunatilaka%26aufirst%3DA.%2BA.%2BL.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novobiocin%2520analogues%2520as%2520potential%2520heat%2520shock%2520protein%252090%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D5118%26epage%3D5129%26doi%3D10.1016%2Fj.bmc.2013.06.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Huang, Y.-T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">A library of noviosylated coumarin analogues</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3609</span><span class="NLM_x">–</span> <span class="NLM_lpage">3613</span><span class="refDoi"> DOI: 10.1021/jo062083t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo062083t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=3609-3613&author=Y.-T.+Huangauthor=B.+S.+J.+Blagg&title=A+library+of+noviosylated+coumarin+analogues&doi=10.1021%2Fjo062083t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">A Library of Noviosylated Coumarin Analogs</span></div><div class="casAuthors">Huang, Yung-Tzung; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3609-3613</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The DNA gyrase inhibitor, novobiocin, was recently shown to inhibit Hsp90 via a previously unrecognized C-terminal ATP-binding site.  Previous structure-activity relationship studies identified key moieties that appear important for Hsp90 inhibitory activity.  In an effort to provide a more efficacious lead compd., a parallel library of noviosylated coumarin analogs was prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6Ua-e-5E017Vg90H21EOLACvtfcHk0lhLcsIS6NJvxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSiur8%253D&md5=c780fa0523dc934c067e77655c3cd653</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjo062083t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo062083t%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-T.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DA%2520library%2520of%2520noviosylated%2520coumarin%2520analogues%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D3609%26epage%3D3613%26doi%3D10.1021%2Fjo062083t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Kusuma, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duerfeldt, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">7170</span><span class="NLM_x">–</span> <span class="NLM_lpage">7174</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2011.09.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bmcl.2011.09.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=22014546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVaqtr7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=7170-7174&author=B.+R.+Kusumaauthor=A.+S.+Duerfeldtauthor=B.+S.+J.+Blagg&title=Synthesis+and+biological+evaluation+of+arylated+novobiocin+analogs+as+Hsp90+inhibitors&doi=10.1016%2Fj.bmcl.2011.09.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors</span></div><div class="casAuthors">Kusuma, Bhaskar Reddy; Duerfeldt, Adam S.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7170-7174</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Novobiocin analogs, e.g. I, lacking labile glycosidic ether have been designed, synthesized and evaluated for Hsp90 inhibitory activity.  Replacement of the synthetically complex noviose sugar with simple arom. side chains produced analogs that maintain moderate cytotoxic activity against MCF7 and SkBR3 breast cancer cell-lines.  Rationale for the prepn. of des-noviose novobiocin analogs in addn. to their synthesis and biol. evaluation are presented herein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrswRCtFLZbcrVg90H21EOLACvtfcHk0lhLcsIS6NJvxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVaqtr7K&md5=9bf52107a44ca6f6ad0562ae142ac584</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.09.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.09.073%26sid%3Dliteratum%253Aachs%26aulast%3DKusuma%26aufirst%3DB.%2BR.%26aulast%3DDuerfeldt%26aufirst%3DA.%2BS.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520arylated%2520novobiocin%2520analogs%2520as%2520Hsp90%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D7170%26epage%3D7174%26doi%3D10.1016%2Fj.bmcl.2011.09.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Kusuma, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundstrom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrowsky, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">5797</span><span class="NLM_x">–</span> <span class="NLM_lpage">5812</span><span class="refDoi"> DOI: 10.1021/jm300544c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300544c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1SmsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5797-5812&author=B.+R.+Kusumaauthor=L.+Zhangauthor=T.+Sundstromauthor=L.+B.+Petersonauthor=R.+T.+Dobrowskyauthor=B.+S.+J.+Blagg&title=Synthesis+and+evaluation+of+novologues+as+C-terminal+Hsp90+inhibitors+with+cytoprotective+activity+against+sensory+neuron+glucotoxicity&doi=10.1021%2Fjm300544c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Evaluation of Novologues as C-Terminal Hsp90 Inhibitors with Cytoprotective Activity against Sensory Neuron Glucotoxicity</span></div><div class="casAuthors">Kusuma, Bhaskar Reddy; Zhang, Liang; Sundstrom, Teather; Peterson, Laura B.; Dobrowsky, Rick T.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5797-5812</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compd. 2 (KU-32) is a first-generation novologue (a novobiocin-based, C-terminal, heat shock protein 90 (Hsp90) inhibitor) that decreases glucose-induced death of primary sensory neurons and reverses numerous clin. indexes of diabetic peripheral neuropathy in mice.  The current study sought to exploit the C-terminal binding site of Hsp90 to det. whether the optimization of hydrogen bonding and hydrophobic interactions of second-generation novologues could enhance neuroprotective activity.  Using a series of substituted phenylboronic acids to replace the coumarin lactone of 2, we identified that electroneg. atoms placed at the meta-position of the B-ring exhibit improved cytoprotective activity, which is believed to result from favorable interactions with Lys539 in the Hsp90 C-terminal binding pocket.  Consistent with these results, a meta-3-fluorophenyl substituted novologue (13b) exhibited a 14-fold lower ED50 for protection against glucose-induced toxicity of primary sensory neurons compared to 2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrS4gyFThKBPLVg90H21EOLACvtfcHk0lhLcsIS6NJvxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1SmsL4%253D&md5=2ade8768ae7ba197b3a633babb7d6a3b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm300544c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300544c%26sid%3Dliteratum%253Aachs%26aulast%3DKusuma%26aufirst%3DB.%2BR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSundstrom%26aufirst%3DT.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DDobrowsky%26aufirst%3DR.%2BT.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520novologues%2520as%2520C-terminal%2520Hsp90%2520inhibitors%2520with%2520cytoprotective%2520activity%2520against%2520sensory%2520neuron%2520glucotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5797%26epage%3D5812%26doi%3D10.1021%2Fjm300544c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Marcu, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulte, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span> </span><span class="NLM_article-title">Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins</span> <span class="citation_source-journal">J. Nat. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">242</span><span class="NLM_x">–</span> <span class="NLM_lpage">248</span><span class="refDoi"> DOI: 10.1093/jnci/92.3.242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1093%2Fjnci%2F92.3.242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10655441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtFShsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2000&pages=242-248&author=M.+G.+Marcuauthor=T.+W.+Schulteauthor=L.+Neckers&title=Novobiocin+and+related+coumarins+and+depletion+of+heat+shock+protein+90-dependent+signaling+proteins&doi=10.1093%2Fjnci%2F92.3.242"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins</span></div><div class="casAuthors">Marcu, Monica G.; Schulte, Theodore W.; Neckers, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">242-248</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Heat shock protein 90 (Hsp90) interacts with and stabilizes several oncogenic protein kinases (e.g., p185erbB2, p60v-src, and Raf-1) and is required for the stability and dominant-neg. function of mutated p53 protein.  Two unrelated antibiotics, geldanamycin and radicicol, bind specifically to an atypical nucleotide-binding pocket of Hsp90, a site that shares homol. with the ATP-binding domain of bacterial DNA gyrase B.  This interaction leads to destabilization of proteins that interact with Hsp90.  Since the nucleotide-binding site of gyrase B is targeted by coumarin antibiotics (e.g., novobiocin), we investigated whether these drugs can also interact with Hsp90 and affect its activity.  We used immobilized novobiocin, geldanamycin, or radicicol to isolate either endogenous Hsp90 from cell lysates or Hsp90 deletion fragments translated in vitro.  Effects of the coumarin antibiotics novobiocin, chlorobiocin, and coumermycin A1 on several proteins interacting with Hsp90 were assessed in vitro and in vivo.  Hsp90 binding to immobilized novobiocin was competed by sol. coumarins and ATP but not by geldanamycin or radicicol.  A carboxy-terminal Hsp90 fragment bound immobilized novobiocin but not immobilized geldanamycin, while a geldanamycin-binding amino-terminal fragment did not bind novobiocin.  All three coumarins markedly reduced cellular levels of p185erbB2, p60v-src, Raf-1, and mutated p53.  Furthermore, novobiocin reduced Raf-1 levels in the spleens of mice treated with the drug.  These coumarin antibiotics, particularly novobiocin, represent a first-generation alternative to other Hsp90-targeting drugs that are not as well tolerated.  Novobiocin's unique interaction with Hsp90 identifies an addnl. site on this protein amenable to pharmacol. interference with small mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSMDAYykmhSbVg90H21EOLACvtfcHk0lhdRmiOPcEbmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtFShsbk%253D&md5=05873d976f0d6a3e721576732e580ff2</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2F92.3.242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252F92.3.242%26sid%3Dliteratum%253Aachs%26aulast%3DMarcu%26aufirst%3DM.%2BG.%26aulast%3DSchulte%26aufirst%3DT.%2BW.%26aulast%3DNeckers%26aufirst%3DL.%26atitle%3DNovobiocin%2520and%2520related%2520coumarins%2520and%2520depletion%2520of%2520heat%2520shock%2520protein%252090-dependent%2520signaling%2520proteins%26jtitle%3DJ.%2520Nat.%2520Cancer%2520Inst.%26date%3D2000%26volume%3D92%26spage%3D242%26epage%3D248%26doi%3D10.1093%2Fjnci%2F92.3.242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Matthews, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manthe, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaguturu, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matts, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J. M.</span><span> </span><span class="NLM_article-title">Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells</span> <span class="citation_source-journal">Prostate</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">36</span><span class="refDoi"> DOI: 10.1002/pros.21035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1002%2Fpros.21035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=19739131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1KjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=27-36&author=S.+B.+Matthewsauthor=G.+A.+Vielhauerauthor=C.+A.+Mantheauthor=V.+K.+Chaguturuauthor=K.+Szablaauthor=R.+L.+Mattsauthor=A.+C.+Donnellyauthor=B.+S.+Blaggauthor=J.+M.+Holzbeierlein&title=Characterization+of+a+novel+novobiocin+analogue+as+a+putative+C-terminal+inhibitor+of+heat+shock+protein+90+in+prostate+cancer+cells&doi=10.1002%2Fpros.21035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells</span></div><div class="casAuthors">Matthews, Shawna B.; Vielhauer, George A.; Manthe, Craig A.; Chaguturu, Vamsee K.; Szabla, Kristen; Matts, Robert L.; Donnelly, Alison C.; Blagg, Brian S. J.; Holzbeierlein, Jeffrey M.</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-36</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">PURPOSE: Hsp90 is important in the folding, maturation and stabilization of pro-tumorigenic client proteins and represents a viable drug target for the design of chemotherapies.  Previously, we reported the development of novobiocin analogs designed to inhibit the C-terminal portion of Hsp90, which demonstrated the ability to decrease client protein expression.  We now report the characterization of the novel novobiocin analog, F-4, which demonstrates improved cytotoxicity in prostate cancer cell lines compared to the N-terminal inhibitor, 17-AAG.  MATERIALS AND METHODS: LNCaP and PC-3 cells were treated with 17-AAG or F-4 in anti-proliferative, apoptosis, cell cycle and cytotoxicity assays.  Western blot and prostate specific antigen (PSA) ELISAs were used to det. client protein degrdn., induction of Hsp90 and to assess the functional status of the androgen receptor (AR) in response to F-4 treatment.  Surface plasmon resonance (SPR) was also used to det. the binding properties of F-4 to Hsp90.  RESULTS: F-4 demonstrated improved potency and efficacy compared to novobiocin in anti-proliferative assays and decreased expression of client proteins.  PSA secretion was inhibited in a dose-dependent manner that paralleled a decrease in AR expression.  The binding of F-4 to Hsp90 was detd. to be saturable with a binding affinity (Kd) of 100 μM.  In addn., superior efficacy was demonstrated by F-4 compared to 17-AAG in expts. measuring cytotoxicity and apoptosis.  CONCLUSIONS: These data reveal distinct modes of action for N-terminal and C-terminal Hsp90 inhibitors, which may offer unique therapeutic benefits for the treatment of prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOcr8uVjuhsbVg90H21EOLACvtfcHk0lhdRmiOPcEbmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1KjtbY%253D&md5=aa51b9498eaf8db0f4bf167cbd231148</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fpros.21035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.21035%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DS.%2BB.%26aulast%3DVielhauer%26aufirst%3DG.%2BA.%26aulast%3DManthe%26aufirst%3DC.%2BA.%26aulast%3DChaguturu%26aufirst%3DV.%2BK.%26aulast%3DSzabla%26aufirst%3DK.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%2BM.%26atitle%3DCharacterization%2520of%2520a%2520novel%2520novobiocin%2520analogue%2520as%2520a%2520putative%2520C-terminal%2520inhibitor%2520of%2520heat%2520shock%2520protein%252090%2520in%2520prostate%2520cancer%2520cells%26jtitle%3DProstate%26date%3D2010%26volume%3D70%26spage%3D27%26epage%3D36%26doi%3D10.1002%2Fpros.21035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Shelton, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shawgo, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabla, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanol, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajewski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matts, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, J. D.</span><span> </span><span class="NLM_article-title">KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">1314</span><span class="NLM_x">–</span> <span class="NLM_lpage">1322</span><span class="refDoi"> DOI: 10.1124/mol.109.058545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1124%2Fmol.109.058545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=19741006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFajtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=1314-1322&author=S.+N.+Sheltonauthor=M.+E.+Shawgoauthor=S.+B.+Matthewsauthor=Y.+Luauthor=A.+C.+Donnellyauthor=K.+Szablaauthor=M.+Tanolauthor=G.+A.+Vielhauerauthor=R.+A.+Rajewskiauthor=R.+L.+Mattsauthor=B.+S.+Blaggauthor=J.+D.+Robertson&title=KU135%2C+a+novel+novobiocin-derived+C-terminal+inhibitor+of+the+90-kDa+heat+shock+protein%2C+exerts+potent+antiproliferative+effects+in+human+leukemic+cells&doi=10.1124%2Fmol.109.058545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells</span></div><div class="casAuthors">Shelton, Shary N.; Shawgo, Mary E.; Matthews, Shawna B.; Lu, Yuanming; Donnelly, Alison C.; Szabla, Kristen; Tanol, Mehmet; Vielhauer, George A.; Rajewski, Roger A.; Matts, Robert L.; Blagg, Brian S. J.; Robertson, John D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1314-1322</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The 90-kDa heat shock protein (Hsp90) assists in the proper folding of numerous mutated or overexpressed signal transduction proteins that are involved in cancer.  Consequently, there is considerable interest in developing chemotherapeutic drugs that specifically disrupt the function of Hsp90.  Here, we investigated the extent to which a novel novobiocin-derived C-terminal Hsp90 inhibitor, designated KU135, induced antiproliferative effects in Jurkat T-lymphocytes.  The results indicated that KU135 bound directly to Hsp90, caused the degrdn. of known Hsp90 client proteins, and induced more potent antiproliferative effects than the established N-terminal Hsp90 inhibitor 17-allylamino-demethoxygeldanamycin (17-AAG).  Closer examn. of the cellular response to KU135 and 17-AAG revealed that only 17-AAG induced a strong up-regulation of Hsp70 and Hsp90.  In addn., KU135 caused wild-type cells to undergo G2/M arrest, whereas cells treated with 17-AAG accumulated in G1.  Furthermore, KU135 but not 17-AAG was found to be a potent inducer of mitochondria-mediated apoptosis as evidenced, in part, by the fact that cell death was inhibited to a similar extent by Bcl-2/Bcl-xL overexpression or the depletion of apoptotic protease-activating factor-1 (Apaf-1).  Together, these data suggest that KU135 inhibits cell proliferation by regulating signaling pathways that are mechanistically different from those targeted by 17-AAG and as such represents a novel opportunity for Hsp90 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnRfCmPO43irVg90H21EOLACvtfcHk0lhiUVoGXZpocQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFajtbzK&md5=03fe82110c457194b6a58a9222ffaeac</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.058545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.058545%26sid%3Dliteratum%253Aachs%26aulast%3DShelton%26aufirst%3DS.%2BN.%26aulast%3DShawgo%26aufirst%3DM.%2BE.%26aulast%3DMatthews%26aufirst%3DS.%2BB.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DSzabla%26aufirst%3DK.%26aulast%3DTanol%26aufirst%3DM.%26aulast%3DVielhauer%26aufirst%3DG.%2BA.%26aulast%3DRajewski%26aufirst%3DR.%2BA.%26aulast%3DMatts%26aufirst%3DR.%2BL.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%26aulast%3DRobertson%26aufirst%3DJ.%2BD.%26atitle%3DKU135%252C%2520a%2520novel%2520novobiocin-derived%2520C-terminal%2520inhibitor%2520of%2520the%252090-kDa%2520heat%2520shock%2520protein%252C%2520exerts%2520potent%2520antiproliferative%2520effects%2520in%2520human%2520leukemic%2520cells%26jtitle%3DMol.%2520Pharmacol.%26date%3D2009%26volume%3D76%26spage%3D1314%26epage%3D1322%26doi%3D10.1124%2Fmol.109.058545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Yu, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neckers, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronk, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Hsp90 inhibitors identified from a library of novobiocin analogues</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">12778</span><span class="NLM_x">–</span> <span class="NLM_lpage">12779</span><span class="refDoi"> DOI: 10.1021/ja0535864</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0535864" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1Whs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2005&pages=12778-12779&author=X.+M.+Yuauthor=G.+Shenauthor=L.+Neckersauthor=H.+Blakeauthor=J.+Holzbeierleinauthor=B.+Cronkauthor=B.+S.+J.+Blagg&title=Hsp90+inhibitors+identified+from+a+library+of+novobiocin+analogues&doi=10.1021%2Fja0535864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90 Inhibitors Identified from a Library of Novobiocin Analogues</span></div><div class="casAuthors">Yu, Xiao Ming; Shen, Gang; Neckers, Len; Blake, Helen; Holzbeierlein, Jeff; Cronk, Benjamin; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">12778-12779</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novobiocin is a C-terminal inhibitor of the Hsp90 protein folding machinery, which is responsible for the conformational maturation of numerous proteins involved in cancer growth and survival.  Due to novobiocin's poor inhibitory activity (∼700 μM), very little attention has been paid toward the development of novobiocin analogs for Hsp90 inhibition.  In this study, a parallel library of 20 novobiocin derivs. was prepd. and the biol. activity of each evaluated by Western blot anal. of Hsp90 client proteins.  A4 was found to be a potent inhibitor of Hsp90 as detd. by its ability to cause the degrdn. of several Hsp90 client proteins in both breast and prostate cancer cell lines.  In the presence of 1 μM A4, several Hsp90 client proteins were degraded, including AKT, Her2, Hif-1α, and the androgen receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB6oRUcNBq9rVg90H21EOLACvtfcHk0lhiUVoGXZpocQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1Whs7g%253D&md5=85673a4859f2dd938c5d9f0cc28737e0</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fja0535864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0535864%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DX.%2BM.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DNeckers%26aufirst%3DL.%26aulast%3DBlake%26aufirst%3DH.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DCronk%26aufirst%3DB.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DHsp90%2520inhibitors%2520identified%2520from%2520a%2520library%2520of%2520novobiocin%2520analogues%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2005%26volume%3D127%26spage%3D12778%26epage%3D12779%26doi%3D10.1021%2Fja0535864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Zhao, H.; Blagg, B. S. J.</span> In  <span class="citation_source-book">Inhibitors of Molecular Chaperones as Therapeutic Agents</span>; <span class="NLM_contrib-group">Machajewski, T.; Gao, Z.</span>, Eds.; <span class="NLM_publisher-name">Royal Society of Chemistry</span>: <span class="NLM_publisher-loc">Cambridge</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">; </span>Vol.  <span class="NLM_volume">37</span>, p  <span class="NLM_fpage">259</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1039%2F9781849739689-00259" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=259&author=H.+Zhao&author=B.+S.+J.+Blaggauthor=T.+Machajewski&author=Z.+Gao&title=Inhibitors+of+Molecular+Chaperones+as+Therapeutic+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1039%2F9781849739689-00259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1039%252F9781849739689-00259%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26btitle%3DInhibitors%2520of%2520Molecular%2520Chaperones%2520as%2520Therapeutic%2520Agents%26aulast%3DMachajewski%26aufirst%3DT.%26pub%3DRoyal%2520Society%2520of%2520Chemistry%26date%3D2013%26volume%3D37%26spage%3D259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Novobiocin analogues with second-generation noviose surrogates</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">552</span><span class="NLM_x">–</span> <span class="NLM_lpage">557</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2012.11.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.bmcl.2012.11.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=552-557&author=H.+Zhaoauthor=B.+S.+J.+Blagg&title=Novobiocin+analogues+with+second-generation+noviose+surrogates&doi=10.1016%2Fj.bmcl.2012.11.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.11.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.11.022%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DNovobiocin%2520analogues%2520with%2520second-generation%2520noviose%2520surrogates%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D552%26epage%3D557%26doi%3D10.1016%2Fj.bmcl.2012.11.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donnelly, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kusuma, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rajewski, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">3839</span><span class="NLM_x">–</span> <span class="NLM_lpage">3853</span><span class="refDoi"> DOI: 10.1021/jm200148p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200148p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvVSltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=3839-3853&author=H.+Zhaoauthor=A.+C.+Donnellyauthor=B.+R.+Kusumaauthor=G.+E.+Brandtauthor=D.+Brownauthor=R.+A.+Rajewskiauthor=G.+Vielhauerauthor=J.+Holzbeierleinauthor=M.+S.+Cohenauthor=B.+S.+J.+Blagg&title=Engineering+an+antibiotic+to+fight+cancer%3A+optimization+of+the+novobiocin+scaffold+to+produce+anti-proliferative+agents&doi=10.1021%2Fjm200148p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Engineering an Antibiotic to Fight Cancer: Optimization of the Novobiocin Scaffold to Produce Anti-proliferative Agents</span></div><div class="casAuthors">Zhao, Huiping; Donnelly, Alison C.; Kusuma, Bhaskar R.; Brandt, Gary E. L.; Brown, Douglas; Rajewski, Roger A.; Vielhauer, George; Holzbeierlein, Jeffrey; Cohen, Mark S.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3839-3853</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety.  These species exhibit ∼700-fold improved anti-proliferative activity vs. the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines.  Utilization of structure-activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest mid-nanomolar activity against a panel of cancer cell lines and serve as lead compds. that manifest their activities through Hsp90 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7QwyWM4aQ1rVg90H21EOLACvtfcHk0lhiUVoGXZpocQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvVSltL8%253D&md5=3ab2c790e0155c35edadf87f24c9d42b</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1021%2Fjm200148p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200148p%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DDonnelly%26aufirst%3DA.%2BC.%26aulast%3DKusuma%26aufirst%3DB.%2BR.%26aulast%3DBrandt%26aufirst%3DG.%2BE.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DRajewski%26aufirst%3DR.%2BA.%26aulast%3DVielhauer%26aufirst%3DG.%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DEngineering%2520an%2520antibiotic%2520to%2520fight%2520cancer%253A%2520optimization%2520of%2520the%2520novobiocin%2520scaffold%2520to%2520produce%2520anti-proliferative%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D3839%26epage%3D3853%26doi%3D10.1021%2Fjm200148p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">331</span><span class="refDoi"> DOI: 10.1021/ml300018e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300018e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=327-331&author=H.+Zhaoauthor=B.+Yanauthor=L.+B.+Petersonauthor=B.+S.+J.+Blagg&title=3-Arylcoumarin+derivatives+manifest+anti-proliferative+activity+through+Hsp90+inhibition&doi=10.1021%2Fml300018e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fml300018e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300018e%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DPeterson%26aufirst%3DL.%2BB.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3D3-Arylcoumarin%2520derivatives%2520manifest%2520anti-proliferative%2520activity%2520through%2520Hsp90%2520inhibition%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D327%26epage%3D331%26doi%3D10.1021%2Fml300018e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haling, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heald, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hewitt, J. F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zak, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peck, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orr, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luoh, S.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiesmann, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ultsch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span> </span><span class="NLM_article-title">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">501</span><span class="NLM_x">, </span> <span class="NLM_fpage">232</span><span class="NLM_x">–</span> <span class="NLM_lpage">236</span><span class="refDoi"> DOI: 10.1038/nature12441</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnature12441" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=23934108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=501&publication_year=2013&pages=232-236&author=G.+Hatzivassiliouauthor=J.+R.+Halingauthor=H.+Chenauthor=K.+Songauthor=S.+Priceauthor=R.+Healdauthor=J.+F.+M.+Hewittauthor=M.+Zakauthor=A.+Peckauthor=C.+Orrauthor=M.+Merchantauthor=K.+P.+Hoeflichauthor=J.+Chanauthor=S.-M.+Luohauthor=D.+J.+Andersonauthor=M.+J.+C.+Ludlamauthor=C.+Wiesmannauthor=M.+Ultschauthor=L.+S.+Friedmanauthor=S.+Malekauthor=M.+Belvin&title=Mechanism+of+MEK+inhibition+determines+efficacy+in+mutant+KRAS-+versus+BRAF-driven+cancers&doi=10.1038%2Fnature12441"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Haling, Jacob R.; Chen, Huifen; Song, Kyung; Price, Steve; Heald, Robert; Hewitt, Joanne F. M.; Zak, Mark; Peck, Ariana; Orr, Christine; Merchant, Mark; Hoeflich, Klaus P.; Chan, Jocelyn; Luoh, Shiuh-Ming; Anderson, Daniel J.; Ludlam, Mary J. C.; Wiesmann, Christian; Ultsch, Mark; Friedman, Lori S.; Malek, Shiva; Belvin, Marcia</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">501</span>
        (<span class="NLM_cas:issue">7466</span>),
    <span class="NLM_cas:pages">232-236</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">KRAS and BRAF activating mutations drive tumorigenesis through constitutive activation of the MAPK pathway.  As these tumors represent an area of high unmet medical need, multiple allosteric MEK inhibitors, which inhibit MAPK signaling in both genotypes, are being tested in clin. trials.  Impressive single-agent activity in BRAF-mutant melanoma has been obsd.; however, efficacy has been far less robust in KRAS-mutant disease.  Owing to distinct mechanisms regulating MEK activation in KRAS- vs. BRAF-driven tumors, different mechanisms of inhibition are required for optimal antitumor activity in each genotype.  Structural and functional anal. illustrates that MEK inhibitors with superior efficacy in KRAS-driven tumors (GDC-0623 and G-573, the former currently in phase I clin. trials) form a strong hydrogen-bond interaction with S212 in MEK that is crit. for blocking MEK feedback phosphorylation by wild-type RAF.  Conversely, potent inhibition of active, phosphorylated MEK is required for strong inhibition of the MAPK pathway in BRAF-mutant tumors, resulting in superior efficacy in this genotype with GDC-0973 (also known as cobimetinib), a MEK inhibitor currently in phase III clin. trials.  The authors' study highlights that differences in the activation state of MEK in KRAS-mutant tumors vs. BRAF-mutant tumors can be exploited through the design of inhibitors that uniquely target these distinct activation states of MEK.  These inhibitors are currently being evaluated in clin. trials to det. whether improvements in therapeutic index within KRAS vs. BRAF preclin. models translate to improved clin. responses in patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQUdtElnPqJLVg90H21EOLACvtfcHk0lhKOqqT1PkbQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1Cgtr3N&md5=12ceb67132291cbaff64c20c67b61b32</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fnature12441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12441%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DHaling%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DPrice%26aufirst%3DS.%26aulast%3DHeald%26aufirst%3DR.%26aulast%3DHewitt%26aufirst%3DJ.%2BF.%2BM.%26aulast%3DZak%26aufirst%3DM.%26aulast%3DPeck%26aufirst%3DA.%26aulast%3DOrr%26aufirst%3DC.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DChan%26aufirst%3DJ.%26aulast%3DLuoh%26aufirst%3DS.-M.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%2BC.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DUltsch%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DBelvin%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520MEK%2520inhibition%2520determines%2520efficacy%2520in%2520mutant%2520KRAS-%2520versus%2520BRAF-driven%2520cancers%26jtitle%3DNature%26date%3D2013%26volume%3D501%26spage%3D232%26epage%3D236%26doi%3D10.1038%2Fnature12441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Holderfield, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deuker, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormick, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMahon, M.</span><span> </span><span class="NLM_article-title">Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">467</span><span class="refDoi"> DOI: 10.1038/nrc3760</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnrc3760" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24957944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVamur3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=455-467&author=M.+Holderfieldauthor=M.+M.+Deukerauthor=F.+McCormickauthor=M.+McMahon&title=Targeting+RAF+kinases+for+cancer+therapy%3A+BRAF-mutated+melanoma+and+beyond&doi=10.1038%2Fnrc3760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond</span></div><div class="casAuthors">Holderfield, Matthew; Deuker, Marian M.; McCormick, Frank; McMahon, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">455-467</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The identification of mutationally activated BRAF in many cancers altered our conception of the part played by the RAF family of protein kinases in oncogenesis.  In this Review, we describe the development of BRAF inhibitors and the results that have emerged from their anal. in both the lab. and the clinic.  We discuss the spectrum of RAF mutations in human cancer and the complex interplay between the tissue of origin and the response to RAF inhibition.  Finally, we enumerate mechanisms of resistance to BRAF inhibition that have been characterized and postulate how strategies of RAF pathway inhibition may be extended in scope to benefit not only the thousands of patients who are diagnosed annually with BRAF-mutated metastatic melanoma but also the larger patient population with malignancies harboring mutationally activated RAF genes that are ineffectively treated with the current generation of BRAF kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocz-DIK1jK5LVg90H21EOLACvtfcHk0lhKOqqT1PkbQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVamur3M&md5=d7de7a5409dbb2aefaf3fc9ef6d8f944</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnrc3760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3760%26sid%3Dliteratum%253Aachs%26aulast%3DHolderfield%26aufirst%3DM.%26aulast%3DDeuker%26aufirst%3DM.%2BM.%26aulast%3DMcCormick%26aufirst%3DF.%26aulast%3DMcMahon%26aufirst%3DM.%26atitle%3DTargeting%2520RAF%2520kinases%2520for%2520cancer%2520therapy%253A%2520BRAF-mutated%2520melanoma%2520and%2520beyond%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D455%26epage%3D467%26doi%3D10.1038%2Fnrc3760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Diab, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarasiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proud, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milne, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">MAP kinase-interacting kinases - emerging targets against cancer</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">452</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2014.01.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.chembiol.2014.01.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24613018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjslyitb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2014&pages=441-452&author=S.+Diabauthor=M.+Kumarasiriauthor=M.+Yuauthor=T.+Teoauthor=C.+Proudauthor=R.+Milneauthor=S.+Wang&title=MAP+kinase-interacting+kinases+-+emerging+targets+against+cancer&doi=10.1016%2Fj.chembiol.2014.01.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">MAP Kinase-Interacting Kinases-Emerging Targets against Cancer</span></div><div class="casAuthors">Diab, Sarah; Kumarasiri, Malika; Yu, Mingfeng; Teo, Theodosia; Proud, Christopher; Milne, Robert; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">441-452</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK)-interacting kinases (Mnks) regulate the initiation of translation through phosphorylation of eukaryotic initiation factor 4E (eIF4E).  Mnk-mediated eIF4E activation promotes cancer development and progression.  While the phosphorylation of eIF4E is necessary for oncogenic transformation, the kinase activity of Mnks seems dispensable for normal development.  For this reason, pharmacol. inhibition of Mnks could represent an ideal mechanism-based and nontoxic therapeutic strategy for cancer treatment.  In this review, we discuss the current understanding of Mnk biol. roles, structures, and functions, as well as clin. implications.  Importantly, we propose different strategies for identification of highly selective small mol. inhibitors of Mnks, including exploring a structural feature of their kinase domain, DFD motif, which is unique within the human kinome.  We also argue that a combined targeting of Mnks and other pathways should be considered given the complexity of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8J4FNfWRq27Vg90H21EOLACvtfcHk0liwfAdQhh5fsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjslyitb0%253D&md5=472ef0f62dc9dc457139367b3a573c49</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2014.01.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2014.01.011%26sid%3Dliteratum%253Aachs%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DProud%26aufirst%3DC.%26aulast%3DMilne%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DMAP%2520kinase-interacting%2520kinases%2520-%2520emerging%2520targets%2520against%2520cancer%26jtitle%3DChem.%2520Biol.%26date%3D2014%26volume%3D21%26spage%3D441%26epage%3D452%26doi%3D10.1016%2Fj.chembiol.2014.01.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Holzbeierlein, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Windsperger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vielhauer, G.</span><span> </span><span class="NLM_article-title">Hsp90: a drug target? Curr</span> <span class="citation_source-journal">Curr. Oncol. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">101</span><span class="refDoi"> DOI: 10.1007/s11912-010-0086-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1007%2Fs11912-010-0086-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20425593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=95-101&author=J.+Holzbeierleinauthor=A.+Windspergerauthor=G.+Vielhauer&title=Hsp90%3A+a+drug+target%3F+Curr&doi=10.1007%2Fs11912-010-0086-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Hsp90: a drug target?</span></div><div class="casAuthors">Holzbeierlein, Jeffrey M.; Windsperger, Andrew; Vielhauer, George</div><div class="citationInfo"><span class="NLM_cas:title">Current Oncology Reports</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">95-101</span>CODEN:
                <span class="NLM_cas:coden">CORUAT</span>;
        ISSN:<span class="NLM_cas:issn">1534-6269</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Heat shock protein 90 (Hsp90) is a mol. chaperone involved in the trafficking of proteins in the cell.  Under stressful conditions, Hsp90 stabilizes its client proteins and provides protection to the cell against cellular stressors such as in cancer cells.  Disruption of Hsp90 leads to client protein degrdn. and often cell death.  As Hsp90 has been found to be either overexpressed or constitutively more active in cancer cells, inhibitors of Hsp90 may have cancer cell selectivity.  The N-terminal inhibitors, geldanamycin and radiciol, were the first two described inhibitors of Hsp90, but were not clin. useful.  Subsequent analogs-17 allylamino-17demethoxygeldanamycin and 17 dimethylaminoethylamino-17-demethoxygeldanamycin-were found to be more clin. appropriate and have been studied in a no. of clin. trials since 1999.  In addn., to the N-terminal site of Hsp90, the C-terminal site appears to be another target for inhibition of Hsp90.  More recently, inhibitors of the C terminus of Hsp90 have been developed and studied in vitro with promising results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqR8ds07kZc7Vg90H21EOLACvtfcHk0liwfAdQhh5fsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Cjsb%252FO&md5=a81b2ea571f42173863c0435831e42e4</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs11912-010-0086-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11912-010-0086-3%26sid%3Dliteratum%253Aachs%26aulast%3DHolzbeierlein%26aufirst%3DJ.%26aulast%3DWindsperger%26aufirst%3DA.%26aulast%3DVielhauer%26aufirst%3DG.%26atitle%3DHsp90%253A%2520a%2520drug%2520target%253F%2520Curr%26jtitle%3DCurr.%2520Oncol.%2520Rep.%26date%3D2010%26volume%3D12%26spage%3D95%26epage%3D101%26doi%3D10.1007%2Fs11912-010-0086-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Whitesell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lindquist, S. L.</span><span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">761</span><span class="NLM_x">–</span> <span class="NLM_lpage">772</span><span class="refDoi"> DOI: 10.1038/nrc1716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+L.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer&doi=10.1038%2Fnrc1716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0liwfAdQhh5fsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%2BL.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fnrc1716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Pratt, W. B.</span><span> </span><span class="NLM_article-title">The role of heat shock proteins in regulating the function, folding, and trafficking of the glucocorticoid receptor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">21455</span><span class="NLM_x">–</span> <span class="NLM_lpage">21458</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=1993&pages=21455-21458&author=W.+B.+Pratt&title=The+role+of+heat+shock+proteins+in+regulating+the+function%2C+folding%2C+and+trafficking+of+the+glucocorticoid+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPratt%26aufirst%3DW.%2BB.%26atitle%3DThe%2520role%2520of%2520heat%2520shock%2520proteins%2520in%2520regulating%2520the%2520function%252C%2520folding%252C%2520and%2520trafficking%2520of%2520the%2520glucocorticoid%2520receptor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1993%26volume%3D268%26spage%3D21455%26epage%3D21458" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Hadden, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lubbers, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagg, B. S. J.</span><span> </span><span class="NLM_article-title">Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1173</span><span class="NLM_x">–</span> <span class="NLM_lpage">1182</span><span class="refDoi"> DOI: 10.2174/156802606777812031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.2174%2F156802606777812031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=16842154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD28Xpt1ejtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=1173-1182&author=M.+K.+Haddenauthor=D.+J.+Lubbersauthor=B.+S.+J.+Blagg&title=Geldanamycin%2C+radicicol%2C+and+chimeric+inhibitors+of+the+Hsp90+N-terminal+ATP+binding+site&doi=10.2174%2F156802606777812031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site</span></div><div class="casAuthors">Hadden, M. Kyle; Lubbers, Donna J.; Blagg, Brian S. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1173-1182</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Natural products have continued to drive the development of new chemotherapeutics and elucidation of new biol. targets for the treatment of disease.  Since Whitesell and Neckers' original discovery that geldanamycin does not directly inhibit v-Src, but instead manifests its biol. activity through inhibition of the Hsp90 mol. chaperone, addnl. natural products and natural product derivs. have been identified and developed to inhibit the Hsp90 protein folding machinery.  17-AAG, a geldanamycin analog, is currently in clin. trials for the treatment of several types of cancer.  Recent work has produced improved radicicol analogs that show promising Hsp90 inhibitory activity in vitro.  In addn., chimeric mols. of these two natural products are active in vitro and represent a novel class of Hsp90 inhibitors for cancer treatment.  In addn. to their chemotherapeutic uses, natural product inhibitors and their derivs. have been utilized to probe the biol. mechanisms by which Hsp90 inhibition regulates tumor cell growth.  As a consequence of these studies, the mol. chaperones have emerged as an exciting new class of therapeutic targets.  This review will highlight the utility of the natural products, geldanamycin and radicicol, as well as improved analogs and the activities exhibited by these compds. against various cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogseEm4_LdKrVg90H21EOLACvtfcHk0liwfAdQhh5fsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xpt1ejtL8%253D&md5=6f0493f45767b9a364fadb9cc466a9a2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.2174%2F156802606777812031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802606777812031%26sid%3Dliteratum%253Aachs%26aulast%3DHadden%26aufirst%3DM.%2BK.%26aulast%3DLubbers%26aufirst%3DD.%2BJ.%26aulast%3DBlagg%26aufirst%3DB.%2BS.%2BJ.%26atitle%3DGeldanamycin%252C%2520radicicol%252C%2520and%2520chimeric%2520inhibitors%2520of%2520the%2520Hsp90%2520N-terminal%2520ATP%2520binding%2520site%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2006%26volume%3D6%26spage%3D1173%26epage%3D1182%26doi%3D10.2174%2F156802606777812031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Kobayashi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyooka, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dote, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiura, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyoshi, S.</span><span> </span><span class="NLM_article-title">The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor</span> <span class="citation_source-journal">Lung Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">166</span><span class="refDoi"> DOI: 10.1016/j.lungcan.2011.04.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1016%2Fj.lungcan.2011.04.022" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2012&pages=161-166&author=N.+Kobayashiauthor=S.+Toyookaauthor=J.+Sohauthor=H.+Yamamotoauthor=H.+Doteauthor=K.+Kawasakiauthor=H.+Otaniauthor=T.+Kuboauthor=M.+Jidaauthor=T.+Uenoauthor=M.+Andoauthor=A.+Oginoauthor=K.+Kiuraauthor=S.+Miyoshi&title=The+anti-proliferative+effect+of+heat+shock+protein+90+inhibitor%2C+17-DMAG%2C+on+non-small-cell+lung+cancers+being+resistant+to+EGFR+tyrosine+kinase+inhibitor&doi=10.1016%2Fj.lungcan.2011.04.022"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2011.04.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2011.04.022%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DN.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DSoh%26aufirst%3DJ.%26aulast%3DYamamoto%26aufirst%3DH.%26aulast%3DDote%26aufirst%3DH.%26aulast%3DKawasaki%26aufirst%3DK.%26aulast%3DOtani%26aufirst%3DH.%26aulast%3DKubo%26aufirst%3DT.%26aulast%3DJida%26aufirst%3DM.%26aulast%3DUeno%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DKiura%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DS.%26atitle%3DThe%2520anti-proliferative%2520effect%2520of%2520heat%2520shock%2520protein%252090%2520inhibitor%252C%252017-DMAG%252C%2520on%2520non-small-cell%2520lung%2520cancers%2520being%2520resistant%2520to%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DLung%2520Cancer%26date%3D2012%26volume%3D75%26spage%3D161%26epage%3D166%26doi%3D10.1016%2Fj.lungcan.2011.04.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Takezawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okamoto, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yonesaka, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatashita, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamada, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuoka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span> </span><span class="NLM_article-title">Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6515</span><span class="NLM_x">–</span> <span class="NLM_lpage">6521</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-1076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1158%2F0008-5472.CAN-09-1076" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6515-6521&author=K.+Takezawaauthor=I.+Okamotoauthor=K.+Yonesakaauthor=E.+Hatashitaauthor=Y.+Yamadaauthor=M.+Fukuokaauthor=K.+Nakagawa&title=Sorafenib+inhibits+non-small+cell+lung+cancer+cell+growth+by+targeting+B-RAF+in+KRAS+wild-type+cells+and+C-RAF+in+KRAS+mutant+cells&doi=10.1158%2F0008-5472.CAN-09-1076"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-1076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-1076%26sid%3Dliteratum%253Aachs%26aulast%3DTakezawa%26aufirst%3DK.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DYonesaka%26aufirst%3DK.%26aulast%3DHatashita%26aufirst%3DE.%26aulast%3DYamada%26aufirst%3DY.%26aulast%3DFukuoka%26aufirst%3DM.%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DSorafenib%2520inhibits%2520non-small%2520cell%2520lung%2520cancer%2520cell%2520growth%2520by%2520targeting%2520B-RAF%2520in%2520KRAS%2520wild-type%2520cells%2520and%2520C-RAF%2520in%2520KRAS%2520mutant%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6515%26epage%3D6521%26doi%3D10.1158%2F0008-5472.CAN-09-1076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Sarbassov, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guertin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabatini, D. M.</span><span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">307</span><span class="NLM_x">, </span> <span class="NLM_fpage">1098</span><span class="NLM_x">–</span> <span class="NLM_lpage">1101</span><span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0licZ9gvPnQETw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Sanchez-Laorden, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pedersen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saturno, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zambon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turajlic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cook, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">ra30</span><span class="refDoi"> DOI: 10.1126/scisignal.2004815</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1126%2Fscisignal.2004815" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24667377" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=ra30&author=B.+Sanchez-Laordenauthor=A.+Virosauthor=M.+R.+Girottiauthor=M.+Pedersenauthor=G.+Saturnoauthor=A.+Zambonauthor=D.+Niculescu-Duvazauthor=S.+Turajlicauthor=A.+Hayesauthor=M.+Goreauthor=J.+Larkinauthor=P.+Loriganauthor=M.+Cookauthor=C.+Springerauthor=R.+Marais&title=BRAF+Inhibitors+Induce+Metastasis+in+RAS+Mutant+or+Inhibitor-Resistant+Melanoma+Cells+by+Reactivating+MEK+and+ERK+Signaling&doi=10.1126%2Fscisignal.2004815"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004815%26sid%3Dliteratum%253Aachs%26aulast%3DSanchez-Laorden%26aufirst%3DB.%26aulast%3DViros%26aufirst%3DA.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DPedersen%26aufirst%3DM.%26aulast%3DSaturno%26aufirst%3DG.%26aulast%3DZambon%26aufirst%3DA.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DTurajlic%26aufirst%3DS.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DCook%26aufirst%3DM.%26aulast%3DSpringer%26aufirst%3DC.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DBRAF%2520Inhibitors%2520Induce%2520Metastasis%2520in%2520RAS%2520Mutant%2520or%2520Inhibitor-Resistant%2520Melanoma%2520Cells%2520by%2520Reactivating%2520MEK%2520and%2520ERK%2520Signaling%26jtitle%3DSci.%2520Signaling%26date%3D2014%26volume%3D7%26spage%3Dra30%26doi%3D10.1126%2Fscisignal.2004815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Marusiak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, Z. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugo, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trotter, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, N. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kong, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gartside, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fawdar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitwieser, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lo, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brognard, J.</span><span> </span><span class="NLM_article-title">Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors</span> <span class="citation_source-journal">Nat. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3901</span><span class="refDoi"> DOI: 10.1038/ncomms4901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fncomms4901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24849047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvF2mu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=3901&author=A.+A.+Marusiakauthor=Z.+C.+Edwardsauthor=W.+Hugoauthor=E.+W.+Trotterauthor=M.+R.+Girottiauthor=N.+L.+Stephensonauthor=X.+Kongauthor=M.+G.+Gartsideauthor=S.+Fawdarauthor=A.+Hudsonauthor=W.+Breitwieserauthor=N.+K.+Haywardauthor=R.+Maraisauthor=R.+S.+Loauthor=J.+Brognard&title=Mixed+lineage+kinases+activate+MEK+independently+of+RAF+to+mediate+resistance+to+RAF+inhibitors&doi=10.1038%2Fncomms4901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors</span></div><div class="casAuthors">Marusiak, Anna A.; Edwards, Zoe C.; Hugo, Willy; Trotter, Eleanor W.; Girotti, Maria R.; Stephenson, Natalie L.; Kong, Xiangju; Gartside, Michael G.; Fawdar, Shameem; Hudson, Andrew; Breitwieser, Wolfgang; Hayward, Nicholas K.; Marais, Richard; Lo, Roger S.; Brognard, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">3901</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">RAF inhibitor therapy yields significant redns. in tumor burden in the majority of V600E-pos. melanoma patients; however, resistance occurs within 2-18 mo.  Here we demonstrate that the mixed lineage kinases (MLK1-4) are MEK kinases that reactivate the MEK/ERK pathway in the presence of RAF inhibitors.  Expression of MLK1-4 mediates resistance to RAF inhibitors and promotes survival in V600E-pos. melanoma cell lines.  Furthermore, we observe upregulation of the MLKs in 9 of 21 melanoma patients with acquired drug resistance.  Consistent with this observation, MLKs promote resistance to RAF inhibitors in mouse models and contribute to acquired resistance in a cell line model.  Lastly, we observe that a majority of MLK1 mutations identified in patients are gain-of-function mutations.  In summary, our data demonstrate a role for MLKs as direct activators of the MEK/ERK pathway with implications for melanomagenesis and resistance to RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2UDIQWhrwhbVg90H21EOLACvtfcHk0lggZoQO7kXYQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvF2mu7rO&md5=e98da6e7d453ca3cff433deaec3ea136</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fncomms4901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms4901%26sid%3Dliteratum%253Aachs%26aulast%3DMarusiak%26aufirst%3DA.%2BA.%26aulast%3DEdwards%26aufirst%3DZ.%2BC.%26aulast%3DHugo%26aufirst%3DW.%26aulast%3DTrotter%26aufirst%3DE.%2BW.%26aulast%3DGirotti%26aufirst%3DM.%2BR.%26aulast%3DStephenson%26aufirst%3DN.%2BL.%26aulast%3DKong%26aufirst%3DX.%26aulast%3DGartside%26aufirst%3DM.%2BG.%26aulast%3DFawdar%26aufirst%3DS.%26aulast%3DHudson%26aufirst%3DA.%26aulast%3DBreitwieser%26aufirst%3DW.%26aulast%3DHayward%26aufirst%3DN.%2BK.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DLo%26aufirst%3DR.%2BS.%26aulast%3DBrognard%26aufirst%3DJ.%26atitle%3DMixed%2520lineage%2520kinases%2520activate%2520MEK%2520independently%2520of%2520RAF%2520to%2520mediate%2520resistance%2520to%2520RAF%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2014%26volume%3D5%26spage%3D3901%26doi%3D10.1038%2Fncomms4901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Abel, E. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basile, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugel, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witkiewicz, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amaravadi, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karakousis, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ertel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fortina, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aplin, A. E.</span><span> </span><span class="NLM_article-title">Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2155</span><span class="NLM_x">–</span> <span class="NLM_lpage">2168</span><span class="refDoi"> DOI: 10.1172/JCI65780</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1172%2FJCI65780" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=2155-2168&author=E.+V.+Abelauthor=K.+J.+Basileauthor=C.+H.+Kugelauthor=A.+K.+Witkiewiczauthor=K.+Leauthor=R.+K.+Amaravadiauthor=G.+C.+Karakousisauthor=X.+Xuauthor=W.+Xuauthor=L.+M.+Schuchterauthor=J.+B.+Leeauthor=A.+Ertelauthor=P.+Fortinaauthor=A.+E.+Aplin&title=Melanoma+adapts+to+RAF%2FMEK+inhibitors+through+FOXD3-mediated+upregulation+of+ERBB3&doi=10.1172%2FJCI65780"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1172%2FJCI65780&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI65780%26sid%3Dliteratum%253Aachs%26aulast%3DAbel%26aufirst%3DE.%2BV.%26aulast%3DBasile%26aufirst%3DK.%2BJ.%26aulast%3DKugel%26aufirst%3DC.%2BH.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DLe%26aufirst%3DK.%26aulast%3DAmaravadi%26aufirst%3DR.%2BK.%26aulast%3DKarakousis%26aufirst%3DG.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DSchuchter%26aufirst%3DL.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BB.%26aulast%3DErtel%26aufirst%3DA.%26aulast%3DFortina%26aufirst%3DP.%26aulast%3DAplin%26aufirst%3DA.%2BE.%26atitle%3DMelanoma%2520adapts%2520to%2520RAF%252FMEK%2520inhibitors%2520through%2520FOXD3-mediated%2520upregulation%2520of%2520ERBB3%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D2155%26epage%3D2168%26doi%3D10.1172%2FJCI65780" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Carnahan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beltran, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babij, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rose, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vonderfecht, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagapudi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broome, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fernando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kha, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belmontes, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radinsky, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kendall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, T. L.</span><span> </span><span class="NLM_article-title">Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">2399</span><span class="NLM_x">–</span> <span class="NLM_lpage">23410</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0181</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1158%2F1535-7163.MCT-10-0181" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20663930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=2399-23410&author=J.+Carnahanauthor=P.+J.+Beltranauthor=C.+Babijauthor=Q.+Leauthor=M.+J.+Roseauthor=S.+Vonderfechtauthor=J.+L.+Kimauthor=A.+L.+Smithauthor=K.+Nagapudiauthor=M.+A.+Broomeauthor=M.+Fernandoauthor=H.+Khaauthor=B.+Belmontesauthor=R.+Radinskyauthor=R.+Kendallauthor=T.+L.+Burgess&title=Selective+and+potent+Raf+inhibitors+paradoxically+stimulate+normal+cell+proliferation+and+tumor+growth&doi=10.1158%2F1535-7163.MCT-10-0181"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth</span></div><div class="casAuthors">Carnahan, Josette; Beltran, Pedro J.; Babij, Carol; Le, Quynh; Rose, Mark J.; Vonderfecht, Steven; Kim, Joseph L.; Smith, Adrian L.; Nagapudi, Karthik; Broome, Martin A.; Fernando, Manory; Kha, Hue; Belmontes, Brian; Radinsky, Robert; Kendall, Richard; Burgess, Teresa L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2399-2410</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Raf inhibitors are under clin. investigation, specifically in patients with tumor types harboring frequent activating mutations in B-Raf.  Here, we show that cell lines and tumors harboring mutant B-Raf were sensitive to a novel series of Raf inhibitors (e.g., V600EB-Raf A375, IC50 on cells = 2 nmol/L; ED50 on tumor xenografts = 1.3 mg/kg).  However, in cells and tumors with wild-type B-Raf, exposure to Raf inhibitors resulted in a dose-dependent and sustained activation of mitogen-activated protein kinase signaling.  In some of these cell lines, Raf inhibition led to entry into the cell cycle, enhanced proliferation, and significantly stimulated tumor growth in vivo.  Inhibition with structurally distinct Raf inhibitors or isoform-specific small interfering RNA knockdown of Raf showed that these effects were mediated directly through Raf.  Either A-Raf or C-Raf mediated the Raf inhibitor-induced mitogen-activated protein kinase pathway activation in an inhibitor-specific manner.  These paradoxical effects of Raf inhibition were seen in malignant and normal cells in vitro and in vivo.  Hyperplasia of normal epithelial cells in the esophagus and the stomach was evident in mice with all efficacious Raf inhibitors (n = 8) tested.  An implication of these results is that Raf inhibitors may induce unexpected normal cell and tumor tissue proliferation in patients.  Mol Cancer Ther; 9(8); 2399-410.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN5Uws5uZF4rVg90H21EOLACvtfcHk0lggZoQO7kXYQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpvVOjt7g%253D&md5=c2958b3c22d623571dea9bedf6835834</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0181%26sid%3Dliteratum%253Aachs%26aulast%3DCarnahan%26aufirst%3DJ.%26aulast%3DBeltran%26aufirst%3DP.%2BJ.%26aulast%3DBabij%26aufirst%3DC.%26aulast%3DLe%26aufirst%3DQ.%26aulast%3DRose%26aufirst%3DM.%2BJ.%26aulast%3DVonderfecht%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%2BL.%26aulast%3DSmith%26aufirst%3DA.%2BL.%26aulast%3DNagapudi%26aufirst%3DK.%26aulast%3DBroome%26aufirst%3DM.%2BA.%26aulast%3DFernando%26aufirst%3DM.%26aulast%3DKha%26aufirst%3DH.%26aulast%3DBelmontes%26aufirst%3DB.%26aulast%3DRadinsky%26aufirst%3DR.%26aulast%3DKendall%26aufirst%3DR.%26aulast%3DBurgess%26aufirst%3DT.%2BL.%26atitle%3DSelective%2520and%2520potent%2520Raf%2520inhibitors%2520paradoxically%2520stimulate%2520normal%2520cell%2520proliferation%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D2399%26epage%3D23410%26doi%3D10.1158%2F1535-7163.MCT-10-0181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Joshi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rice, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belani, C. P.</span><span> </span><span class="NLM_article-title">Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">e0118210</span><span class="refDoi"> DOI: 10.1371/journal.pone.0118210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1371%2Fjournal.pone.0118210" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=e0118210&author=M.+Joshiauthor=S.+J.+Riceauthor=X.+Liuauthor=B.+Millerauthor=C.+P.+Belani&title=Trametinib+with+or+without+vemurafenib+in+BRAF+mutated+non-small+cell+lung+cancer&doi=10.1371%2Fjournal.pone.0118210"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0118210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0118210%26sid%3Dliteratum%253Aachs%26aulast%3DJoshi%26aufirst%3DM.%26aulast%3DRice%26aufirst%3DS.%2BJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DMiller%26aufirst%3DB.%26aulast%3DBelani%26aufirst%3DC.%2BP.%26atitle%3DTrametinib%2520with%2520or%2520without%2520vemurafenib%2520in%2520BRAF%2520mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26spage%3De0118210%26doi%3D10.1371%2Fjournal.pone.0118210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Nakamura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arita, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donelan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chouitar, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carideo, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okaniwa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshida, S.</span><span> </span><span class="NLM_article-title">Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">7043</span><span class="NLM_x">–</span> <span class="NLM_lpage">7055</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1825</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1158%2F0008-5472.CAN-13-1825" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=24121489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVKhu77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=7043-7055&author=A.+Nakamuraauthor=T.+Aritaauthor=S.+Tsuchiyaauthor=J.+Donelanauthor=J.+Chouitarauthor=E.+Carideoauthor=K.+Galvinauthor=M.+Okaniwaauthor=T.+Ishikawaauthor=S.+Yoshida&title=Antitumor+activity+of+the+selective+pan-RAF+inhibitor+TAK-632+in+BRAF+inhibitor-resistant+melanoma&doi=10.1158%2F0008-5472.CAN-13-1825"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma</span></div><div class="casAuthors">Nakamura, Akito; Arita, Takeo; Tsuchiya, Shuntarou; Donelan, Jill; Chouitar, Jouhara; Carideo, Elizabeth; Galvin, Katherine; Okaniwa, Masanori; Ishikawa, Tomoyasu; Yoshida, Sei</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7043-7055</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of melanoma cells.  Somatic mutations in BRAF and NKAS are frequently obsd. in melanoma.  Recently, the BRAF inhibitors vemurafenib and dabrafenib have emerged as promising agents for the treatment of melanoma patients with BRAF-activating mutations.  Flowever, as BRAF inhibitors induce RAF paradoxical activation via RAF dimerization in BRAF wild-type cells, rapid emergence of acquired resistance and secondary skin tumors as well as presence of few effective treatment options for melanoma bearing wild- type BRAF (including NRAS-mutant melanoma) are clin. concerns.  Here, we demonstrate that the selective pan-RAF inhibitor TAK-632 suppresses RAF activity in BRAF wild-type cells with minimal RAF paradoxical activation.  Our anal. using RNAi and TAK-632 in preclin. models reveals that the MAPK pathway of NRAS-mutated melanoma cells is highly dependent on RAF.  We also show that TAK-632 induces RAF dimerization but inhibits the kinase activity of the RAF dimer, probably because of its slow dissocn. from RAF.  As a result, TAK-632 demonstrates potent antiproliferative effects both on NRAS-mutated melanoma cells and BRAF-mutated melanoma cells with acquired resistance to BRAF inhibitors through NRAS mutation or BRAF truncation.  Furthermore, we demonstrate that the combination of TAK-632 and the MAPK kinase (MEK) inhibitor TAK-733 exhibits synergistic antiproliferative effects on these cells.  Our findings characterize the unique features of TAK-632 as a pan-RAF inhibitor and provide rationale for its further investigation in NRAS-mutated melanoma and a subset of BRAF-mutated melanomas refractory to BRAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1LknpOlxiFrVg90H21EOLACvtfcHk0lhL63xgdTq2vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVKhu77L&md5=beeec0a6c53216a97762c91af9df8c0e</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1825&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1825%26sid%3Dliteratum%253Aachs%26aulast%3DNakamura%26aufirst%3DA.%26aulast%3DArita%26aufirst%3DT.%26aulast%3DTsuchiya%26aufirst%3DS.%26aulast%3DDonelan%26aufirst%3DJ.%26aulast%3DChouitar%26aufirst%3DJ.%26aulast%3DCarideo%26aufirst%3DE.%26aulast%3DGalvin%26aufirst%3DK.%26aulast%3DOkaniwa%26aufirst%3DM.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DYoshida%26aufirst%3DS.%26atitle%3DAntitumor%2520activity%2520of%2520the%2520selective%2520pan-RAF%2520inhibitor%2520TAK-632%2520in%2520BRAF%2520inhibitor-resistant%2520melanoma%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D7043%26epage%3D7055%26doi%3D10.1158%2F0008-5472.CAN-13-1825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Hatzivassiliou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandhuber, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokoe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gloor, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigers, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morales, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aliagas, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoeflich, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaiswal, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seshagiri, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeppen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friedman, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">464</span><span class="NLM_x">, </span> <span class="NLM_fpage">431</span><span class="NLM_x">–</span> <span class="NLM_lpage">435</span><span class="refDoi"> DOI: 10.1038/nature08833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=10.1038%2Fnature08833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=20130576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=431-435&author=G.+Hatzivassiliouauthor=K.+Songauthor=I.+Yenauthor=B.+J.+Brandhuberauthor=D.+J.+Andersonauthor=R.+Alvaradoauthor=M.+J.+Ludlamauthor=D.+Stokoeauthor=S.+L.+Gloorauthor=G.+Vigersauthor=T.+Moralesauthor=I.+Aliagasauthor=B.+Liuauthor=S.+Siderisauthor=K.+P.+Hoeflichauthor=B.+S.+Jaiswalauthor=S.+Seshagiriauthor=H.+Koeppenauthor=M.+Belvinauthor=L.+S.+Friedmanauthor=S.+Malek&title=RAF+inhibitors+prime+wild-type+RAF+to+activate+the+MAPK+pathway+and+enhance+growth&doi=10.1038%2Fnature08833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</span></div><div class="casAuthors">Hatzivassiliou, Georgia; Song, Kyung; Yen, Ivana; Brandhuber, Barbara J.; Anderson, Daniel J.; Alvarado, Ryan; Ludlam, Mary J. C.; Stokoe, David; Gloor, Susan L.; Vigers, Guy; Morales, Tony; Aliagas, Ignacio; Liu, Bonnie; Sideris, Steve; Hoeflich, Klaus P.; Jaiswal, Bijay S.; Seshagiri, Somasekar; Koeppen, Hartmut; Belvin, Marcia; Friedman, Lori S.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7287</span>),
    <span class="NLM_cas:pages">431-435</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Activating mutations in KRAS and BRAF are found in more than 30% of all human tumors and 40% of melanoma, resp., thus targeting this pathway could have broad therapeutic effects.  Small mol. ATP-competitive RAF kinase inhibitors have potent antitumor effects on mutant BRAF(V600E) tumors but, in contrast to mitogen-activated protein kinase kinase (MEK) inhibitors, are not potent against RAS mutant tumor models, despite RAF functioning as a key effector downstream of RAS and upstream of MEK.  Here we show that ATP-competitive RAF inhibitors have two opposing mechanisms of action depending on the cellular context.  In BRAF(V600E) tumors, RAF inhibitors effectively block the mitogen-activated protein kinase (MAPK) signalling pathway and decrease tumor growth.  Notably, in KRAS mutant and RAS/RAF wild-type tumors, RAF inhibitors activate the RAF-MEK-ERK pathway in a RAS-dependent manner, thus enhancing tumor growth in some xenograft models.  Inhibitor binding activates wild-type RAF isoforms by inducing dimerization, membrane localization and interaction with RAS-GTP.  These events occur independently of kinase inhibition and are, instead, linked to direct conformational effects of inhibitors on the RAF kinase domain.  On the basis of these findings, we demonstrate that ATP-competitive kinase inhibitors can have opposing functions as inhibitors or activators of signalling pathways, depending on the cellular context.  Furthermore, this work provides new insights into the therapeutic use of ATP-competitive RAF inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGounpcMETzVoLVg90H21EOLACvtfcHk0lhL63xgdTq2vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVygtb8%253D&md5=eb48bdf352ee9c9e182e63e38fd820a5</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2Fnature08833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08833%26sid%3Dliteratum%253Aachs%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DBrandhuber%26aufirst%3DB.%2BJ.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DAlvarado%26aufirst%3DR.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DStokoe%26aufirst%3DD.%26aulast%3DGloor%26aufirst%3DS.%2BL.%26aulast%3DVigers%26aufirst%3DG.%26aulast%3DMorales%26aufirst%3DT.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DJaiswal%26aufirst%3DB.%2BS.%26aulast%3DSeshagiri%26aufirst%3DS.%26aulast%3DKoeppen%26aufirst%3DH.%26aulast%3DBelvin%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DL.%2BS.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DRAF%2520inhibitors%2520prime%2520wild-type%2520RAF%2520to%2520activate%2520the%2520MAPK%2520pathway%2520and%2520enhance%2520growth%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D431%26epage%3D435%26doi%3D10.1038%2Fnature08833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i25"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01354">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_23734"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01354">10.1021/acs.jmedchem.5b01354</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">A549 cell lysate western blot experiments and NMR and HPLC data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01354/suppl_file/jm5b01354_si_001.pdf">jm5b01354_si_001.pdf (3.2 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01354&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01354%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-3%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01354" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a7df3fcfa3bec","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
